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General introduction and outline of the 
thesis
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clotting factor concentrates in bleeding 
disorders: Towards individualization of 
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1
HEMOSTASIS AND THROMBOSIS: A DELICATE BALANCE
When functioning adequately, hemostasis and thrombosis are in perfect balance. 
This balance is achieved by the various hemostatic and antithrombotic factors which 
safeguard individuals from bleeding and thrombosis. In various bleeding disorders, this 
balance is disrupted resulting in a bleeding tendency due to the presence of abnormal 
or the deficiency of coagulation factors. If clinically relevant, this can cause significant 
morbidity and even mortality when adequate treatment is not available or administered.
BLEEDING DISORDERS: A SHORT OVERVIEW
The most prevalent bleeding disorder is von Willebrand disease (VWD). VWD affects 
approximately 1% of the general population, although only 0.01% has clinical relevant 
bleedings.1 VWD patients have either a quantitative and/or qualitative defect of von 
Willebrand factor (VWF) which leads to impairment of primary hemostasis.2 VWD is 
classified as either type 1 (quantitative disorder), type 2 (qualitative disorder) or type 3 
(quantitative disorder). Type 2 VWD is further categorized according to laboratory test 
results into type 2A, 2B, 2M and 2N. VWF is essential for the formation of the platelet 
plug as it activates platelets and leads to platelet adhesion and aggregation.3
During this process of primary hemostasis, secondary hemostasis is activated result-
ing in formation of thrombin. To enhance thrombin formation and to consequently 
stabilize the hemostatic clot by fibrin formation, factor VIII (FVIII) and factor IX (FIX) are 
indispensable (Figure 1). Therefore, in the bleeding disorders hemophilia A, caused by 
a deficiency or abnormal function of FVIII and hemophilia B caused by a deficiency or 
abnormal function of FIX, secondary hemostasis is incapacitated.
Hemophilia A and B are X-linked inherited bleeding disorders, mainly characterized by 
bleeding in joints and muscles. Hemophilia has a much lower prevalence than VWD. 
Global prevalence of hemophilia A is estimated at 1 in 5.000 male births and of he-
mophilia B at 1 in 30.000 male births.4 Hemophilia patients are classified according to 
baseline FVIII or FIX plasma levels into severe (<0.01 IUmL-1), moderate severe (0.01-0.05 
IUmL-1) or mild (>0.05 IUmL-1) hemophilia.5 Severe and some moderate severe hemo-
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philia patients, suffer from spontaneous bleeding into joints or muscles resulting in joint 
damage, hemophilia arthropathy and long-term disability.
The availability of replacement therapy with factor concentrates both prophylactically 
and “on demand”, has greatly improved the lives of patients with a bleeding disorder. 
Thus leading to decreased morbidity and mortality and a great improvement of quality 
of life in these patient populations.6 However although treatment has been successful, it 
is also costly. Therefore, it is continuously important to evaluate health care outcomes in 
these diseases and to evaluate if treatment can be improved.
CURRENT TREATMENT
In VWD, the majority of patients are only treated with replacement therapy with VWF (/
FVIII) concentrates or desmopressin (DDAVP) for acute bleeding or to prevent bleeding 
in case of trauma and/or dental or surgical procedures.3 Only type 3 VWD patients, which 
account for less than 5% of all cases, may require prophylactic treatment with factor 
concentrate when bleeding occurs frequently. Most type 1 and some type 2 VWD pa-
tients are treated with DDAVP if a good response is established by an individual DDAVP 
test. DDAVP is a vasopressin analogue which increases endogenous release of VWF and 
FVIII from the endothelium. When patients do not respond to DDAVP or have contraindi-
Figure 1. Steps towards the hemostatic clot
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1cations for its use, treatment with factor concentrate is indicated. Factor concentrates for VWD patients often consist of combined VWF/FVIII concentrates derived from human plasma. The ratio of VWF activity versus FVIII may differ between concentrates.7, 8 Dosing is usually based on both residual VWF and FVIII levels.3 Although VWD is considered a 
milder bleeding disorder than hemophilia in most patients, treatment can be more chal-
lenging due to variation in VWD disease types and VWF gene mutations2, 9, the varying 
residual endothelial VWF production, as well as VWF secretion and clearance and the 
different ratios of VWF and FVIII in available factor concentrates.
To prevent spontaneous bleeding events in severely affected hemophilia patients, re-
placement therapy with factor concentrates is administered prophylactically. Long-term 
prophylactic treatment, so called prophylaxis, in hemophilia is based on the observation 
that patients with baseline levels above 0.01 IUmL-1 have far fewer joint bleeds and less 
subsequent arthropathy.10 This was confirmed in a randomized controlled trial in 65 
boys younger than 30 months of age by Manco Johnson et al.11, comparing prophy-
lactic treatment consisting of infusions of 25 IUkg-1 every other day and “on demand” 
treatment in a dose of 40 IUkg-1 at the time of clinically recognized joint hemorrhage. 
Prophylactic treatment was associated with less cartilage damage in large joints on 
MRI imaging and an overall decrease of bleeding events, including joint hemorrhage. 
Moreover, several studies have proven that an initiation of prophylaxis at an early age is 
beneficial for joint status and may also prevent development of neutralizing antibodies 
against the deficient coagulation factor.12-16 Prophylaxis consists of regular weekly infu-
sions of factor concentrates usually two to three times per week in severe and moderate 
hemophilia A and two times per week for patients with severe or moderate hemophilia 
B. When initiating or monitoring prophylaxis, indication for treatment, clinical bleeding 
phenotype, and patient’s daily activities are taken into account.17 Dosage protocols vary 
from 15-40 IUkg-1 two to three times per week in both hemophilia A and B.5, 15, 18-20
“On-demand” treatment in hemophilia consists of replacement therapy after a bleed or 
to prevent bleeding in case of trauma, dental procedures or in the perioperative setting. 
Dosage recommendations in these settings (e.g. amount and duration; and predefined 
target ranges), are dependent on the severity of bleeding and type of surgical procedure 
respectively.21, 22 For example, a bolus infusion of 50 IUkg-1 followed by twice a day 25 
IUkg-1 in case of a life-threatening bleeding event in a hemophilia A patient aiming for a 
peak level of 1.00 IUmL-1 and subsequent trough levels of 0.50 IUmL-1.
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In general in hemophilia, dosing of replacement therapy is based primarily on the re-
sidual FVIII or FIX plasma concentration and body weight in kilograms (kg) while aiming 
for predefined target levels taking the average in vivo recovery (IVR) per factor concen-
trate into account. Often the treating physician is also influenced by clinical phenotype, 
and severity of (risk of ) bleeding and crude estimates of factor concentrate clearance. 
Guidelines for FVIII dosing have always been based on an in vivo recovery (IVR) of 2.0 as 
postulated by Ingram et al. in 1981. This encompasses an increase of 2.0 IUdL-1 per one 
IUkg-1 infused FVIII factor concentrate.23 An IVR of 2.0 is assumed to be equivalent to a 
plasma volume of 0.5 dLkg-1.23 For FIX dosing, an IVR of 1.0 is used. Amount of factor 
concentrate to achieve a certain FVIII or FIX plasma concentration is then calculated 
using the formula: body weight (kg) x desired FVIII increase (IUdL-1)/2 in case of hemo-
philia A and body weight (kg) x desired FIX increase (IUdL-1)/1 in case of hemophilia B. 
Accordingly, a target level level of 100 IUdL-1 in a severe hemophilia A patient weighing 
80 kg is approximately achieved by a dose of 4000 IU (80 x 100 / 2). However, this calcula-
tion does not take the interindividual differences in pharmacokinetic (PK) parameters of 
factor concentrates in individual patients into account. Therefore, we aimed to evalu-
ate if adaptation of current dosing strategies may further individualize treatment and 
optimize quality of care.
Several examples underline this statement. In the first publication by Ingram et al. it 
was already stated that IVR of the factor concentrate could not be applied in over- and 
underweighted patients.23 More recently it was also demonstrated that children have 
a lower IVR, a relatively larger volume of distribution and higher clearance when com-
pared to adults.24 In general, a larger volume of distribution will lead to a longer half-
life. However, contrastingly, children have a shorter half-life, due to a higher clearance 
when compared to adults.24 Henrard et al. showed that a lower IVR was observed in 23 
underweighted patients, namely a median IVR of 1.6 instead of 2.0.25 In addition, this 
same group reported higher IVR values with a median IVR of 2.7 in 35 obese hemophilia 
A patients with a body mass index (BMI) > 29.6 kgm-2), which will result in structural 
overdosing if these individuals are dosed according to the 2.0 IVR assumption.25 All data 
support the generally accepted fact that plasma volume does not increase linearly with 
body weight, as documented in 1977 by Feldschuh et al.26 and therefore body weight 
alone cannot possibly predict adequate dose in all individuals.
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1
PHARMACOKINETIC PRINCIPLES IN TREATMENT OF BLEEDING DISORDERS
Pharmacokinetics (PK) describes drug absorption, distribution, metabolism and excre-
tion of an externally administered drug. Application of PK principles in dosing of medi-
cation was first introduced by Buchanan in 1847. In this study, plasma concentrations 
were used to establish volume of distribution of aether as used in general anaesthesia.27 
PK of a drug may exhibit a large interindividual as well as an intra-individual variation. As 
replacement therapy in bleeding disorders is currently dosed primarily based on body 
weight, further individualization may be possible by application of PK principles. Knowl-
edge of individual PK parameters (clearance, volume of distribution and elimination 
half-life) makes it possible to establish dosing intervals for a specific factor concentrate 
in a specific individual, in case of prophylaxis aiming for minimal trough levels. When 
considering the use of an average half-life of a factor concentrate, it is important to 
realize that half-life is determined by both volume of distribution and clearance (Figure 
2). The latter are both variable between- and within patients. Furthermore, these PK 
parameters may vary depending on circumstances when the process of hemostasis is 
altered, prophylactic treatment versus “on demand” treatment in case of bleeding and 
to prevent bleeding in the perioperative period.
In the Bayesian procedure (“Bayesian forecasting”), PK data from a specific population is 
used to estimate the clearance and volume of distribution of a drug in a specific individual 
in which a limited blood sampling of the specific drug has taken place. This information 
is subsequently used to calculate the most appropriate dose for the individual patient 
(Figure 3). More importantly, within these population models covariates are imple-
mented which are able to explain and quantify both inter-individual and intra-individual 
variability. In 2009 and 2013, Björkman et al. developed a population PK model for FVIII 
and FIX concentrate for treatment in the prophylactic setting.28, 29 However, implementa-
tion of the Bayesian approach has not yet been achieved on a broader scale. This seems 
due to lack of knowledge of PK, and the complexity of necessary pharmaco-statistical 
analyses. Current developments described in this thesis, suggest that individualization 
of therapy by application of Bayesian analysis is promising and may be within reach.
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AIMS OF THIS THESIS
The aim of this thesis is to evaluate the current dosing strategies of factor concentrates 
in von Willebrand disease and hemophilia A and B patients; and to establish whether 
more individualized dosing based on PK guided dosing using Bayesian techniques is 
feasible.
OUTLINE OF THE THESIS
In part I, we evaluated current treatment strategies in perioperative patients with a 
bleeding disorder by specification of concentrate administration and subsequently 
achieved peak and trough levels. These peak and trough levels were compared to target 
levels as prescribed by National guidelines to identify patients with levels under and 
Figure 2. Description of PK parameters
Description of PK parameters using non-compartimental principles. Administration of a bolus infusion 
of factor concentrate results in a peak plasma concentration, defined as Cmax. Half-life is derived from 
clearance (Cl) and volume of distribution (Vd) and is defined as the time required for the concentration 
to decrease with 50%. Clearance (Cl) is the volume of plasma cleared of the drug per unit time and is 
calculated as dose divided by the area under the curve. Volume of distribution (Vd) is the apparent vol-
ume in which a drug is distributed. In vivo recovery (IVR) is calculated as body weight (BW) (kilograms) x 
observed increase FVIII/FIX divided by the dose (in IU). Area under the curve (AUC) is the integral of the 
concentration-time curve.
General introduction and outline of the thesis • 17
1
Figure 3. Bayesian analysis; relationship between population and individual pharmacokinetic curves
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In Bayesian analysis, pharmacokinetic parameters in an individual patient are estimated from a limited 
number of plasma concentrations (depicted by red dots), and population pharmacokinetic data (depicted 
by black lines). The individual curve can be estimated for the individual patient, which is indicated by the 
red line. This process is repeated every time new plasma concentrations are obtained in the patient. Each 
measurement leading to optimization of the predictive value of the model to describe necessary doses to 
achieve specific plasma concentrations.
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above target range. Moreover, potential predictors of levels under target range and 
above target range, as well as variables associated with concentrate consumption were 
collected and evaluated. In chapter 2, this was performed in severe and moderate severe 
hemophilia A patients needing replacement therapy with FVIII concentrate aiming to 
identify the extent and predictors of underdosing and overdosing in the perioperative 
period. In chapter 3, FIX concentrate infusion and achieved FIX plasma levels during 
surgical procedures in severe and moderate severe hemophilia B patients from both the 
Netherlands and the United Kingdom (UK) were analyzed and related to target levels 
stated in National guidelines of both countries, in order to investigate perioperative 
management and to assess predictors of low and high FIX levels. In chapter 4, VWF/FVIII 
concentrate infusion and achieved FVIII and VWF levels were analyzed in VWD patients 
requiring a surgical procedure, in order to investigate current perioperative manage-
ment of VWD patients in a resource rich country.
In part II, two perioperative population PK models are presented which were con-
structed based on data described in part I. In chapter 5, a perioperative population PK 
model for patients with severe and moderate severe hemophilia A was constructed with 
data on amount of FVIII concentrate and all subsequently achieved FVIII plasma levels. 
The aim of such a model is to allow individualization of perioperative FVIII therapy for 
severe and moderate hemophilia A patients by Bayesian adaptive dosing. In chapter 6, 
a perioperative population PK model was constructed for severe and moderate severe 
hemophilia B patients. This constructed model describes factor IX concentrations and 
interpatient variability in the perioperative period, during FIX replacement therapy, 
ultimately leading to more individualized therapy.
In part III, different approaches to validate and to prove the feasibility of PK-guided 
dosing of factor concentrates in patients with a bleeding disorder are presented. In 
chapter 7, the design of the first large randomized controlled trial comparing PK-guided 
dosing with standard treatment in the perioperative setting is described. The aim of this 
study is to investigate whether perioperative PK-guided dosing of FVIII concentrate in 
hemophilia A patients receiving FVIII replacement therapy using a Bayesian approach, 
leads to a significant reduction in perioperative clotting factor consumption and more 
optimal dosing with achievement of FVIII levels within target range as prescribed by 
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1National guidelines. In chapter 8, alternative dosing strategies of factor concentrates in overweight and obese hemophilia A patients are analyzed with the aim to establish the relevance of PK in individualization of treatment in these patient populations. In Chapter 9, the feasibility of PK-guided dosing using an individual PK profile and a 
perioperative population PK model in a complex hemophilia A patient at risk for both 
bleeding and thrombosis during a renal transplantation is illustrated.
In part IV, the current benefits and limitations of PK-guided dosing are extensively dis-
cussed (chapter 10). In addition, a summary of the highlights of this thesis is provided 
(chapter 11).
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PART I
CURRENT PERIOPERATIVE 
TREATMENT OF PATIENTS 
WITH BLEEDING 
DISORDERS

 Chapter 2
Perioperative treatment of hemophilia A 
patients: Blood group O patients are at 
risk of bleeding complications
H.C.A.M. Hazendonk, J. Lock, R.A.A. Mathôt, K. Meijer, M. Peters, 
B.A.P. Laros-van Gorkom, F.J.M. van der Meer, M.H.E. Driessens, F.W.G. 
Leebeek, K. Fijnvandraat, M.H. Cnossen, for the “OPTI-CLOT” study group
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SUMMARy
Background Perioperative administration of factor VIII (FVIII) concentrate in hemophilia 
A may result in both underdosing and overdosing, leading to respectively a risk of bleed-
ing complications or unnecessary costs.
Objective This retrospective observational study aims to identify the extent and predic-
tors of underdosing and overdosing in perioperative hemophilia A patients (FVIII levels 
<0.05 IUmL-1).
Methods One hundred-nineteen patients undergoing 198 elective, minor or major 
surgical procedures were included (median age 40 years, median body weight 75 ki-
lograms). Perioperative management was evaluated by quantification of perioperative 
infusion of FVIII concentrate and achieved FVIII levels. Predictors of underdosing and 
(excessive) overdosing were analyzed by logistic regression analysis. Excessive overdos-
ing was defined as upper target level plus ≥0.20IUmL-1.
Results Depending on postoperative day, 7-45% of achieved FVIII levels were under 
and 33-75% were above predefined target ranges as stated by National guidelines. A 
potential reduction of FVIII consumption of 44% would have been attained if FVIII levels 
had been maintained within target ranges. Blood group O and major surgery were pre-
dictive of underdosing (OR=6.3 95%CI[2.7-14.9];OR=3.3 95%CI[1.4-7.9]). Blood group O 
patients had more bleeding complications in comparison to patients with blood group 
non-O (OR=2.02 95%CI[1.00-4.09]). Patients with blood group non-O were at higher risk 
of overdosing (OR=1.5 95%CI[1.1-1.9]). Additionally, patients treated with bolus infu-
sions were at higher risk of excessive overdosing (OR=1.8 95%CI[1.3-2.4]).
Conclusion Quality of care and cost-effectiveness can be improved by refining of dosing 
strategies based on individual patient characteristics such as blood group and mode of 
infusion.
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INTRODUCTION
Hemophilia A is an X-linked inherited bleeding disorder caused by a deficiency of coagula-
tion factor VIII (FVIII). It is characterized by spontaneous bleeding or bleeding after minor 
trauma, typically in joints and muscles. In case of bleeding, patients are treated with 
intravenously administered factor replacement therapy. In severe (FVIII <0.01 IUmL-1) and 
some moderate severe (FVIII between 0.01-0.05 IUmL-1) cases, prophylactic treatment is 
administered to prevent spontaneous and frequent bleeding.1, 2 In order to safeguard 
hemostasis in the perioperative setting, FVIII plasma levels are targeted according to 
guidelines for up to two weeks after surgery and consist of a FVIII bolus infusion of 50 
IUkg-1, followed by either continuous infusion or intermittent daily infusions based on a 
clearance rate of 3-4 ml kg-1 hour-1, and under daily monitoring of FVIII plasma levels (Table 
1).3 Perioperative factor concentrate consumption is substantial and amounts to 15% of 
annual use in the hemophilia population.4-6 To illustrate this, in the Netherlands over €100 
million ($109 million) is spent annually on total factor concentrate for 1600 hemophilia 
patients per year, including €15 million ($16.4 million) alone for perioperative replacement 
therapy.3, 4, 6 Fortunately, treatment is extremely effective as perioperative bleeding is rare, 
in those cases where replacement therapy is adequately available.7, 8
Table 1. Target FVIII levels in the perioperative period
Time 
Target FVIII level (IUmL-1)
Day Hours  
1 0- 24   0.80-1.00
2-5 24- 120 0.50-0.80
 ≥6 > 120   0.30-0.50
* According to the National Hemophilia Consensus of the Netherlands3
IUmL-1 = International Units per milliliter
The standard perioperative dosing regimen, as described by the Consensus, consists of a FVIII bolus dose 
directly prior to surgery of 50 IUkg-1, followed by either continuous infusion or intermittent daily bolus 
infusions. The rate of infusion (IU hour-1) is obtained by multiplying the patient’s bodyweight (kg) with 
clearance (3-4 mL kg-1 hour-1) and target FVIII level (IUmL-1). Subsequent FVIII clotting factor concentrate 
dosing will be based on daily monitoring of FVIII levels and adjusted according to doctor’s opinion, based 
on a standard clearance of 3-4 mL kg-1 hour-1. 
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Previous studies evaluating perioperative dosing of FVIII concentrate in hemophilia 
A suggest that improvement is warranted as overdosing is widely reported.9-16 This is 
attributed to current dosing strategies based on body weight and crude estimations 
of clearance, without taking other individual patient characteristics into account. Addi-
tionally, the complexity of achieving targeted factor levels, and fear of bleeding play an 
important role in overdosing. Strikingly, in reported studies extent and timing of under-
dosing and overdosing have not been specified. Moreover, risk factors for underdosing 
and overdosing have hardly been explored and are urgently required to individualize 
dosing in the near future.
We aim to quantify the extent and timing of underdosing and overdosing in the periop-
erative setting and to identify its predictors in severe and moderate severe hemophilia A 
patients. We believe that both underdosing and overdosing can be reduced by alterna-
tive dosing strategies that take individual patient characteristics into account, leading to 
optimization of care and a greater efficacy of consumption of costly factor concentrate.
MATERIALS AND METHODS
Patients
This is a retrospective multicenter observational cohort study. Eligible patients were 
males with severe or moderate severe hemophilia A (FVIII levels <0.05 IUmL-1) of all 
ages undergoing elective, minor or major surgery (Supplemental Table 1)17 between 
2000 and 2013 under FVIII concentrate replacement therapy with monitoring of FVIII 
plasma levels. First surgical procedure was performed on January 7th 2000 and last 
surgical procedure on February 19th 2013. Patients were recruited from five Academic 
Hemophilia Treatment Centers in the Netherlands (Erasmus University Medical Center 
Rotterdam (n=32); Academic Medical Center Amsterdam (n=32); University Medical 
Center Groningen (n=35); Radboud university medical center (n=12); and Leiden Univer-
sity Medical Center (n=8). Exclusion criteria included: the perioperative presence of FVIII 
neutralizing antibodies, patients with severe infections during the perioperative period 
and patients lacking accurate perioperative documentation. The study was not subject 
to the Medical Research Involving Human Subjects Act, as patient data were analyzed 
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anonymously. Moreover, the study was approved by all local Medical Ethics Committees; 
one center requiring prior patient informed consent.
Objectives
Objective of the study was to evaluate perioperative FVIII concentrate management in 
hemophilia A with regard to defined FVIII target ranges as stated by the National Hemo-
philia Consensus of the Netherlands and to identify potential predictors of underdosing 
and overdosing.
Methods
Data were collected on patient characteristics, type of surgical procedure, timing, 
dosing of FVIII administration and timing of blood sampling of FVIII plasma levels in 
IUmL-1, during the hospitalization period. FVIII plasma levels were generally monitored 
daily and were measured by one-stage clotting assays in all participating centers. 
Perioperative blood loss and hemostasis were evaluated according to the definitions of 
the International Society of Thrombosis and Hemostasis18 and quantified by severity of 
complications and/or necessity of second surgical intervention, hemoglobin decrease of 
≥1.24 mmol/l and/or red blood cell transfusion (RBCTF) necessity, or bleeding prolong-
ing hospitalization.
For our analysis we defined severe bleeding complications as bleeding requiring a sec-
ond surgical intervention and/or the necessity of a RBCTF. Duration of hospitalization 
was defined by day of discharge minus day of surgical procedure and initiation of FVIII 
concentrate infusion. To increase data reliability, data were collected and checked by 
two individual researchers.
To acquire accurate insight into achieved FVIII plasma levels with regard to the target 
ranges stated in guidelines, only steady state FVIII plasma levels were included when 
replacement therapy was administered by continuous infusion and only FVIII trough 
plasma levels in case of administration by bolus infusion. Steady state FVIII plasma levels 
were defined as perioperative FVIII measurements sampled when FVIII concentrate 
substitution is equal to clearance and FVIII trough plasma levels as FVIII measurements 
prior to FVIII concentrate bolus infusion. FVIII peak levels after FVIII bolus infusion were 
not included in this analysis.
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Statistical analysis
For comparison of FVIII concentrate consumption between groups the non-parametric 
Mann-Whitney U test was used. P for trend analysis using one-way ANOVA was per-
formed to evaluate trends in FVIII consumption on consecutive days. Calculations were 
performed only on the first surgical procedure in each individual patient. Descriptive 
statistics are presented as median and interquartile range [IQR] for continuous variables 
and as number (No.) and percentages (%) for categorical variables. Comparison between 
proportions was done by means of Pearson Chi-Square test.
A hypothetical reduction of FVIII concentrate consumption, if National guidelines for 
perioperative target ranges had been maintained, was calculated by comparing the dif-
ference of achieved FVIII plasma level in each individual at different time points, to the 
prescribed lowest and highest target range level at that time point. First-order elimina-
tion curves were used to calculate the actual amount of FVIII concentrate underdosed 
or overdosed for the total population. The percentage of FVIII concentrate which could 
have been saved was calculated after subtraction of the amount of FVIII concentrate 
which was underdosed.
Prediction model for underdosing and overdosing
Underdosing was defined as all FVIII plasma levels under lowest predefined target range 
level and overdosing as all FVIII plasma levels above highest predefined target range 
level. Excessive overdosing was arbitrarily defined as the upper target range level with 
a deviation of ≥0.20 IUmL-1 to overcome the logistic delays caused by laboratory moni-
toring and adjustment of treatment. Potential predictors of underdosing in the first 24 
hours after surgery, as well as overdosing and excessive overdosing were analyzed by a 
backward stepwise logistic regression analysis with elimination of variables with p>0.10. 
Potential predictors of underdosing or overdosing were defined before analysis on the 
basis of their potential effect on the pharmacokinetic parameters: clearance and/ or vol-
ume of distribution of infused FVIII concentrate. The following variables were collected: 
firstly, patient characteristics: age, body weight19, blood group20-22, historical values of 
von Willebrand Factor (VWF) antigen and VWF activity23, history of FVIII neutralizing 
antibodies8, type and brand of factor concentrate (recombinant or plasma-derived)24 
and mode of infusion (continuous or bolus infusion)25. Secondly, surgical characteristics: 
type and severity of surgical procedure categorized according to Koshy et al.17
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Data management and statistical analysis were performed with IBM SPSS statistics for 
Windows, version 21.0 (IBM Corp, Armonk, NY, USA). A p-value of <0.05 was considered 
statistically significant.
RESULTS
Patient and surgical characteristics
Our study population consisted of 119 patients undergoing a total of 198 surgical proce-
dures; 75 adults (140 surgical procedures; median age: 48 years; median body weight: 80 
kg) and 44 children (58 surgical procedures; median age: 4 years; median body weight: 
19 kg) (Table 2). The majority of patients were severe hemophilia A patients on prophy-
lactic treatment (70%). Approximately, half of all patients were known with blood group 
O (51%). In adults median VWF:Ag level was 1.23 IUmL-1 and median VWF:Act level was 
1.39 IUmL-1. In children median VWF:Ag was 0.92 IUmL-1 and VWF:Act was 0.88 IUmL-1.
Forty-four patients underwent multiple surgical procedures; nine of these had more 
than four surgical procedures (Table 2). In adults, mainly major surgical procedures 
Figure 1. Achieved FVIII levels in adults and children receiving clotting factor replacement therapy
Achieved FVIII levels in hemophilia patients treated by continuous infusion (blue) and by bolus infusions 
(red). Predefined target levels as stated by the National Hemophilia Consensus are depicted as green box-
es.3
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Table 2. General characteristics
Total cohort Adults Children
No. (%); or Median [IQR]
Patient characteristics
No. of patients 119 75 44
Age (years) 40 [9-54] 48 [37-60] 4 [2-8]
Height (cm) 175 [162-182] 178 [173-182.0] 114 [89-136]
Body weight (kg) 75 [35-85] 80 [73-90] 19 [12-29]
Body mass index (kgm-2) 23 [17-26] 25 [23-28] 16 [14-18]
Severe hemophilia (FVIII levels <0.01 IUmL-1) 83 (70) 49 (65) 34 (77)
On prophylaxis 84 (71) 51 (68) 33 (75)
Blood group O* 51 (51) 34 (50) 17 (52)
Neutralizing antibody titer
No 131 (66) 82 (59) 49 (85)
Historically 67 (34) 58 (41) 9 (15)
Maximum titer (BU) 0.3 [0.2-0.7] 0.3 [0.2-0.5] 0.2 [0.2-2.4]
Historical VWF levels (IUmL-1)
Antigen# 1.1 [0.9-1.4] 1.2 [1.0-1.4] 0.9 [0.7-1.2]
Activity$ 1.1 [0.9-1.6] 1.4 [1.1-1.7] 0.9 [0.7-1.2]
Chronic hepatitis C 57 (48) 55 (73) 2 (5)
Surgical characteristics
No. of surgical procedures 198 140 58
Total no. of patients undergoing:
1 75 (63.0) 43 (57.3) 32 (72.7)
2 26 (21.8) 15 (20.0) 11 (25.0)
3 9 (7.6) 9 (12.0) 0 (0.0)
>4 9 (7.6) 8 (10.7) 1 (2.3)
Major surgical procedure 97 (49.0) 86 (61.4) 11 (19.0)
Type of surgical procedure
General 6 (3.0) 6 (4.3) NA NA
Colo-rectal 5 (2.5) 4 (2.9) 1 (1.7)
Vascular 1 (0.5) 1 (0.7) NA NA
Cardio-thoracic 1 (0.5) 1 (0.7) NA NA
Orthopedic 94 (47.5) 91 (65.0) 3 (5.2)
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Table 2. General characteristics (continued)
Total cohort Adults Children
No. (%); or Median [IQR]
Urology 12 (6.1) 4 (2.9) 8 (13.8)
Maxillofacial 2 (1.0) 2 (1.4) NA NA
Ear-Nose-Throat 11 (5.6) 6 (4.3) 5 (8.6)
Eye 3 (1.5) 3 (2.1) NA NA
(Re)placement central intravenous catheters 32 (16.2) 1 (0.7) 31 (53.4)
Miscellaneous 31 (15.7) 21 (15.0) 10 (17.2)
Replacement therapy with factor concentrate, hospitalization and blood loss
Mode of infusion
Continuous 115 (58) 88 (63) 27 (47)
Bolus 83 (42) 52 (37) 31 (53)
Product type
Plasma derived 46 (23) 41 (29) 5 (9)
Recombinant 152 (77) 99 (71) 53 (91)
Duration of hospitalization (days) 9 [5-12] 9.0 [5-14] 7 [6-10]
Complications during the perioperative period
No. of patients suffering from a complication
Bleeding 48 (24) 45 (32) 3 (5)
Re-operation 6 (3) 6 (4) NA NA
Hemoglobin drop >1,24 mmolL-1 and/
or RBCTF
38 (19) 36 (26) 2 (3)
Bleeding with prolonged 
hospitalization
5 (3) 4 (3) 1 (2)
Thrombosis NA NA NA NA NA NA
No.=number (percentages); Median [IQR=Inter quartile range 25-75%]; cm=centimeter; kg=kilogram; 
kgm-2=kilogram per square meter; FVIII=clotting factor VIII; IUmL-1=international units per milliliter; 
BU=Bethesda Units; VWF=von Willebrand factor; mmolL-1=millimolar per liter; NA=not applicable; 
RBCTF=red blood cell transfusion; *Blood group available in 101 patients (172 surgical procedures); #VWF 
antigen available in 67 patients (118 surgical procedures); $VWF activity available in 57 patients (98 surgical 
procedures)
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(n=86; 61%) were performed, which were most often orthopedic procedures (n=91; 
65%). Children mainly underwent minor surgical procedures (n=47; 81%), most fre-
quently an insertion or removal of a central venous device (n=31; 53%) (Table 2). In 115 
(58%) surgical procedures, FVIII replacement therapy was given by continuous infusion; 
these patients were mainly adults (n=88; 63%). In 83 (42%) surgical procedures, patients 
were treated by bolus infusion (Table 2). In 152 surgical procedures (77%) patients were 
treated with recombinant factor concentrates. Duration of hospitalization was similar in 
both adults and children treated by continuous infusion as compared to bolus infusion 
(adults nine [IQR: 6-15] versus eight [IQR: 4-13] days, p=0.09; children seven [IQR: 6-10] 
versus seven [IQR: 6-10] days, p=0.99).
Achievement of FVIII target range levels
Most perioperative FVIII plasma concentrations were outside the predefined target 
range in both adults and children. Achieved FVIII plasma concentrations in relationship 
to defined target ranges on consecutive days are depicted in Figure 1. In summary, on 
consecutive days deviations of FVIII levels with regard to predefined target range levels 
were increasingly significant (p for trend <0.01). The overall median deviation of FVIII 
plasma concentrations below the lowest required target range level varied from 0.17-
0.11 IUmL-1 for consecutive postoperative days and above the highest required target 
range level from 0.23-0.31 IUmL-1 for consecutive postoperative days (Table 3). In the 
first 24 hours after surgery, 45% of measured FVIII levels were below lowest target range 
level with a median deviation below the lowest required target level of 0.17 IUmL-1. After 
six days of postsurgical hospitalization, 75% of the FVIII levels were above highest target 
range level with a median deviation of 0.31 IUmL-1. No evidence was found with regard to 
changes in dosing regimen over time during the overall study period as the proportion 
of underdosed and overdosed patients did not differ for surgical procedures performed 
before 2005 and after 2005 (Supplemental Table 2). In addition, specific treatment center 
was not associated with proportion of under- or overdosing (data not shown).
Predictors of underdosing and (excessive) overdosing
In our logistic regression model, blood group O and major surgery were predictive of un-
derdosing (respectively OR=6.3 [95%CI: 2.7-14.9] and OR=3.3 [95%CI:1.4-7.9]) (Table 4). 
Complementary, blood group non-O, increasing age (per year) and replacement therapy 
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with a plasma derived product and by bolus infusion were predictive of overdosing 
(Table 4). Replacement therapy with a plasma derived product and by bolus infusion 
and increasing age (per year) were associated with excessive overdosing.
Clotting factor VIII concentrate consumption
For the first surgical procedure in each individual, the median total amount of infused 
FVIII concentrate per kilogram per day during hospitalization was significantly higher in 
children when compared to adults (children: 93 IUkg-1 day-1 [IQR: 75-119 IUkg-1 day-1] and 
adults: 57 IUkg-1 day-1 [IQR: 41-77 IUkg-1 day-1]; p<0.001) (Table 5). Mode of infusion, type 
of concentrate (plasma derived or recombinant) and severity of surgical procedures 
were not associated with the amount of FVIII consumption for both children and adults. 
As expected, an overall decrease was observed in infused FVIII concentrates over con-
Table 4. Predictors of underdosing and (excessive) overdosing
OR 95% confidence interval
Underdosing
Age (per year)* 1.03 0.99 - 1.07
Blood group O** 6.30 2.65 - 14.93
Major surgical procedure$ 3.30 1.38 - 7.90
Overdosing
Age 1.02 1.02 - 1.03
Blood group O** 1.47 1.13 - 1.91
Product type (recombinant) $$ 0.52 0.38 - 0.72
Mode of infusion (bolus)*** 1.78 1.34 - 2.37
Excessive overdosing
Age 1.02 1.01 - 1.02
Product type (recombinant)$$ 0.48 0.37 - 0.63
Mode of infusion (bolus)*** 1.92 1.45 - 2.54
Stepwise backward logistic regression analysis. OR=Odds Ratio;
CI=Confidence Interval;* Increasing age (per year) ** versus blood group non-O; *** versus continuous infu-
sion; $ versus minor surgical procedure; $$ versus plasma derived clotting factor concentrate
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Figure 2. Total amount of FVIII consumption underdosed and overdosed in the perioperative setting
Figure 2 shows the total amount of FVIII consumption underdosed and overdosed in the perioperative 
setting
Figure 3. Blood group O patients have more bleeding complications
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Figure 3 shows that blood group O patients suffer from more bleeding complications in comparison to 
blood group non O patients.
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secutive postoperative days, both in adults and children, as set target range values also 
decrease accordingly (p for trend < 0.001) (Supplemental Figure 1).
Total FVIII concentrate consumption of the whole study cohort during the entire periop-
erative period amounted to a total of 6,800,000 IU. If predefined FVIII target ranges had 
been maintained according to the National guidelines this would have led to a reduction 
of consumption of FVIII concentrate of 44% (Figure 2). This percentage was calculated 
by subtracting the total amount of FVIII concentrate under lowest target range level e.g. 
491,000 FVIII IU from FVIII concentrate consumed above highest target range level e.g. 
3,510,000 IU and dividing it by total consumption as defined earlier.
Perioperative blood loss and hemostasis
Forty-five (32%) of the surgical procedures in adults and three (5%) surgical procedures 
in children were complicated by perioperative bleeding. In patients with blood group O 
overall more bleeding complications were observed than in patients with blood group 
non-O (blood group O, n=29 (64%); blood group non-O, n=16 (36%); p=0.047; OR=2.02 
95%CI[1.01-4.09]) (Figure 3). These patients also experienced more severe bleeding as 15 
(33%) severe bleeding complications were observed in patients with blood group O in 
comparison to 8 (18%) in blood group non-O patients. Overall, with regard to severity of 
bleeding, six of the 45 bleeding complications in adult patients and none of the bleeding 
complications in pediatric patients required a reoperation (Supplemental Table 3 and 
Table 4). These six reoperations encompassed five for intra-articular bleeding in a total 
knee replacement and one for bleeding after drain removal. Bleeding complications 
were overall more common in patients undergoing an orthopedic surgical procedure.
Overall, we did not find an association between bleeding complications and actual FVIII 
plasma level at the time of the bleeding episode in adults (median FVIII level for patients 
with a bleeding complication or without a bleeding complication: 0.81 IUmL-1 [0.65-0.99 
IUmL-1] or 0.82 IUmL-1 [0.62-1.07 IUmL-1]; p=0.92) and children (median FVIII level for 
patients with a bleeding complication or without a bleeding complication: 0.66 IUmL-1 
[0.43-0.92 IUmL-1] vs 0.72 IUmL-1 [0.46-0.92 IUmL-1]; p=0.66). No thrombotic complica-
tions and no deaths were reported.
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DISCUSSION
This is presently the largest study evaluating perioperative FVIII concentrate dosing in 
hemophilia A patients. Our data illustrates the challenges of maintaining FVIII target 
levels in current perioperative dosing and the magnitude of underdosing and overdos-
ing when targeting prescribed FVIII ranges according to guidelines in a resource rich 
country. In this study, depending on postoperative day, 7-45% of achieved FVIII plasma 
levels were under the lowest predefined target range level recommended by National 
guidelines and 33-75% above the highest predefined target range level.3 If target ranges 
had been adequately maintained, an impressive overall reduction of FVIII consumption 
of 44% would have been possible. Patients with blood group O were at increased risk of 
underdosing and had a higher rate of both overall bleeding and severe bleeding com-
plications. In this retrospective analysis, we were not able to demonstrate an association 
between an actual lower FVIII plasma level at the time of a bleeding episode, as FVIII 
levels were often not available directly during the event. The data, do however suggest 
that patients with blood group O may have a higher perioperative bleeding risk due to 
overall lower FVIII levels. Most probably, this is explained by lower VWF levels in patients 
with blood group O. Unfortunately, VWF antigen and activity levels were only sporadi-
cally available in this study, as perioperative VWF testing is currently not common prac-
tice, making it difficult to analyze this association. Previous studies, have reported that 
lower VWF levels lead to shorter FVIII half-life as VWF protects FVIII against proteolytic 
degradation in the circulation.20-23 Inversely in this study, overdosing was predicted by 
blood group non O and older age. This also may be explained by VWF levels, which 
are generally higher in blood group non-O and higher with increasing age.26 Further 
supportive of this hypothesis, are data collected by Kahlon et al. in healthy individuals, 
describing a decrease of VWF levels 30 minutes after incision and higher VWF levels 
one day after surgery.27 If patients with lower baseline VWF levels decrease according 
to this principle at initiation of surgery and are not able to subsequently increase VWF 
levels, this may coincide with a higher perioperative bleeding risk. Further predictors 
of overdosing, other than blood group non O and older age, were replacement therapy 
with plasma derived clotting factor concentrates and treatment by bolus infusion.
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Strengths and limitations
Strengths of the study are the large number of included patients and surgical procedures, 
not documented before, as well as the fact that patients were included from numerous 
treatment centers all working dedicatedly according to one National guideline.3 The 
guideline was developed and approved by all hemophilia treatment centers collabo-
rating within the NVHB (Hemophilia Doctors Organization in the Netherlands). In the 
study, actual dosing regimens and subsequent FVIII plasma samples over the past ten 
years were collected thoroughly and complications were extensively documented. Data 
were collected and checked by two independent researchers. The cohort is therefore 
representative of severe and moderate hemophilia A patients undergoing surgery in a 
resource rich country.
Study limitations include the retrospective nature of the data. Therefore, not all peri-
operative patients were monitored as intensively, and analyses of modifiers of con-
sumption were difficult as data were not collected prospectively according to protocol. 
Major surgical procedures may be overrepresented in the study as these were of course 
monitored more intensely than minor surgical procedures. However, earlier reports 
show a similar prevalence of surgical procedures in other hemophilia populations.28, 29 
In addition, quantification and documentation of blood loss is notoriously difficult, es-
pecially in retrospective studies. Due to this fact, criteria were applied for blood loss as 
defined by the ISTH18, leading to possible over reporting of blood loss as this definition 
is quite sensitive. Therefore, we additionally reported clinically relevant, severe bleeding 
as defined simply and reliably by necessary RBCT and/or reoperation.
Potentially, the use of one-stage laboratory assays to measure FVIII plasma levels may 
lead to biased results with regard to achieved FVIII plasma levels. Especially, as these 
assays generally lead to higher FVIII levels in higher FVIII ranges than two stage (chro-
mogenic) assays.30-32 This, with the exception of the measured FVIII levels after infusion 
of one specific B domain-deleted FVIII concentrate, which was also administered in this 
study. In this B domain-deleted FVIII concentrate, one stage assays lead to measure-
ment of lower FVIII plasma levels, potentially leading to overdosing specifically in these 
patients. Due to the latter, consumption was analyzed extensively according to product 
type in our study cohort. However, no association was found between consumption of 
FVIII concentrate and specific product type. Prospective studies in perioperative hemo-
philia A patients are required to verify the data with regard to FVIII levels and type of 
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FVIII assay. Currently, the one stage assay is overall still the most applied assay and study 
results depict daily practice in the majority of Hemophilia Treatment Centers.
FVIII consumption and mode of infusion of replacement therapy
In our study, median total amount of infused FVIII concentrates per kilogram per day 
during hospitalization was comparable to previous reports, both in adults and in 
children.13, 33-38 As expected, the amount of infused FVIII concentrate per kilogram was 
higher in children when compared to adults, which is explained by a higher clearance 
of FVIII in young children resulting in a shorter half-life19 and due to a larger volume of 
distribution in children in comparison with adults.39 Consequently, variables associated 
with FVIII consumption were analyzed separately for both children and adults.
The extent and timing of FVIII underdosing and overdosing in the perioperative period 
have not been reported earlier. Both underdosing, most significant directly after surgery 
and (excessive) overdosing, most significant more than 6 days after surgery, can clearly 
be improved. During the entire study period, clinical practice in participating centers 
with regard to perioperative management of replacement therapy did not change as 
guidelines were not altered. Patients with preoperative or perioperative FVIII levels that 
were lower than expected, received additional bolus infusion(s) of FVIII concentrate to 
achieve target ranges as set by the consensus. Discrepancies between target ranges and 
actual FVIII plasma levels increased consecutively during the perioperative period. Thus, 
suggestive of a focus on prevention of bleeding and not on prevention of overdosing.
In two prospective studies by Batarova et al. and Bidlingmaier et al., savings of 30-36% 
of FVIII concentrate consumption were calculated for continuous versus intermittent 
bolus infusion.9, 16 Our data however does not support continuous dosing as more cost 
reductive when compared to intermittent bolus infusion. This may be due to the follow-
ing factors. In our study, total amount of FVIII concentrate was corrected for duration 
of hospitalization, and not only for body weight as in previous studies. Furthermore, 
confounding by indication, e.g. severity of surgical procedure may have influenced 
outcome, as continuous infusion was more often used in more severe procedures. More-
over, when intermittent bolus infusion was applied in our study it was often dosed more 
frequently per day in lower doses, therefore mimicking continuous dosing. All of the 
above may have led to smaller differences in FVIII concentrate consumption between 
modes of administration of therapy. Lastly, type of concentrate and severity of surgical 
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procedure were not associated with the overall amount of FVIII consumption in both 
children and adults. Most probably due to collinearity between these specific variables.
Complications
In this cohort, representative for surgical patients in Hemophilia Treatment Centers in re-
source rich countries28, 29 bleeding complications were seen in 32% of adult patients and 
in 5% of pediatric patients. This high percentage seems due to the broad ISTH definition 
applied in our study for bleeding, not used in comparable studies.29, 33, 35, 40 Cases were 
mainly defined by the decrease of hemoglobin of ≥1.24 mmol/l included in the defini-
tion, which was not accompanied by hemodynamic problems or low FVIII plasma levels 
in study patients. Severity of bleeding was similar to earlier reports, as the percentage of 
study patients requiring a reoperation (3%) was comparable to a previous study, which 
reported a percentage of 2.7%.33 We could not demonstrate that FVIII plasma levels were 
under lowest target range levels in patients with bleeding complications.33 Although 
this may be due to a lack of FVIII testing at the bleeding occurrence and FVIII plasma 
levels measured after acute FVIII concentrate administration.
Theoretically, in our study, optimal maintenance of predefined target FVIII levels by 
refined dosing would have led to a reduction of FVIII consumption of maximally 44%, 
with a concomitant reduction of treatment costs. However, when using a strategy of 
optimal target value maintenance, it is of course not possible to completely eliminate 
underdosing and overdosing as the logistic delays caused by laboratory monitoring and 
assessment of FVIII values and adjustment of treatment will persist. Although currently 
not yet available due to the lack of perioperative PK population models, we believe 
more optimal treatment will consist of individually dosed FVIII concentrate based on 
an individual FVIII PK-profile with adaptive dosing according to a perioperative FVIII PK 
population model. Until recently, most studies on PK-guided dosing were performed 
in the prophylactic setting.41-43 In the few studies in which perioperative PK profiling is 
mentioned it was solely used to establish a preoperative PK- guided loading dose.9, 11, 13
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CONCLUSION
In conclusion, our findings demonstrate significant underdosing and (excessive) over-
dosing of FVIII concentrate and identify its predictors, during the perioperative period 
with current dosing strategies based on body weight and crude estimations of clearance. 
Blood group O proved to be predictive of underdosing and was associated with a higher 
risk of bleeding complications; blood group non-O was demonstrated to be a predictor 
of overdosing. With regard to excessive overdosing, older age and replacement therapy 
by bolus infusion were shown to be predictive. Currently available PK population mod-
els for FVIII replacement therapy in the prophylactic setting support that age influence 
FVIII plasma concentrations significantly.20, 41 These data underline that quality of care 
and cost-effectiveness can be improved by future refining of dosing strategies based on 
individual patient characteristics such as the predictors blood group and mode of infu-
sion. However, we also believe that not all variables of influence on dosing and clearance 
of FVIII concentrate have yet been defined. Therefore, novel developments with regard 
to pharmacokinetic (PK)-guided dosing based on PK population models and Bayesian 
analysis, taking both known and unknown modifying factors into account as proposed 
by Bjorkman et al.41 are more than promising.
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Supplemental Tables
Supplemental Table 1. Classification of included surgical procedures
Surgical Type High Risk** Major Minor
General
Laparotomy Major
Liver Biopsy Major
Cholecystectomy and exploration of common duct Major
Colo-Rectal Surgery
Excision of anal fistula Minor
Gastro duodenoscopy (biopt) Major
Diagnostic laparoscopy Major
Vascular
Amputation of limb Major
Cardiothoracic Surgery
Insertion of defibrillator Major
Coronary Angioplasty High
Coronary Artery Bypass Graft (CABG) High
Excision of mediastinal mass High
Neurosurgery
Craniotomy High
Meningioma High
Shunt procedures High
Orthopedics
Arthroscopy (shoulder/knee) Major
Foot or ankle surgery Minor
Incision drainage Minor
Internal fixation of tibia or fibula Major
Revision of total hip and knee replacement Major
Scoliosis surgery High
Total joint replacement (elbow, hip, shoulder, knee) Major
Hand or wrist surgery Minor
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Supplemental Table 1. Classification of included surgical procedures (continued)
Surgical Type High Risk** Major Minor
Urology
Circumcision Minor
Vasectomy Minor
Prostatectomy Major
Urethroplasty Major
Urerthrolithotomy Major
Maxillofacial
Bimaxillary osteotomy Major
Craniofacial Surgery High
ENT (Ear-Nose-Throat)
Adenoidectomy Minor
Adenoido-tonsillectomy Major
ENT: insertion of stents Minor
Tonsillectomy Major
Eye Surgery
Orbital surgery Major
Catarract/Virectomy/Retinal surgery Minor
Miscellaneous
Dental surgery Minor
Drainage of abscess Minor
Excision burns scars Minor
Excision of lipoma Minor
Hernia repair (inguinal/umbilical) Minor
Central venous catheter removal/insertion Minor
*Surgical risk score according to Koshy et al. 1995; **Excluded
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Supplemental Table  2. Frequency of underdosing and overdosing in the perioperative period before 
2005 and after 2005
2000 - 2013 < 2005* > 2005**
Underdosing (%)
0-24 hours 45 38 47
24-120 hours 7 10 4
>120 hours 8,5 12 8
Overdosing (%)
0-24 hours 33 36 31
24-120 hours 59 58 58
>120 hours 73 64 73
Supplemental Table 3. Characteristics of patients with a severe bleeding complication requiring a reop-
eration
Patient Surgical 
procedure
Day of 
occurrence of 
the bleeding 
complication
Description FVIII 
level 
(IUmL-1)
Mode of 
infusion
Other 
medication
Blood 
group
1 Total knee 
replacement
Day 5 Intra-articular 
bleed
0.99 Bolus Heparin Non-O
2 Total knee 
replacement
Day 5 Intra-articular 
bleed
1.03 Continuous Heparin O
3 Total knee 
replacement
Day 4 Intra-articular 
bleed
0.68 Continuous Tranexamic 
acid
O
4 Fixation of 
hip/humerus
Day 2 Bleed after 
removal of a 
drain
0.99 Continuous Tranexamic 
acid
O
5 Total knee 
replacement
Day 7 Intra-articular 
bleed
0.50 Continuous Tranexamic 
acid, heparin
O
6 Total knee 
replacement
Day 9 Intra-articular 
bleed
0.64 Continuous Tranexamic 
acid, heparin
O
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Supplemental Table  4. Surgical and patient characteristics of all bleeding complications and severe 
bleeding complications
Bleeding complication* Severe bleeding 
complication
No yes Reoperation RBCTF
Type of surgical procedure
General 4 2 0 0
Colo-rectal 4 1 0 1
Vascular 0 1 0 1
Cardio-thoracic 0 1 0 0
Orthopedic 64 30 6 12
Urology 10 2 0 1
Maxillofacial 1 1 0 1
Ear-Nose-Throat 7 4 0 1
Eye 3 0 0 0
(Re)placement central intravenous catheters 32 0 0 0
Miscellaneous 25 6 0 1
Mode of infusion
Continuous 83 32 5 12
Bolus 67 16 1 6
Blood group
O 60 29 5 10
Non-O 67 16 1 7
*according to the ISTH definition; RBCTF=red blood cell transfusion
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Supplemental Figure
Supplemental Figure 1. Amount of infused FVIII clotting factor concentrate.
Figure 1 shows a decrease in total amount of infused FVIII concentrate per kilogram on consecutive days of 
hospitalization for both adults and children, p for trend is <0.001 (F(1,354)=41.4) tested by one-way ANOVA. 
IUkg-1=International Units per kilogram
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SUMMARy
Background Hemophilia B is caused by a deficiency of coagulation factor IX (FIX) and 
characterized by bleeding in muscles and joints. In the perioperative setting, patients 
are treated with FIX replacement therapy striving for physiological FIX levels to secure 
hemostasis. Targeting of specified FIX levels is challenging and requires frequent moni-
toring and adjustment of therapy.
Objective We conducted a retrospective international multicenter study to evaluate 
perioperative management in hemophilia B, including monitoring of FIX infusions 
(consumption) and observed FIX levels, whereby predictors of low and high FIX levels 
were assessed.
Methods Hemophilia B patients with FIX<0.05 IUmL-1 undergoing elective, minor or 
major surgical procedures between 2000-2015 were included. Data were collected on 
patient, surgical and treatment characteristics. Observed FIX levels were compared to 
target levels as recommended by guidelines.
Results A total of 255 surgical procedures were performed in 118 patients (median 
age 40 years, median body weight 79 kg). Sixty percent of FIX levels within 24 hours of 
surgery were below target with a median difference of 0.22 IUmL-1 [IQR 0.12-0.36]; while 
> six days after surgery 59% of FIX levels were above target with a median difference 
of 0.19 IUmL-1 [IQR 0.10-0.39]. Clinically relevant bleeding complications (necessity of a 
second surgical intervention or red blood cell transfusion) occurred in three procedures 
(1.2%).
Conclusion This study demonstrates that targeting of FIX levels in the perioperative 
setting is complex and suboptimal, but despite this bleeding is minimal. Alternative 
dosing strategies taking patient and surgical characteristics, as well as pharmacokinetic 
principles into account, may help to optimize and individualize treatment.
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INTRODUCTION
Hemophilia B is an X-linked hereditary bleeding disorder characterized by a deficiency 
of coagulation factor IX (FIX). Treatment consists of prophylactic or on demand replace-
ment therapy with recombinant or plasma derived FIX concentrates. However, replace-
ment therapy with factor concentrates is costly. In the United Kingdom, 60 million 
international units of FIX concentrates are administered annually in 663 hemophilia B 
patients.1 This will most probably increase further in the near future, due to the aging 
hemophilia patient population and necessity of orthopedic surgery for joint replace-
ment.
In the perioperative setting, patients receive FIX concentrates to normalize FIX levels for 
7-10 consecutive days postoperatively. Efficacious perioperative treatment is of impor-
tance to prevent underdosing with a risk of bleeding and overdosing with a possible risk 
of thrombosis and waste of expensive concentrates. However, treatment is complex due 
to a large interpatient variability which is not taken into account in National guidelines. 
Recently, we identified both underdosing and overdosing in perioperative hemophilia 
A patients and the need for optimization of treatment strategies.2 Collected data were 
subsequently used to construct a population pharmacokinetic (PK) model, currently 
being validated in a randomized controlled trial.3 Few studies have reported on safety 
and efficacy of perioperative management in hemophilia B.4, 5 To evaluate perioperative 
management, we conducted an international multicenter retrospective observational 
study to collect FIX levels after factor IX concentrate administration during and after 
minor and major surgery as well as clinical outcome measures (FIX consumption and 
bleeding/thrombotic complications) in order to identify predictive factors of low and 
high FIX levels.
METHODS
Patients
In this international multicenter retrospective observational cohort study, patients were 
included with severe and moderate hemophilia B (FIX <0.05 IUmL-1) who underwent elec-
tive minor or major surgical procedures with FIX replacement therapy between January 
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1st 2000 and December 1st 2015. The procedures were classified by surgical risk score as 
established by Koshy et al.6 Patients attended one of ten Hemophilia Treatment Centers 
in the Netherlands and United Kingdom (Erasmus University Medical Center Rotterdam; 
Academic Medical Center Amsterdam; University Medical Center Groningen; Leids Uni-
versity Medical Center Leiden and Radboud university medical center Nijmegen; Great 
Ormond Street Haemophilia Centre, London; Arthur Bloom Haemophilia Centre, Cardiff, 
Wales; Katharine Dormandy Haemophilia Centre, Royal Free London; Churchill Hospital, 
Oxford; The Royal London Hospital, London). Patients received recombinant or plasma 
derived FIX concentrates to normalize FIX levels. Administered recombinant FIX con-
centrate was Benefix (Pfizer Wyeth Pharmaceuticals Inc, Kent, UK). Plasma derived FIX 
concentrates included: Alphanine (Grifols Biologicals Inc. Los Angeles, USA), Replenine 
(BPL Bio Products Laboratory, Hertfordshire, UK); Haemonine (Biotest Pharma GmbH, 
Dreierich, Germany), Mononine (CSL Behring GmbH, Marbourg, Germany), Nonafact 
(Sanquin, Amsterdam, the Netherlands). Patients with possible disseminated intravas-
cular coagulation due to sepsis and patients who developed FIX neutralizing antibod-
ies during the perioperative period were excluded. The study was not subject to the 
Medical Research Involving Human Subjects Act and was approved by all Medical Ethics 
Committee in the Netherlands. In the United Kingdom, the study was approved by the 
Research Ethics Committee (NRES committee South Central-Berkshire, REC reference 15/
SC/0367); an opt-out consent procedure was used to collect anonymized clinical data.
Objective
Study objective was to evaluate perioperative management of hemophilia B patients by 
documentation of timing and dosing of FIX infusions, and observed FIX levels, compared 
to target FIX levels according to National and/or hospital guidelines (Table 1).7 Moreover, 
clinical outcome measures were assessed, consisting of FIX consumption and identifica-
tion of bleeding and thrombotic complications. Also, predictors of low and high levels 
were identified by collection of data on patient, surgical and treatment characteristics.
Methods
The following information was extracted from the medical notes; patient characteristics, 
including: age, body weight, baseline FIX level and history of FIX neutralizing inhibit-
ing antibodies. Surgical and treatment characteristics consisted of severity of surgical 
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procedure (minor and major), mode of infusion (continuous and bolus infusion), type of 
product (recombinant and plasma derived FIX concentrates), FIX concentrate infusion 
time and dose, and time of FIX level monitoring measured in IUmL-1. FIX levels were 
monitored daily and measured by one-stage assays in participating centers according 
to local protocol. Bleeding complications were defined as need of a second surgical 
intervention, hemoglobin decrease of >1.24 mmolL-1 (>20 gL-1) and/or red blood cell 
transfusion, or bleeding prolonging hospitalization, according to the International So-
ciety of Thrombosis and Haemostasis guidelines for major bleeding.8 Clinically relevant 
Table 1.  Specifications of perioperative replacement therapy, definition of bleeding complications and 
typical surgical procedures
Specified FIX target ranges in the perioperative period*
Time FIX target level (IUmL-1)
Day Hours
1 0-24 0.80-1.00
2-5 24-120 0.50-0.80
≥6 >120 0.30-0.50
*According to the National and/or hospital guidelines of the Netherlands and United Kingdom
IUmL-1 = International Units per milliliter
Definition of bleeding complications$ Definition of clinical relevant bleeding
Re-operation Re-operation
Red blood cell transfusion Red blood cell transfusion
Hemoglobin drop >1,24 mmolL-1
Bleeding with prolonged hospitalization
$According to the International Society of Thrombosis and Haemostasis6
Examples of typical minor and major surgical procedures included in the study#
Minor Major
Dental procedures or surgery Total knee/ hip and shoulder replacement
Excision of lipoma Adenoido-tonsillectomy
Insertion/removal of intravenous catheters Colo-rectal surgery
Vascular surgery
Maxillo-facial surgery (bimaxillary osteotomy)
#According to the surgical risk score of Koshy et al.4
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bleeding complications were defined as bleeding complications requiring a second 
surgical intervention and/or necessity of a red blood cell transfusion. The duration of 
the perioperative period in the study was equivalent to duration of hospitalization (day 
of discharge minus day of surgery and start of infusion of FIX concentrates).
All patients received replacement therapy with FIX concentrate during hospitalization 
according to National and/or hospital guidelines with daily monitoring of FIX, while 
aiming for target FIX levels as prescribed (Table 1).7 Perioperative treatment in severe 
and moderate hemophilia B patients consisted of FIX bolus infusion of approximately 
100 IUkg-1, followed by either continuous infusion or intermittent bolus infusions.7 Only 
measured trough and steady state FIX levels were compared to predefined FIX target 
ranges. Trough FIX levels were measured prior to next FIX bolus infusion, if treatment 
by bolus was performed. Steady state FIX levels were defined as FIX levels measured 
when FIX concentrate substitution was equal to clearance in patients with treatment by 
continuous infusion. In general, it is assumed that steady state is reached after a loading 
dose is administered and continuous infusion is started. FIX peak levels after FIX bolus 
infusions were not included in analysis of this data set. Low FIX levels were defined as all 
FIX levels below lowest predefined target range level. High FIX levels were defined as all 
FIX levels above highest predefined target range level. FIX levels. A difference of ≥0.20 
IUmL-1 above the highest FIX target range were defined as excessively high. This cut-off 
of 0.20 IUmL-1 was chosen arbitrarily to overcome inclusion of high FIX levels solely due 
to logistic delay of adjustment of treatment.
Potential predictors of FIX levels lower or higher than the target range were identified 
before analysis and based on the potential effects that they may have on PK parameters 
e.g. clearance and/or volume of distribution of infused FIX concentrate. These consisted 
of age, body weight, history of FIX neutralizing inhibiting antibodies, type of product 
(recombinant or plasma-derived FIX), mode of infusion (continuous or bolus infusion), 
severity of surgical procedure. Also the influence of a clinically relevant bleeding com-
plication was evaluated. In calculations of total perioperative FIX consumption, only FIX 
concentrate administered during the hospitalization period and during first surgical 
procedure in each individual patient was included.
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Statistical analysis
The non-parametric Mann Whitney U test was used for comparison of FIX consumption 
between groups. To evaluate trends in FIX consumption a “p for trend analysis by one-way 
ANOVA” was used. A stepwise forward and backward logistic regression analysis was per-
formed to identify predictors of FIX levels lower or higher than target FIX levels with elimina-
tion of variables with p>0.10. A Pearson Chi-Square test was used for comparisons between 
proportions. General characteristics are presented as median and 25-75% interquartile range 
(IQR) and as number and percentages for respectively continuous and categorical variables. 
Data management and statistical analysis were performed with SPSS for Windows, version 
21.0 (SPSS Inc, Chicago, IL, USA). A P-value of <0.05 was considered statistically significant.
RESULTS
A total of 118 severe and moderate hemophilia B patients who underwent a total of 255 
surgical procedures were included. Of these, 85 (72%) were severe hemophilia B patients, 
of which 36 were on prophylactic treatment. Patient characteristics are shown in Table 2. 
Eighty-two adult patients underwent a total of 201 surgical procedures (median age 46 
years; median body weight 85 kg) and 36 children underwent a total of 54 surgical proce-
dures (median age 6 years; median body weight 19 kg). Twenty-five patients with 51 surgical 
procedures were included from Hemophilia Treatment Centers in the Netherlands and 91 
patients with 208 surgical procedures from Hemophilia Treatment Centers in the United 
Kingdom. Only six patients were documented to have had a FIX neutralizing antibody in the 
past. Several patients underwent multiple surgical procedures; with 28 (34%) adult patients 
undergoing ≥ three surgical procedures. In children, 25 (46%) of all surgical procedures con-
sisted of an insertion or removal of a central intravenous catheter; adult patients underwent 
an orthopedic surgical procedure most frequently (n=92; 46%). Most patients (n=199; 78%) 
received their replacement therapy by bolus infusion therapy. In 201 (79%) surgical proce-
dures, patients were treated with recombinant factor concentrates. Children had a higher FIX 
consumption than adults (children: 145 IUkg-1 day-1 [IQR 71-234 IUkg-1 day-1]; adults: 68 IUkg-1 
day-1 [IQR 34-97 IUkg-1 day-1]; p<0.001). In accordance with guidelines, FIX consumption was 
highest on day 1 in both adults and children. Strikingly, FIX consumption did not decrease as 
prescribed during hospitalization from day two until day seven (p for trend = 0.92) (Figure 1).
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Table 2. General characteristics
Total cohort Adults Children
No. (%); or Median [IQR]
Patient characteristics
No. of patients 118 82 36
Age (years) 40 [22-58] 46 [34-59] 6 [2-11]
Body weight (kg) 79 [65-92] 85 [73-95] 19 [13-39]
Severe hemophilia B (<0.01 IUmL-1) 85 (72) 57 (70) 28 (78)
On prophylaxis 36 (31) 28 (34) 8 (22)
Blood group O* 33 (28) 24 (29) 9 (25)
Neutralizing antibodies (historically) 6 (5) 5 (6) 1 (3)
Chronic hepatitis C 47 (40) 46 (56) 1 (3)
Surgical characteristics
No. of surgical procedures 255 201 54
Total no. of patients undergoing:
1 55 33 22
2 31 21 10
≥3 42 28 4
Major surgical procedure 120 (47) 105 (52) 15 (28)
Type of surgical procedure
General 19 (7) 16 (8) 3 (6)
Colo-rectal 16 (6) 14 (7) 2 (4)
Vascular 9 (4) 9 (4) 0 (0)
Cardio-thoracic 3 (1) 2 (1) 1 (2)
Orthopedic 99 (39) 92 (46) 7 (13)
Urological 11 (4) 11 (5) 0 (0)
Maxillofacial 1 (0) 1 (0) 0 (0)
Ear-Nose-Throat 9 (4) 5 (2) 4 (7)
Neurosurgery 1 (0) 1 (0) 0 (0)
Eye surgery 2 (1) 2 (1) 0 (0)
(Re)placement central intravenous catheters 27 (11) 2 (1) 25 (46)
Dental extractions 31 (12) 25 (12) 6 (11)
Miscellaneous 27 (11) 21 (10) 6 (11)
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Perioperative complications
In only three (1.2%) surgical procedures clinically relevant bleeding complications were 
observed. Two of these three patients underwent total knee replacements followed by 
hemarthrosis requiring a second intervention. One of these three patients received a red 
blood cell transfusion after surgery. No association between FIX levels and occurrence 
of a bleeding complication was found. However, FIX testing was limited during bleeding 
events. No predictors of clinically relevant bleeding complications could be established. 
Although one patient was suspected for deep vein thrombosis (DVT), a compression 
ultrasonography was negative.
Table 2. General characteristics (continued)
Total cohort Adults Children
No. (%); or Median [IQR]
Replacement therapy with factor concentrate, hospitalization and blood loss
Mode of infusion
Continuous 56 (22) 54 (27) 2 (4)
Bolus 199 (78) 147 (73) 52 (96)
Product type
Recombinant$ 201 (79) 150 (75) 51 (91)
Plasma derived# 54 (21) 51 (25) 3 (6)
Duration of hospitalization (days) 4 [2-9] 5 [2-11] 4 [2-5]
Complications during perioperative period
No. of patients suffering from a complication
Bleeding
Re-operation 2 (2) 2 (2) 0 (0)
Hemoglobin drop >1,24 mmolL-1 23 (19) 17 (21) 6 (17)
Red blood cell transfusion 1 (1) 1 (1) 0 (0)
Thrombosis 0 (0) 0 (0) 0 (0)
No. = number; IQR = inter-quartile range; kg = kilogram; IUmL-1 = international units per milliliter; * Blood 
group available in 80 patients; $ including BeneFix (Pfizer Wyeth Pharmaceuticals Inc., Kent, UK); # Including 
AlphaNine (Grifols Biologicals Inc. Los Angeles, USA); Replenine (Bio Products Laboratory, Hertfordshire, 
UK); Haemonine (Biotest Pharma GmbH, Dreierich, Germany); Mononine (CSL Behring GmbH, Marbourg, 
Germany); Nonafact (Sanquin, Amsterdam, the Netherlands).
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Observed FIX levels and comparison to target ranges
No differences were observed between observed FIX levels between treatment centers 
and between countries. Daily monitoring of FIX levels revealed that most periopera-
tive FIX levels were outside specified target ranges (Figure 2). More specifically, 60% of 
trough or steady state FIX levels were below target range with a median difference of 
0.22 IUmL-1 [IQR 0.12-0.36 IUmL-1] within 24 hours of the surgical procedure. Relative 
under dosing decreased over time with only 9% of values under target range at six days 
after surgery (median difference 0.09 IUmL-1 [IQR 0.05-0.20 IUmL-1]. Conversely, an in-
crease in proportion of FIX levels above target range was observed over time, with 59% 
of FIX levels above target range with a median difference of 0.19 IUmL-1 [IQR 0.10-0.39 
IUmL-1] six days after surgery.
Predictors of lower and higher FIX levels than target range
When analyzing the complete perioperative period in the total study population, both 
treatment by bolus infusion and minor surgical procedures were predictive of lower FIX 
levels than required by guidelines (respectively OR=5.4 95%CI 3.5-8.3, OR=2.0 95%CI 
1.2-3.2). During the first 24 hours after surgery, only bolus infusion was predictive of 
lower FIX levels in comparison to continuous infusion (OR=6.1 95%CI 2.8-13.4) (Table 
Figure 1. Perioperative FIX consumption on consecutive days
FIX consumption on consecutive days postoperatively. The amount of FIX administered factor concentrates 
was higher on day 1 in comparison to following days. P-for trend analysis using one-way ANOVA showed no 
differences between amount of FIX concentrates administered postoperatively.
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3). Occurrence of a clinically relevant bleeding complication and treatment with con-
tinuous infusion were associated with excessively high FIX levels (≥0.20 IUmL-1 above 
target). No differences were observed between achieved FIX levels between treatment 
centers or between countries (data not shown).
Figure 2. Achieved trough and steady state FIX levels in the perioperative period
Frequency of lower and higher FIX levels than target range and median difference of target range 
0-24 hours 24-120  hours >120 hours
Median difference 
(IUmL-1) [IQR]
Median difference 
(IUmL-1) [IQR]
Median difference 
(IUmL-1) [IQR]
Total no. of samples 232 381 273
Lower FIX levels 140 (60) 0.22 [0.12-0.36] 81 (21) 0.11 [0.05-0.19] 25 (9) 0.09 [0.05-0.20]
Higher FIX levels 41 (18) 0.15 [0.08-0.28] 148 (39) 0.16 [0.09-0.32] 162 (59) 0.19 [0.10-0.39]
Achieved trough and steady state FIX levels are shown of both patients treated by bolus infusion replace-
ment therapy (blue) and by continuous infusion (red). Bolus infusion therapy was predictive of lower levels 
in the first 24 hours after surgery in comparison to replacement therapy by continuous infusion. Frequency 
of lower and higher FIX levels than target range with median difference in IUmL-1 and corresponding 25-
75% interquartile range (IQR) during the perioperative period are shown corresponding to specified target 
ranges (green) as defined by National and/or hospital guidelines.
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DISCUSSION
This is the largest cohort of perioperative hemophilia B patients described to date with a 
total of 255 surgical procedures in 118 patients. This study demonstrates the challenges 
of perioperative FIX concentrate dosing as most perioperative FIX levels were outside 
the predefined target ranges recommended by National and/or hospital guidelines. 
Importantly, 60% of trough and steady state FIX levels were below the target level in the 
first 24 hours after surgery, while 59% of FIX levels were above target more than six days 
after surgery. Despite the lower FIX levels clinically relevant bleeding complications 
were uncommon (3/255, 1.2%).
The lower FIX levels observed immediately after surgery in our study, are most likely 
due to increased clearance of FIX concentrate during and directly after surgery4 as well 
as increased consumption of FIX due to activation of hemostasis by tissue damage and 
Table 3. Predictors of lower and (excessive) higher FIX levels than target range*
OR 95%CI
Lower FIX levels (0-24 hours)
Bolus infusion (versus continuous) 6.1 [2.8-13.4]
Age (increasing per year) 1.0 [1.00-1.03]
Lower FIX levels (total perioperative period)
Minor surgical procedure (versus major) 2.0 [1.2-3.2]
Bolus infusion (versus continuous) 5.4 [3.5-8.3]
Age (increasing per year) 1.0 [1.00-1.02]
Higher FIX levels
Continuous infusion (versus bolus) 3.1 [2.2-4.5]
Age (decreasing per year) 1.0 [1.0-1.0]
Excessive higher FIX levels
Continuous infusion (versus bolus) 1.6 [1.03-2.5]
Bleeding complication (versus not present) 2.8 [1.4-5.8]
*Stepwise forward and backward logistic regression analysis. OR=Odds Ratio; CI=Confidence Interval
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blood loss. Bolus infusion therapy was predictive of FIX levels lower than target range, 
most prominently in the first 24 hours after surgery. This is in accordance to pharmaco-
kinetic principles as bolus infusions generally lead to overall lower trough levels when 
frequency of dosing is not sufficient. In addition, the somewhat higher FIX levels in 
patients treated by continuous infusion may be attributed to overall lower FIX clearance 
rates due to saturation of FIX binding sites and additional extravascular localization of 
FIX.5 Moreover, it should be considered that clinicians may have neglected to adapt con-
tinuous infusion rates and may have tolerated or aimed for higher FIX levels in patients 
undergoing major surgical procedures. This is further supported by the observation, 
although not remarkable, that minor surgical procedures were predictive of underdos-
ing, when the total perioperative period was evaluated. Minor surgical procedures are 
often treated for a shorter period of time, with possible aiming of lower FIX levels. Also, 
guidelines do not distinguish between severity of surgical procedure.7 Furthermore, 
as may be expected, patients with a clinically relevant bleeding complication showed 
excessively high FIX levels, due to repetitive bolus infusions and/ or increased infusion 
rates in cases of continuous infusion.
Study strengths and limitations
The large number of patients and variety of surgical procedures included from ten Aca-
demic Hemophilia Treatment Centers in two countries makes this study representative 
for perioperative management in high income countries in severe and moderate severe 
hemophilia B. Moreover, no differences were observed between observed FIX levels and 
FIX consumption between these treatment centers and between countries. This study 
is one of the few studies evaluating perioperative management in hemophilia B with 
identification of predictors of FIX levels lower and higher than target ranges specified 
by guidelines. Study limitations include the retrospective nature of the data. However, 
treatment characteristics, including FIX timing and dosing and timing of FIX sampling 
were collected thoroughly, and complications were extensively documented. Yet, docu-
mentation of blood loss remained difficult, although we do feel that clinically relevant 
bleeding defined as necessity of a second surgical intervention and/or necessity of a 
red blood cell transfusion depicts noteworthy bleeding in this cohort of perioperative 
patients. Patients with an established neutralizing antibody to FIX were excluded from 
analysis as these influence FIX clearance due to other, immunological mechanisms. This 
68 • Chapter 3
study may lead to both refinement of current guidelines with regard to target ranges. 
In addition, these data underline the potential of alternative dosing strategies based on 
pharmacokinetic principles which are more specific than body weight and crude estima-
tions of clearance currently applied.
Perioperative bleeding
Overall in our study population, perioperative bleeding in hemophilia B in both coun-
tries was rare (1.2%), and was not correlated with low FIX levels. However, FIX testing 
was limited during bleeding events. In literature, in two case series consisting of 36 and 
25 surgical procedures respectively4, 5, higher percentages of clinically relevant bleed-
ing events as defined in our study have been reported (4-8.3%). In addition, most of 
these included patients underwent an orthopedic surgical procedure. Contrastingly, in a 
cohort of 74 hemophilia B patients undergoing 81 surgical procedures, no red blood cell 
transfusions were reported and hemostatic efficacy was rated as excellent by surgical 
teams.9 In this study, also different minor and major surgical procedures were included, 
which was similar compared to our cohort. Exceptions are made for certain surgical 
procedures as a recent report by Kapadia et al. showed that lower extremity total 
joint arthroplasty leads to significantly more red blood cell transfusions in hemophilia 
patients (15.1%) in comparison to a large matched cohort without a known bleeding 
history (9.8%); OR 1.60 (95% CI 1.11-2.31).10
Current guidelines and possible refinements
Although target ranges in most National and/or hospital guidelines do not differ be-
tween hemophilia A and B7, 11-13, other international guidelines such as set by the World 
Federation of Hemophilia (WFH), prescribe lower FIX levels in the perioperative set-
ting.14 In developing countries with scarce resources, even lower FIX levels are advised 
(FIX levels of 0.20-0.50 for 1-5 days postoperatively).14 A low frequency of perioperative 
bleeding under replacement therapy with lower FVIII and FIX target levels was reported 
by Srivastava et al. in a single center respective study of 11 hemophilia A and seven 
hemophilia B patients.15 In this study, FIX trough levels were set at 0.15-0.30 IUmL-1 on 
day 1-3 postoperatively and at 0.10-0.20 IUmL-1 more than four days postoperatively, 
until the wound had healed and sutures had been removed. Only one of these seven 
hemophilia B patients experienced postoperative bleeding due to surgical reasons as 
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verified by the surgeon. Our study supports these last findings, as in only three of 255 
surgical procedures (1.2%) a clinically relevant bleeding complication was documented 
despite underdosing within 24 hours after surgery in 60% of FIX levels. We conclude 
that there may be growing evidence that it may be possible to maintain lower FIX target 
ranges in the perioperative setting.
Perioperative FIX consumption and individualization of therapy
Although a significant proportion of the study population was underdosed without 
bleeding, a significant proportion was overdosed, especially >6 days after surgery with 
59% of trough and steady state FIX levels above target. Current costs of health care for 
society warrant avoidance of excessive dosing without a clinical effect. Overdosing may 
be prevented by more individualized dosing strategies that take patient, and surgical 
characteristics as well as individual pharmacokinetics of concentrates into account.
Children had a higher FIX consumption when compared to adults, which is explained by 
a large volume of distribution and higher clearance.16
In prophylactic treatment, it has been proven that FIX consumption can be significantly 
reduced by individualization of dosing based on pharmacokinetic modelling.17-20 Several 
studies have also shown that preoperative dosing based on an individual pharmaco-
kinetic profile is safe, effective and applicable.5, 21 However, the real challenge is to 
implement iterative pharmacokinetic-guided FIX concentrate dosing in the periopera-
tive period. This has not been possible to date, as a reliable perioperative population 
pharmacokinetic model has been lacking. Widespread application of such a model will 
help to implement individualization of dosing, thereby increasing the proportion of 
patients with FIX levels within the target range.
This study shows that targeting of FIX levels in the perioperative setting is complex 
and results are suboptimal as both lower and higher levels than targeted are observed. 
Individualization of dosing by identification of predictors of volume of distribution and 
clearance of FIX concentrate may improve outcomes. In addition, a critical assessment 
of current FIX target ranges seems warranted as few bleeding complications occurred in 
patients with lower levels than prescribed by National and/or hospital guidelines. Phar-
macokinetic-guided dosing may help attain this goal, as lowering of FIX target ranges as 
specified ranges can be achieved reliably. Moreover, this may also decrease overdosing 
in the last days of the perioperative period. Therefore, we suggest that construction of 
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population pharmacokinetic models and dosing according to these models will lead to 
refinement of current target ranges in hemophilia B and towards overall optimization of 
perioperative management.
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SUMMARy
Background Von Willebrand disease (VWD) patients are regularly treated with factor 
concentrates in cases of acute bleeding, trauma or surgical procedures.
Objective In this multicenter retrospective study current perioperative management 
with von Willebrand factor (VWF)/Factor VIII (FVIII) (Haemate P®) concentrate in VWD 
patients was evaluated.
Methods VWD patients undergoing minor or major surgery between 2000-2015 and 
treated with VWF/FVIII concentrate (Haemate P®) were included. Achieved VWF:Act/
FVIII:C during FVIII:C-based treatment regimens were compared to predefined target 
levels in National guidelines.
Results In total, 103 VWD patients (148 surgeries) were included: 54 type 1 (73 surger-
ies), 43 type 2 (67 surgeries) and 6 type 3 (8 surgeries). Overall, treatment resulted in 
high VWF:Act/FVIII:C levels, defined as ≥0.20 IUmL-1 above predefined levels. In type 
1 VWD patients, respectively 65% and 91% of trough VWF:Act and FVIII:C levels were 
higher than target levels. In type 2 VWD and type 3 respectively, 53% and 57% of trough 
VWF:Act and 72% and 73% of trough FVIII:C levels were higher than target level. Further-
more, FVIII accumulation over time was observed, with significantly higher levels than 
VWF:Act.
Conclusion High VWF:Act and accumulation of FVIII:C levels was observed after peri-
operative FVIII:C-based replacement therapy in VWD patients, both underlining the 
necessity of more efficient and individualized therapy in order to optimize treatment.
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INTRODUCTION
Von Willebrand Disease (VWD) is the most common inherited bleeding disorder with 
a prevalence of 0.5-1%.1 It is caused by a quantitative or qualitative defect of von Wil-
lebrand Factor (VWF) and is characterized by mucocutaneous bleeding.2 In more severe 
VWD, factor VIII (FVIII) can also be very low, as VWF prevents FVIII from clearance due 
to proteolysis.3 Generally, VWD patients are treated “on demand” with desmopressin 
(DDAVP) or factor concentrate when acute bleeding or trauma occurs, or to prevent 
bleeding in the surgical setting. The aim of treatment is to correct VWF deficiency, and to 
correct FVIII deficiency if this is also present. When patients do not respond adequately 
to DDAVP or have contra-indications for its use, treatment usually consists of combined 
VWF/FVIII factor concentrates amongst which the ratios of VWF activity (VWF:Act) over 
FVIII (FVIII:C) may differ.4, 5
Although clinical symptoms are generally milder than in hemophilia, treatment in VWD 
is more challenging due to variation in VWD disease types and mutations2, 6, interpatient 
variability of residual endothelial VWF production, VWF secretion and clearance, as well 
as heterogeneity in types of factor concentrates with different ratios of VWF:Act/FVIII:C 
and VWF:Act/VWF:Ag.4, 5 Previous studies have reported that surgical procedures can 
be performed safely in VWD patients and that treatment with VWF/FVIII concentrate 
is efficacious.7-16 In many countries, specific target levels are defined in guidelines to 
safeguard hemostasis during surgery. These target values are based on expert opinion 
and limited observational research (Figure 1).17
VWF:Act/ VWF:Ag ratio of available concentrates corresponds with presence of high 
molecular weight multimers (HMWM) and therefore with hemostatic potential. World-
wide, the most frequently used VWF/FVIII concentrate is Haemate P® and is considered 
as gold standard for the management of VWD patients.18 VWF/FVIII concentrates can be 
classified into three different groups according to VWF:Act/FVIII:C and VWF:Act/VWF:Ag 
ratios.4 More specifically, products with a VWF:Act/FVIII:C ratio of approximately 1 (1.2:1; 
low and high content of HMWM). Secondly, with a ratio of >1 (2.4:1 and high content 
of HMWM) and lastly VWF concentrates with a ratio of >10 (10:1 and high content of 
HMWM). The latter, are scarcely applied in the perioperative setting, as FVIII:C is only 
minimally supplemented with these concentrates.19 Moreover, it has been suggested 
that FVIII:C is crucial to prevent surgical bleeding due to its importance in thrombin 
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generation and consolidation of the fi brin plug.16 Furthermore, it has been reported that 
repetitive dosing of concentrates with a VWF:Act/FVIII:C ratio >1 results in less accumu-
lation of FVIII:C than concentrates with a ratio of approximately 1.7
Intensity of perioperative treatment in VWD is dependent on type and extent of the 
surgical procedure, as target levels vary; but is also dependent on type and severity 
of VWD due to varying residual VWF and FVIII levels. In addition, treatment may diff er 
due to interindividual diff erences in pharmacokinetic (PK) parameters such as clearance 
Figure 1. Target VWF:Act and FVIII:C in VWD patients in the perioperative setting*
Preoperative
Loading dose
VWF:Act:    >0.80 IUmL-1
FVIII:C: >0.80 IUmL-1
Severity of surgical 
procedureMinor Major
36-72 hours 
VWF:Act: not defined
 FVIII:C: >0.50 IUmL-1
72-168 hours 
VWF:Act: not defined
 FVIII:C: >0.30 IUmL-1
0-36 hours
VWF:Act:   >0.80 IUmL-1
FVIII:C: >0.80 IUmL-1
Maintenance dose
36-240 hours
VWF:Act: not defined
 FVIII:C: >0.50 IUmL-1
* According to National guidelines17. Guidelines describe a standard perioperative dosing regimen of 
VWD patients undergoing minor and/or major surgery. A loading dose of VWF/FVIII factor concentrate of 
50IUkg-1 FVIII (30-50 IUkg-1 in case of minor surgery) followed by maintenance doses of 15-25 IUkg-1 FVIII 
twice daily, depending on FVIII:C measurements. Both, VWF:Act and FVIII:C are targeted at trough and/or 
steady state levels.
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and half-life of both exogenous and endogenous VWF/FVIII. Studies report that periop-
erative VWF/FVIII concentrate consumption indeed varies substantially, from 27 to 146 
VWF:Act IUkg-1 day-1.7, 16 As achieved VWF and FVIII levels have rarely been evaluated and 
reported in literature in relation to effi  cacy20, we aimed to evaluate current perioperative 
management of VWF/FVIII concentrate in VWD patients. This was done by assessing to 
what extent predefi ned VWF:Act and FVIII:C target levels were actually achieved as well 
as by analyzing predictors of higher or lower VWF:Act and FVIII:C levels than targeted. 
Insight in these factors will help realize more effi  cacious and individualized treatment in 
VWD in the near future.
MATERIALS AND METHODS
This multicenter retrospective observational cohort study was conducted in fi ve Aca-
demic Hemophilia Treatment Centers in the Netherlands (Erasmus University Medical 
Center Rotterdam (n=51); Academic Medical Center Amsterdam (n=15); University 
Medical Center Groningen (n=14); Leiden University Medical Center (n=12), Radboud 
university medical center (n=11). This study was not subject to the Medical Research 
Involving Human Subjects Act, as retrospective anonymized data were analyzed, and 
therefore, according to Dutch law, review by the Ethical Committee and informed con-
sent were not required.
Subject selection
Patients with a clinical and laboratory diagnosis of VWD (historically lowest levels of 
VWF antigen (VWF:Ag) ≤0.30 IUmL-1 and/or VWF:Act ≤0.30 IUmL-1 and/or FVIII:C ≤0.40 
IUmL-1) were included. Patients who underwent a minor or major surgical procedure as 
defi ned by Koshy et al.21, under replacement therapy with a plasma derived VWF/FVIII 
concentrate (Haemate P®) between January 1st 2000 and January 1st 2015 were eligible. 
Monitoring of minimally two VWF:Act and FVIII:C levels was obligatory. Patients with 
other known hemostatic disorders and patients lacking accurate documentation were 
excluded.
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Study objective
The study objective was to evaluate current perioperative management with a specific 
VWF/FVIII factor concentrate (Haemate P®) in VWD patients by specification of concen-
trate administration and subsequently achieved peak and trough levels of VWF:Act and 
FVIII:C in comparison to target VWF and FVIII levels as prescribed by National guidelines 
(Figure 1).17 In this study, both potential predictors of low and high levels of VWF:Act/
FVIII:C as well as variables associated with VWF/FVIII concentrate consumption were 
collected and evaluated.
Laboratory assessment
VWF:Act and FVIII:C were generally monitored daily during hospitalization. Immediately 
before surgery, peak levels were assessed, in the days after surgery trough levels were 
measured. In all cases, perioperative dosing was based on FVIII:C levels as VWF:Act re-
sults were standardly not rapidly available. FVIII:C was measured by one-stage clotting 
assays in all participating centers. In various centers, VWF activity (VWF:Act) assays were 
performed according to local protocol.
Figure 2. Number and type of surgical procedures
Number (No.) and type of surgical procedures
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Data collection
Patient, surgical and treatment characteristics during the hospitalization period were 
collected retrospectively. Patient characteristics included age, body weight, gender, 
type of VWD, historically lowest baseline VWF:Ag, VWF:Act and FVIII:C, ABO blood group, 
and VWF gene mutation if available. Surgical characteristics consisted of procedure 
severity as classified by surgical risk score,21 duration of surgery, perioperative blood 
loss and postsurgical bleeding complications. Bleeding complications were assessed 
according to definition by the International Society of Thrombosis and Hemostasis22 and 
defined as necessity of second surgical intervention, hemoglobin decrease of ≥20 gL-1 
and/or requiring red blood cell transfusion, or bleeding prolonging patient hospitaliza-
tion. A clinically relevant bleeding complication was defined as a bleeding complication 
requiring a second surgical intervention and/or red blood cell transfusion. Treatment 
characteristics included: timing and dosing of VWF/FVIII concentrate administration 
and achieved VWF:Act and FVIII:C during and after surgical procedure; mode of infu-
sion (continuous or bolus infusion) of VWF/FVIII concentrate and co-medication with 
effect on hemostasis (desmopressin, tranexamic acid, low molecular weight heparin, 
non-steroidal anti-inflammatory drugs) as well as duration of hospitalization. Duration 
of hospitalization was defined as day of discharge minus day of surgical procedure and 
initiation of replacement therapy with VWF/FVIII concentrate.
National guideline and evaluation of perioperative VWF/FVIII concentrate 
management
National guidelines prescribe a FVIII-based regimen with a loading dose of VWF/FVIII 
concentrate (ratio of 2.4:1) of 50 IUkg-1 FVIII for major surgery and 30-50 IUkg-1 FVIII for 
minor surgical interventions followed by maintenance doses of 15-25 IUkg-1 FVIII twice 
daily with regular monitoring of VWF:Act and FVIII:C. Dosing is adjusted according to 
VWF:Act and FVIII:C target levels specified in guidelines and depicted in Figure 1.17 In 
general, patients are treated 7-10 days in case of a major surgical procedure, and 4-7 
days in case of a minor surgical procedure. This is in accordance to the UKHCDO and 
Nordic guidelines.23, 24 Perioperative dosing was left to discretion of treating physician. 
Most patients received thromboprohylaxis using low molecular weight heparin.
Perioperative management of VWF/ FVIII concentrate after first peak values, was evalu-
ated by comparing achieved VWF:Act and FVIII:C trough and steady state levels to target 
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VWF:Act and FVIII:C levels. Trough levels were defined as measurements prior to bolus 
infusion or measurements at least 12 hours after infusion, when no subsequent factor 
concentrate infusion was given. Redundantly, no peak levels after bolus infusion were 
included in these analyses. Steady state samples were defined as VWF and FVIII levels 
sampled when concentrate substitution is expected to equal elimination of VWF/FVIII 
concentrate when administered continuously. In general, it is assumed that steady state 
will be reached after a loading dose is administered and continuous infusion is started.
Analysis of predictors of low and high levels of VWF:Act/FVIII:C could only be performed 
in type 1 and type 2 VWD disease patients, due to limited numbers of patients with type 
3 VWD. A stepwise forward and backward logistic regression analysis was performed 
with low levels defined as VWF:Act or FVIII:C below predefined target levels stated by 
guidelines and high levels of VWF:Act/FVIII:C, as all VWF:Act or FVIII levels above the 
predefined target level with a deviation of ≥0.20 IUmL-1. Potential predictors included 
in the analysis, were severity of surgical procedure, blood group O versus non-O, body 
weight, age, mode of infusion and treatment center.
Statistical analysis
Descriptive data are presented as numbers with percentages for categorical variables 
and as medians with an interquartile range (IQR) for continuous variables, as data were 
not normally distributed. The non-parametric Mann-Whitney U test was used to compare 
VWF/FVIII concentrate consumption between surgical procedures of different severity. 
If a patient was subjected to two or more surgeries, calculations were only performed 
for the first surgical procedure. Potential predictors of lower and higher VWF:Act/FVIII:C 
levels than aimed for were analyzed by stepwise backward and forward logistic regres-
sion analysis with elimination of variables with P>0.10. A linear regression analysis was 
performed to calculate if FVIII accumulation occurred after repetitive dosing of VWF/FVIII 
concentrate, whereby regression coefficients were compared between both VWF:Act 
and FVIII:C. Data management and statistical analysis were performed with IBM SPSS 
statistics for Windows, version 23.0 (IBM Corp, Armonk, NY, USA). A P-value of <0.05 was 
considered statistically significant.
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RESULTS
The study population consisted of 103 patients undergoing a total of 148 surgical 
procedures; 54 type 1 VWD patients (73 surgical procedures), 43 type 2 VWD patients 
(67 procedures) and 6 type 3 VWD patients (8 surgical procedures) (Table 1). Half of 
patients had blood group O (51%). Median historical baseline VWF:Ag level and VWF:Act 
level was 0.30 and 0.22 IUmL-1 for VWD type 1 patients; 0.29 and 0.10 IUmL-1 for VWD 
type 2 and 0.05 and <0.10 IUmL-1 for VWD type 3 patients. Some patients in the study 
population underwent multiple surgical procedures (Table 1). Procedures were mainly 
orthopedic (n=36; 24%), general (n=26; 18%) and gynecological (n=24; 16%) (Figure 2). 
No differences in number and type of surgical procedures between VWD types were 
observed. Almost all patients received replacement therapy by bolus infusion (90%). 
Median duration of hospitalization was six days and did not differ between the different 
types of VWD (Table 1). Eleven (29%) and 52 (47%) patients with respectively a minor 
and major surgical procedure received thromboprophylaxis with low molecular weight 
heparin.
Actual VWF:Act and FVIII levels compared to predefined target levels
No differences were observed in achieved VWF:Act and FVIII:C levels between type 1, 
type 2 and type 3 VWD patients (Figure 3) after replacement therapy. In all VWD types, 
most perioperative VWF:Act and FVIII:C levels were well above predefined target levels. 
Postoperatively, accumulation of FVIII was observed after repetitive dosing of VWF/FVIII 
concentrates, resulting in increased FVIII:C in comparison to VWF:Act (p<0.01) (Figure 
4). No differences in FVIII accumulation were observed between type 1 and type 2 VWD 
patients (data not shown). Thirteen (8%) FVIII:C trough levels were above 2.70 IUmL-1.
In the 54 type 1 VWD patients, in the first 36 hours after surgery, median trough VWF:Act 
was 1.48 IUmL-1 (IQR 1.03-1.87). Eighty-four percent of trough and steady state levels 
were above predefined target level with a median deviation of 0.80 IUmL-1 (IQR 
0.38-1.11). Seven levels were below target level (median deviation: 0.24 IUmL-1 [IQR 
0.03-0.38]). All these patients underwent a major surgical procedure, and received an 
additional bolus infusion with VWF/FVIII concentrate to correct lower levels. With regard 
to FVIII:C, median trough and steady state was 1.46 IUmL-1 (IQR 1.14-1.82) in this time 
period. Ninety-two percent of measured levels were above predefined target level with 
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Figure 3. Achieved VWF:Act and FVIII:C levels in the perioperative period
The red lines indicate predefined target VWF:Act and FVIII:C according to National guidelines17. Preopera-
tive peak VWF:Act and FVIII:C levels are shown < 0 hours. Postoperative trough and steady state VWF:Act 
and FVIII:C measurements are shown after surgery. Time of surgical procedure was defined as t=0 hours. 
A) Achieved VWF:Act and B) Achieved FVIII:C levels. No differences in achieved VWF:Act and FVIII:C are ob-
served between types of VWD.
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a median deviation of 0.70 IUmL-1 (IQR 0.43-1.07) above target level. Only five patients 
(9%) had a FVIII:C below the predefined target level. All were administered additional 
treatment: in four patients this consisted of VWF/FVIII concentrate, and in one patient of 
intravenous desmopressin. In the period 36 hours until 72 hours after surgery, all trough 
and steady state FVIII:C levels were above FVIII target level (median FVIII:C 1.80 IUmL-1 
[IQR 1.35-2.11]).
Overall, no differences in achieved VWF:Act and FVIII:C were observed for minor versus ma-
jor surgical procedures, blood group non-O versus O, adults versus children and between 
modes of infusion (data not shown). Moreover, high VWF:Act and FVIII:C levels (defined as 
>0.20 IUmL-1 above target) were predominant as illustrated by the fact that 65% of trough 
and steady state VWF:Act levels and 91% of FVIII:C values were above target.
In the 43 type 2 and 6 type 3 VWD patients, 62% and 71% of trough VWF:Act levels were 
above predefined target level in the first 36 hours after surgery (not significantly different 
from type 1 VWD). Median VWF:Act in this period was 1.07 IUmL-1 [IQR 0.68-1.50] and 1.30 
IUmL-1 [IQR 0.82-1.68], respectively. Eighty-six percent and 89% of trough FVIII:C were 
Figure 4. Accumulation of FVIII:C after repetitive dosing of VWF/FVIII concentrate*
Accumulation of FVIII was present after repetitive dosing of VWF/FVIII concentrates, resulting in increased 
FVIII:C in comparison to VWF:Act (p<0.01) (F=6.90 DFn=1, DFd=209); *Haemate P®
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above target in the first 36 hours with a median deviation of 0.40 IUmL-1 [IQR 0.26-0.85] 
and 0.47 IUmL-1 [IQR 0.28-0.71], respectively for type 2 and type 3 VWD patients. In addi-
tion, all FVIII:C were above target after 36 hours of hospitalization for both major and minor 
surgical procedures. High VWF:Act and FVIII:C (≥0.20 IUmL-1) were present in 53% and 57% 
of VWF:Act and in 72% and 73% of FVIII:C for type 2 and type 3 VWD patients respectively.
Complications
Overall, occurrence of bleeding complications was not associated with a low trough 
VWF:Act and/or low FVIII:C (p=0.95 and 0.25 respectively). Exception was one patient, 
undergoing a craniotomy with excessive blood loss with need for blood cell transfusions 
and presenting with lower trough VWF:Act (0.40 IUmL-1) and FVIII:C (0.60 IUmL-1) levels 
(Table 2). Clinically relevant bleeding only occurred in 5 (3.4%) surgical procedures, as 
four surgical procedures required red blood cell transfusion postsurgery and only one 
a second surgical intervention (Table 2). Despite excessive FVIII:C levels, no thrombotic 
complications were reported.
Treatment
Two patients with VWD type 1 received desmopressin prior to surgery in order to 
achieve VWF:Act and FVIII:C target levels. After surgery, trough VWF:Act and FVIII:C were 
0.56/0.55 and 0.59/0.48 IUmL-1, respectively. Consecutively, treating physician adminis-
tered VWF/FVIII concentrate on following postoperative days.
In VWD type 1 patients, median loading dose for minor and major surgical procedures 
did not differ as these were 32 IUkg-1 and 38 IUkg-1 respectively (Figure 5). Strikingly, 
maintenance dose on day 1 (0-24 hours) after surgery differed between minor and major 
procedures with a significantly higher dose in cases of minor surgery (33 IUkg-1 and 26 
IUkg-1 respectively). Patients who underwent a minor procedure were generally treated 
with VWF/FVIII concentrate for a median of 48 hours. Median duration of hospitalization 
for patients undergoing a minor or major surgical procedure did not differ significantly 
(respectively 4 [IQR 4-8] versus 6 [IQR 4-8] days, p=0.88). Loading dose and maintenance 
doses did not differ between type 1 and type 2 VWD patients; median 36 IUkg-1 [IQR 27-
49] and 43 IUkg-1 [IQR 37-52], p=0.12 for loading dose and median maintenance doses 
ranged from 22-27 IUkg-1 versus 21-35 IUkg-1. No differences between minor and major 
surgical procedures were observed for loading and maintenance doses in type 2 VWD.
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Figure 5. Loading and maintenance doses in minor and major surgical procedures in type 1 and type 2 
VWD patients
Loading and maintenance doses in minor and major surgical procedures are shown using a scatter dot 
plot with median and 5-95% quartile ranges for A. Type 1 and B. Type 2 VWD patients. The non-parametric 
Mann-Whitney U test was used to compare VWF/FVIII concentrate consumption between minor and major 
surgical procedures.
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Predictors of low and high VWF:Act and FVIII:C levels
It was only possible to evaluate predictors in VWD type 1 and type 2 patients, due to a 
limited number of type 3 patients. This was performed for both VWF:Act and FVIII:C by 
both stepwise backward logistic regression analysis as well as stepwise forward logistic 
regression analysis. In type 1 VWD, in the total postoperative period, only blood group O 
was predictive of high VWF:Act levels (VWF:Act levels ≥0.20 IUmL-1above target) (OR 2.9; 
95%CI [1.3-6.6]); not for FVIII:C. No other predictors were found for low and high VWF:Act 
and FVIII:C levels in both type 1 and type 2 VWD patients.
DISCUSSION
This study is the largest so far evaluating perioperative management of VWD patients 
in a resource rich country. We present data that underline the complexity of VWF/FVIII 
concentrate dosing in this patient population, as illustrated by the fact that in type 1 
VWD patients, 65% of trough and steady state VWF:Act and 91% of FVIII:C levels were 
≥0.20 IUmL-1 above predefined target levels. In type 2 and type 3 VWD respectively 53% 
and 57% for VWF:Act and 72% and 73% for FVIII:C were ≥0.20 IUmL-1 above predefined 
target levels. In contrast to results in perioperative severe and moderate hemophilia A 
patients25, only a small percentage of type 1 VWD patients experienced low levels in the 
first 36 hours after surgery, as only 16% of VWF:Act levels and only 8% of FVIII:C levels 
were under prescribed target level. This is probably due to FVIII:C-based dosing per-
formed according to National guidelines applied in this study. Although both VWF:Act 
and FVIII:C were measured perioperatively, VWF:Act was not directly available in most 
cases and could not be used to monitor perioperative VWF/FVIII concentrate manage-
ment. In our cohort, prevalence of clinically relevant bleeding complications was low 
(3.4%) and not associated with achieved VWF:Act and/or FVIII:C. This is supported by 
others8, 12, 14, 15, 26 and confirms that other causal factors for bleeding than VWF:Act and 
FVIII:C, either hemostatic or surgical must be involved. In this study, no predictors of 
bleeding could be identified. Strikingly, blood group O was predictive of high VWF:Act 
levels (≥0.20 IUmL-1 above target) in type 1 VWD in the total postoperative period. Most 
probably this is explained by lower endogenous baseline VWF:Act and FVIII:C levels 
resulting in administration of higher dosages of VWF/FVIII concentrates.
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Analyses were performed for the total VWD population as well as separately for each 
type of VWD, as it has been shown that clearance mechanisms of the endogenous VWF 
differ between VWD types.2, 6 However, no differences were found in achieved VWF:Act 
and FVIII:C after preoperative loading and subsequent maintenance doses between 
type 1 and type 2 VWD. Also, VWF/FVIII consumption did not differ between types of 
VWD. Strikingly, on day 1 (0-24 hours) after surgery, a significantly higher VWF/FVIII con-
centrate consumption was observed for minor surgical procedure when compared to 
major surgical procedures. This is probably explained by the fact that patients undergo-
ing a minor surgical procedure received less frequent but higher dosed bolus infusions 
within a shorter period of time. This finding is supported by a previous study in 29 VWD 
patients of types, in which no differences in consumption between patients undergoing 
minor or major surgical procedures was observed.12
In this perioperative study, accumulation of FVIII:C was observed after repetitive dos-
ing of VWF/FVIII concentrates with median FVIII:C values increasing with time (Figure 
4). Increasing FVIII:C levels, due to concomitant increase of both endogenous and 
exogenous FVIII, were significantly higher than VWF:Act levels (p<0.01). This may be 
partly explained by findings by Kahlon et al.27 who observed an intraoperative decrease 
and postoperative increase of VWF and FVIII levels in 30 individuals without a bleeding 
disorder undergoing surgery. In these healthy individuals, mean VWF:Act and FVIII:C 
levels were greater than 1.00 IUmL-1 at all intra- and postoperative time points. This 
physiological response to surgery may reflect an increased need of VWF in the periop-
erative period. Current guidelines are not in line with these physiological responses to 
surgery, as perioperative target VWF:Act and FVIII:C levels are >0.80 IUmL-1 (0-36 hours 
postoperatively) and >0.30/0.50 IUmL-1 (36-240 postoperatively) and thus below 1.00 
IUmL-1. Although we observed high FVIII:C levels that confer a risk for thrombosis28-30, no 
thrombo-embolic complications were observed. Previously Wells et al. demonstrated 
that FVIII:C levels above 2.70 IUmL-1 are associated with a higher risk of thrombosis 
in non-surgical patients.31 In our study, 8% of trough levels of FVIII:C were above 2.70 
IUmL-1. Also, observed postoperative VWF:Act and FVIII:C levels were increased for only a 
brief period of time and coincide with physiological levels in healthy individuals without 
a bleeding disorder.27 Mannucci et al. also reported this scarcity of thrombosis in periop-
erative VWD patients on replacement therapy.28 In our study, it must also be taken into 
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account that almost half of patients undergoing a major surgical procedure received 
thromboprophylaxis with low molecular weight heparin.
As reported, plasma derived VWF/FVIII concentrate in this study (Haemate P ®), has a 
VWF:Act/FVIII:C ratio of 2.4:1 and contains large amounts of HMWM. Earlier, in vivo recov-
ery (IVR) studies have demonstrated a median IVR of 2.0 for VWF:Act and 2.0 for FVIII:C, 
implying a rise of 0.02 IUmL-1 in VWF:Act and FVIII:C for each infused IUkg-1 for VWF:Act 
or FVIII:C. Theoretically, for each infused IUkg-1 of FVIII:C an increase of approximately 
0.05 IUmL-1 VWF:Act will be observed (2.4*0.02 IUmL-1). Currently, it is common practice 
to apply IVR to dose and monitor replacement therapy.12, 14 However, dosing based on 
body weight and IVR does not take interindividual differences in clearance and volume 
of distribution into account that are associated with half-life of VWF/FVIII concentrates. 
Individualized perioperative dosing based on IVR deducted from a preoperative PK 
profile is not possible, as PK profile is not representative for clearance during surgery 
as shown by Di Paola et al.11 In this study, only a weak correlation was shown between 
IVR values of VWF:Act obtained 1 week prior to surgery and IVR values obtained directly 
after surgery (n=41; r=0.41).11 Both the changes of IVR following surgery and differences 
in half-life between VWD types demonstrate the complexity and importance of develop-
ment of alternative dosing algorithms to individualize treatment for each VWD patient. 
Hypothetically, VWD population PK models will be able to incorporate these differences 
between VWD types due to: mutational variation, differences in baseline values of en-
dogenous VWF:Act and FVIII:C, higher FVIII:C levels with a longer half-life32, differences 
in clearance of endogenous and exogenous VWF:Ag and VWF:Act, and differences in 
composition of administered VWF/FVIII concentrates. Also, other known and unknown 
modifying factors that influence clearance and volume of distribution in an on demand-, 
perioperative setting can be incorporated. The development of such models will lead 
to Bayesian adaptive dosing to predict VWF:Act/FVIII:C and effects of treatment more 
precisely. In the long run, we believe such an approach will optimize patient care and 
minimize overdosing and potentially reduce overall costs of treatment.12, 28, 33-35 There-
fore, PK-guided dosing forms a promising approach for more efficient and individualized 
replacement therapy in VWD with considerable clinical and economic impact due to the 
frequency of this bleeding disorder.
In conclusion, although perioperative replacement therapy in VWD patients is success-
ful with few bleeding complications, it can be optimized as patients are currently over 
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treated with accumulation of FVIII:C levels, fortunately without thrombotic complica-
tions. The complexity of treatment in VWD, makes population PK models which incor-
porate known and unknown modifying factors of clearance and other PK parameters 
of VWF/FVIII concentrates into account, a promising tool to individualize replacement 
therapy in all VWD patients.
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SUMMARy
Background The role of pharmacokinetic-guided dosing of factor concentrates in 
hemophilia is currently subject of debate and focuses on long-term prophylactic treat-
ment. Few data are available on its impact in the perioperative period.
Objective In this study, a population pharmacokinetic model for currently registered 
factor VIII concentrates was developed for severe and moderate adult and pediatric 
hemophilia A patients (FVIII levels <0.05 IUmL-1) undergoing elective, minor or major 
surgery.
Methods Retrospective data was collected on FVIII treatment, including timing and dos-
ing, time point FVIII sampling and all achieved FVIII plasma concentrations (trough, peak 
and steady state), brand of concentrate, as well as patient and surgical characteristics. 
Population pharmacokinetic modeling was performed using nonlinear mixed-effects 
modeling.
Results Population pharmacokinetic parameters were estimated in 75 adults undergoing 
140 surgeries (median age: 48 years, median weight: 80 kg) and 44 children undergoing 
58 surgeries (median age: 4.3 years, median weight: 18.5 kg). Pharmacokinetic profiles 
were best described by a two-compartment model. Typical values for clearance, inter-
compartment clearance, central and peripheral volume were 0.15L/h/68 kg, 0.16L/h/68 
kg, 2.81L/68 kg and 1.90L/68 kg. Inter-patient variability in clearance and central volume 
was 37% and 27%. Clearance decreased with increasing age (p<0.01) and increased in 
case of blood group O (26%, p<0.01). In addition, a minor decrease in clearance was 
observed when a major surgical procedure was performed (7%, p<0.01).
Conclusion The developed population model describes the perioperative pharmaco-
kinetic of various FVIII concentrates, allowing individualization of perioperative FVIII 
therapy for severe and moderate hemophilia A patients by Bayesian adaptive dosing.
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INTRODUCTION
Hemophilia A is an X-linked hereditary bleeding disorder characterized by a deficiency 
of coagulation factor VIII (FVIII). Current management of hemophilia patients consists of 
replacement therapy with plasma derived or recombinant factor concentrates in case 
of acute bleeding (“on demand”) or to prevent spontaneous or perioperative bleeding 
(“prophylaxis”). The aim of long-term prophylactic treatment is to prevent severe joint 
damage and subsequent long term invalidity by raising FVIII trough plasma concentra-
tions to at least >0.01 IUmL-1.1, 2 To acquire adequate hemostasis in the surgical setting, 
normalization of coagulation factor levels is advocated for 7-14 days after surgery in 
most perioperative protocols.3
Treatment with factor concentrates is costly. In the Netherlands, total annual costs of 
replacement therapy are estimated at more than €130 million and include costs for 
prophylactic and on demand treatment.4-7 In the Canadian Hemophilia registry, periop-
erative consumption amounts to 1-3% of the total annual amount administered.8
As we have reported earlier, coagulation factor plasma concentrations as recommended 
by National and International Guidelines are often exceeded in the perioperative setting 
to avoid lower plasma concentrations and a possibly higher bleeding risk with additional 
costs.9, 10 In a retrospective analysis of hemophilia A patients undergoing surgery, 45% 
of FVIII plasma concentrations were below the target range during the first 24 hours 
after surgery and 75% of the plasma concentration were above the target range after 
six days of hospitalization. In addition, a reduction of 44% in factor concentrates could 
have been reached if plasma concentrations had been maintained within target levels 
in the perioperative setting.9
In the prophylactic setting, Carlsson et al. have shown that FVIII consumption can be 
significantly reduced by application of pharmacokinetic (PK) modeling to individualize 
dosing regimens.11-14 In the perioperative setting, Longo et al. have reported excessive 
FVIII consumption and clearance in 50% of surgical hemophilia patients due to uniden-
tified factors.15 This suggests mechanisms of increased clearance due to hemostatic 
challenges during surgery. Although an initial preoperative factor concentrate bolus 
dose may be individualized by individual PK parameters obtained after an individual 
PK profile based on a prophylactic population PK model, this may not be applicable as 
soon as a surgical procedure is initiated. A perioperative population PK model, however 
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would make PK-guided iterative adaptive Bayesian dosing with a potential concomitant 
decrease of factor concentrate consumption possible. During this procedure individual 
PK parameters are iteratively updated by combining PK information (e.g. dose, con-
centration, time) from the individual patient with a priori PK information (e.g. average 
clearance, variability) from the population. The latter does not currently exist and has 
therefore never been performed.
In order to construct such a perioperative population PK model facilitating Bayesian 
adaptive dosing in severe and moderate hemophilia A, we collected detailed retrospec-
tive FVIII infusion data in patients who had undergone surgery under replacement 
therapy with various similar FVIII concentrates, from five hemophilia treatment centers.
METHODS
Patients and data collection
Severe and moderate hemophilia A patients of all ages with FVIII plasma concentration 
<0.05 IUmL-1 who had undergone elective, minor or major surgical procedures between 
2000 and 2013 from five Academic Hemophilia Treatment Centers in the Netherlands 
were included.9 Patients received replacement therapy consisting of various recombi-
nant factor concentrates (Kogenate FS (Bayer, Berkely, Ca, USA], Helixate FS (CSL Behring, 
Marburg, Germany], Advate and Recombinate [Baxter Bioscience, Thousand Oaks, CA, 
USA], and Refacto AF [Pfizer, New York, NY USA]) or plasma derived factor concentrates 
(Aafact [Blood Transfusion council of the Netherlands Red Cross], Hemofil M [Baxter 
Bioscience, Thousand Oaks, CA, USA]) to achieve target FVIII plasma concentrations as 
set by the National Hemophilia Consensus. This guideline recommends peak and trough 
FVIII plasma concentrations on consecutive postoperative days (Table 1): 0-24 hours 
0.80-1.00 IUmL-1; 24-120 hours 0.50-0.80 IUmL-1 and >120 hours 0.30-0.50 IUmL-1.3 The 
following retrospective data were collected: FVIII dosages, detailed timing of administra-
tion and timing of FVIII blood sampling, mode of infusion (continuous or bolus infusion), 
all achieved FVIII plasma concentrations (both trough, peak and steady state plasma 
concentrations), patient and surgical characteristics, and concomitant medication 
with a possible effect on hemostasis (i.e. tranexamic acid, heparin, desmopressin and 
nonsteroidal anti-inflammatory drugs). Patient characteristics included: weight, length, 
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lean body mass16, 17, body mass index (BMI)18, blood group, von Willebrand Factor (VWF) 
antigen and VWF activity (historically measured), liver and renal function, clinical bleed-
ing phenotype, history of FVIII inhibiting antibodies, intensity of prophylactic dosing 
regimen, brand of concentrate, and treatment center. Surgical characteristics included: 
type and severity of surgical procedure categorized into minor, major and high risk ac-
cording to Koshy et al.19 In all centers, FVIII plasma concentrations were measured by 
one-stage clotting assays. The study was not subject to the Medical Research Involving 
Human Subjects Act, as patient data were analysed anonymously. Moreover, the study 
was approved by all local Medical Ethics Committees; one center requiring prior patient 
informed consent.
Pharmacokinetic modeling
Population pharmacokinetics (PK) is defined as the study of sources of variability in drug 
concentrations after dosing that occurs within and between patients.20 In the present 
population analysis, all plasma concentration time points were analyzed simultaneously 
using non-linear mixed-effects modelling software (NONMEM (version 7.2.0), Globomax 
LLC, Ellicott City, Maryland, USA).21 All PK related abbreviations and terminology are 
described in supplementary Table 1. More specifically, first-order conditional estimation 
(FOCE) method with interaction was applied, allowing interaction between structural 
and residual variance components. The statistical package R, version 2.14.2 (The R Foun-
dation for Statistical Computing) and Xpose version 422 were used for data set checkout, 
exploration and model diagnostics. Pirana software was used as an interface between 
NONMEM, R and Xpose.23
Model diagnostics included the evaluation of the goodness of fit plots, the objective 
function value (OFV), the precision of the parameter estimates and the shrinkage of 
estimated random parameters. The OFV is a measurement of goodness of fit of the 
Table 1. Prevalence of under- and overdosing in the perioperative period*
Time (hours) 0-24 24-120 >120
Consensus 0.80-1.00 IUmL-1 0.50-0.80 IUmL-1 0.30-0.50 IUmL-1
% above 33% (>1.00 IUmL-1) 59% (>0.80 IUmL-1) 75% (>0.50 IUmL-1)
% below 45% (<0.80 IUmL-1) 7% (<0.50 IUmL-1) 9% (<0.30 IUmL-1)
*According to the National Hemophilia Consensus
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model and is proportional to minus two times the logarithm of the likelihood (-2log 
likelihood) of the data. Competing hierarchical models were compared by calculating 
the difference between their OFV. This ratio is assumed to be χ2 distributed. Therefore, 
if models differ by one parameter, a decrease in OFV of 3.84 corresponds to p = 0.05 (1 
degree of freedom). And OFV decreases of 6.63 and 10.8 correspond to p-values of 0.01 
and 0.001, respectively.
Structural model development
FVIII plasma concentrations were described by a two-compartment PK model. Estimated 
(fixed) parameters were clearance (CL), volume of distribution of the central compart-
ment (V1), intercompartment clearance (Q) and volume of distribution of the peripheral 
compartment (V2). The structural model also accounted for the individual endogenous 
baseline FVIII plasma concentration. PK parameters were allometrically scaled to account 
for the wide range of body weights of both adult and pediatric patients. An allometric 
power model was used with power exponents fixed at 0.75 for clearances and 1.0 for 
volumes of distribution24, as described in the following equations:
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where ηi and κi represent the IIV and IOV, respectively, and are assumed to be symmetrically 
distributed with a mean of 0 and an estimated variance of ω2 and π2. IIV and IOV were included in the 
model if shrinkage was less than 20%.25 The structural model also accounted for under prediction of 
plasma concentrations of a B-domain deleted product (Refacto®) due to known discrepancies and 
inﬂuence of one-stage laboratory assays on plasma concentrations26, 27, as described: 
Cpred,bdp = Cpred x (1 – θbdp) 
Where Cpred,bdp and Cpred are the predicted concentrations of the B-domain deleted product (bdp) and 
other products, respectively, and θ is the fractional decrease in concentration. 
Residual variability in FVIII concentration was described using a combined error model.  
 
In this expression, CLi and Vi are the typical clearance and central volume of distribution 
for an individual i with body weight BWi θCL and θV1 are the respective parameter values 
for a subject with a body weight of 68 kilogram.
The random parameters inter-individual variability (IIV) and inter-occasion variability 
(IOV) of the PK parameters were estimated using an exponential function according to:
CLi = θCL x e(ηi+κi)
where ηi and κi represent the IIV and IOV, respectively, and are assumed to be sym-
metrically distributed with a mean of 0 and an estimated variance of ω2 and π2. IIV and 
IOV were included in the model if shrinkage was less than 20%.25 The structural model 
also accounted for under prediction of plasma concentrations of a B-domain deleted 
product (Refacto®) due to known discrepancies and infl ence of one-stage laboratory 
assays on plasma concentrations26, 27, as described:
Cpred,bdp = Cpred x (1 – θbdp)
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Where Cpred,bdp and Cpred are the predicted concentrations of the B-domain deleted product 
(bdp) and other products, respectively, and θ is the fractional decrease in concentration.
Residual variability in FVIII concentration was described using a combined error model.
Covariate search
After obtaining the structural model individual empirical Bayesian estimates were ob-
tained for all PK parameters. Correlations between these parameters and patient and 
surgical characteristics, and the use of concomitant medication were explored graphi-
cally. All covariates were tested in a univariate analysis. The most clinically relevant and 
statistically significant covariate was retained in the model: a stepwise forward approach 
was used to determine clinical and statistically significant covariates with p-values 
<0.05. Backward elimination was performed to confirm that all included covariates in 
the final model were statistically significant with p<0.01. As the occurrence of a bleeding 
complication could not be related to actual FVIII plasma concentrations9, occurrence of 
a bleeding complication was not included in the final model. Moreover, only a limited 
difference in clearance was observed between patients with and without a bleeding 
complication (7%). Also, time dependent changes in clearance were tested during the 
perioperative period.
Final model and model evaluation
The stability and performance of the final model was checked using an internal valida-
tion procedure via the bootstrap resampling technique in which 1000 bootstrap datasets 
were generated by random sampling with replacement.28 Visual predictive check plots 
obtained after Monte Carlo simulations of the study population were used to evaluate if 
the final model adequately described observed data.29
RESULTS
Patients and treatment in the perioperative setting
Our cohort consisted of 119 hemophilia A patients undergoing a total of 198 surgical 
procedures as described previously.9 Patients were treated for up to two weeks after sur-
gery according to the National Hemophilia Consensus (Table 1).3 Treatment consisted 
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of a preoperative bolus infusion of approximately 50 IUkg-1 followed by a treatment 
scheme with either bolus infusions or continuous infusion therapy based on a clearance 
rate of 3-4ml kg-1 hour-1. General characteristics of these included patients are shown in 
Table 2. Seventy-five patients underwent only one surgical procedure. Half of all patients 
had blood group O (51%). In three percent of all surgical procedures a severe bleeding 
complication occurred, defined as necessity of a red blood cell transfusion (RBCT) and/
or necessity of a second surgical intervention, which could not be related to FVIII plasma 
concentrations. In total 1389 FVIII measurements were obtained, equally distributed 
on consecutive days in the perioperative setting (Figure 1). Approximately 7 samples 
per patient were taken in the perioperative period. In summary, 45% of FVIII plasma 
concentrations were below the target range in the first 24 hours and 75% were above 
the target range after six days of hospitalization (Table 1).
Figure 1. Perioperative FVIII plasma concentrations and visual predictive check for observed FVIII plasma 
concentrations
Perioperative FVIII plasma concentrations consists of trough, peak and steady state concentrations for both 
modes of therapy (continuous infusion and bolus infusion therapy); Visual predictive check for the ob-
served FVIII plasma concentrations, given the final model; observed FVIII plasma concentrations and mean, 
5th percentile and 95th percentile observed and simulated FVIII plasma concentrations.
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Pharmacokinetic modeling
Structural model development
Time profiles of FVIII plasma concentrations were best described by a two-compartment 
model with allometric scaling for body weight (Figure 2). By allometric scaling, all es-
timated PK parameters were normalized for a body weight of 68 kg. Model building 
steps that resulted in significant decrease of the OFV and consequently a better fit of the 
model are shown in Table 3. In the structural model, typical values for CL and V1 were 
190 ml/hour/68 kg and 3030 ml/68 kg (Table 4). It was possible to estimate IIV for CL and 
V1 whereas estimates for IIV of Q and V2 were imprecise and accompanied by a large 
shrinkage of >40%.25 Although this may suggest that inter-patient variability in Q and V2 
is absent, this is due to the fact that available data was not informative enough. The IIV 
for CL and V1 were respectively 45% and 29%, underlining the importance of individual-
ization of therapy. Estimation of IOV on CL and V1 resulted in high shrinkage values for 
both parameters (respective value 34% and 46%); consequently IOV was not included in 
the model. Inclusion of individual endogenous baseline FVIII plasma concentrations and 
inclusion of a structural under prediction of plasma concentrations using a B-domain 
deleted product improved the model. A proportional under prediction of 0.34 (34%) 
in FVIII plasma concentration was estimated for this product. The residual error was 
described using a combined error model.
Figure 2. Visualization of NONMEM analysis and outcomes
Central volume  
2810 mL/68kg Peripheral volume 
1900 mL/68kg 
  
  
Intercompartmental 
clearance 
 160 mL/h/68kg 
IIV (27%) 
(Age/40)-0.09  
IIV (37%) 
(Age/40)-0.17  
Blood group O: 26%  
Major surgery:  7%  
Clearance 
150 mL/h/68kg 
Allometric scaling based on body weight was applied with an allometric exponent of 0.75 for the clearance 
parameters and 1 for the volume terms; Age in years; IIV= inter-individual variability
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Table 2. Population characteristics
Total cohort Adults Children
No. (%); or Median [minimum; maximum]
Patient characteristics
No. of patients 119 75 44
Age (years) 40 [0.2-78] 48 [19-78] 4 [0.2-17.3]
Weight (kg) 75 [5-111] 80 [45-111] 19 [5-85]
Severe hemophilia (FVIII levels <0.01 IUmL-1) 83 (69.7) 49 (65.3) 34 (77.3)
On prophylaxis 84 (70.6) 51 (68.0) 33 (75.0)
Blood group O* 51 (50.5) 34 (50.0) 17 (51.5)
Historical VWF levels
Antigen 1.1 [0.3-2.5] 1.2 [0.3-2.5] 0.9 [0.5-2.3]
Activity 1.1 [0.2-2.7] 1.4 [0.2-2.7] 0.9 [0.4-1.7]
Surgical characteristics
Total no. of surgical procedures 198 140 58
No. of patients undergoing:
1 procedure 75 (63.0) 43 (57.3) 32 (72.7)
2 procedures 26 (21.8) 15 (20.0) 11 (25.0)
3 procedures 9 (7.6) 9 (12.0) 0 (0.0)
>4 procedures 9 (7.6) 8 (10.7) 1 (2.3)
Major surgical procedure 97 (49.0) 86 (61.4) 11 (19.0)
Type of surgical procedure
General 6 (3.0) 6 (4.3) 0 0
Colo-rectal 5 (2.5) 4 (2.9) 1 (1.7)
Vascular 1 (0.5) 1 (0.7) 0 0
Cardio-thoracic 1 (0.5) 1 (0.7) 0 0
Orthopedic 94 (47.5) 91 (65.0) 3 (5.2)
Urology 12 (6.1) 4 (2.9) 8 (13.8)
Maxillofacial 2 (1.0) 2 (1.4) 0 0
Ear-Nose-Throat 11 (5.6) 6 (4.3) 5 (8.6)
Eye 3 (1.5) 3 (2.1) 0 0
(Re)placement of central intravenous catheters 32 (16.2) 1 (0.7) 31 (53.4)
Miscellaneous 31 (15.7) 21 (15.0) 10 (17.2)
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Table 2. Population characteristics (continued)
Total cohort Adults Children
No. (%); or Median [minimum; maximum]
Replacement therapy with factor concentrate, hospitalization and blood loss
Mode of infusion
Continuous 115 (58.1) 88 (62.9) 27 (46.6)
Bolus 83 (41.9) 52 (37.1) 31 (53.4)
Product type
Recombinant 152 (76.8) 99 (70.7) 53 (91.4)
Plasma derived 46 (23.2) 41 (29.3) 5 (8.6)
Duration of hospitalization (days) 9 [1-50] 9 [1-50] 7 [1-16]
Complications during the perioperative period
No. of patients with a complication
Bleeding 48 (24.2) 45 (32.1) 3 (5.2)
Re-operation 6 (3.0) 6 (4.3) 0 0
Hemoglobin drop >20 gL-1 and/or 
erythrocyte transfusion
38 (19.2) 36 (25.7) 2 (3.4)
Bleeding with prolonged hospitalization 5 (2.5) 4 (2.9) 1 (1.7)
Thrombosis 0 0 0 0 0 0
FVIII data
FVIII measurements (trough, peak and SS) 1389 1124 265
Prior to surgery 158 (11.4) 114 (10.1) 44 (16.6)
Day 1 (0 - 24 hours) 323 (23.2) 246 (21.9) 76 (28.7)
Day 2 - 5 (24 - 120 hours) 473 (34.0) 363 (32.3) 110 (41.5)
Day > 6 (>120 hours) 436 (31.4) 401 (35.7) 35 (13.2)
No.=number; %= percentages; kg=kilogram; FVIII=coagulation factor VIII; IUmL-1=international units per 
milliliter; BU=Bethesda Units; VWF=von Willebrand factor; gL-1= gram per liter; *Blood group known of 101 
patients
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Covariate search
In the univariate analysis, significant covariates of clearance were age (p<0.001), blood 
group (p<0.01), severity of surgical procedure (p<0.01), lean body mass (p<0.01), use of 
tranexamic acid and heparin (p<0.05), historically measured VWF antigen and activity 
levels (p<0.05). Treatment center and type of product were not significant covariates. 
After the step forward analysis only age, blood group, and severity of surgical procedure 
were significantly associated with clearance. After the inclusion of age in the model, 
VWF antigen and activity levels were no longer statistically significant. Age was also as-
sociated with V1 (Table 3). Different models were used to test possible time dependent 
Table 3. Model-building steps resulting in significant decreases in objective function value (OFV)
Model NOP OFV
Structural model*
1 One compartment with IIV on V1 and CL 7 -2604.5
2 Two compartment with IIV on V1 and CL 9 -2799.3
3 Inclusion of individual endogenous baseline FVIII plasma concentrations 9 -2816.1
Covariates on CL (added to model 3)
4 Age 10 -2851.8
5 Age, blood group 11 -2862.3
6 Age, blood group, bleeding complication 12 -2886.7
7 Age, blood group, bleeding complication, severity of surgical procedure 13 -2895.2
Covariates on V1 (added to model 7)
8 Age 14 -2911.8
Error model (added to model 8)
9 Center (two categories) 16 -2930.6
*Allometric scaling based on body weight was applied with an allometric exponent of 0.75 for the clear-
ance parameters and 1 for the volume terms; under prediction of FVIII plasma concentrations of a B-domain 
deleted product was implemented
NOP=number of estimated parameters, OFV=objective function value, IIV=inter-individual variability, 
V1=volume of the central compartment, CL=clearance
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changes in clearance during the perioperative period; no differences were observed 
however. Differences in residual error were detected for the different centers.
In the final model, IIV of CL decreased from 45% towards 37% after inclusion of these 
covariates. IIV of V1 decreased from 29% to 27%. The PK parameter estimates of the final 
model are presented in Table 4. Typical PK parameter estimates were described with the 
equations presented in Table 5.
Table 4. Parameter estimates for the final model and bootstrap analysis
Structural 
model
Final model Bootstrap 
analysis final 
model
Parameter Mean (%RSE) Mean (%RSE) Mean (%RSE)
Structural model
θ1 - Clearance (CL; mL/h/68 kg) 190 (5) 150 (8) 160 (5)
θ2 - Volume of central compartment (V1; mL/68 kg) 3030 (3) 2810 (4) 2810 (3)
θ3 - Inter-compartmental clearance (Q; mL/h/68kg) 170 (17) 160 (20) 170 (15)
θ4 - Volume of peripheral compartment (V2; mL/68 kg) 1930 (12) 1900 (11) 1890 (8)
Β-domain deleted product 0.32 (11) 0.34 (13) 0.33 (10)
Covariate parameters
θ5 - CL – Age (change with increasing age) -0.17 (22) -0.16 (13)
θ6 - CL – Blood group O (% difference) 26 (7) 27 (22)
Θ7 - CL – Major surgical procedure (% difference) -7 (6) -7 (34)
Θ8 - V1 – Age (change with increasing age) -0.09 (28) -0.09 (18)
Inter-individual variability
Clearance (% CV) 45 (13) 37 (14) 36 (10)
Volume of central compartment (% CV) 29 (13) 27 (14) 26 (11)
Residual variability
Additive residual error (SD; IUmL-1)
Center 1,2,3 0.15 (12) 0.14 (9)
Center 4,5 0.05 (28) 0.05 (20)
Proportional residual error (% CV)
Center 1,2,3 0.18 (15) 0.18 (9)
Center 4,5 0.23 (9) 0.23 (7)
RSE indicates relative standard error; and CV coefficient of variation
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According to the equation, clearance was 214, 169, 150 and 142 ml/h/68 kg for a typical 
patient (with blood group non-O undergoing a minor surgical procedure) with an age 
of 5, 20, 40 and 55 years, respectively. In case of a major surgical procedure, a small de-
crease in CL was observed of 7% (Table 4). Interestingly, individual post-hoc clearances 
were higher in patients with a major surgical procedure (Figure 3B). This was however 
explained by collinearity between covariates; older patients underwent more major sur-
gical procedures (Figure 4). Clearance increased by 26% in patients with blood group O. 
CL and elimination half-life are depicted as functions of age and body weight in Figure 5.
The adequacy of the derived final model is shown in Figure 6. Population and indi-
vidually predicted concentrations for all patients were plotted against the measured 
concentrations in Figure 6. A good agreement was observed between FVIII concentra-
tions predicted by the model and those assessed by laboratory measurements. Overall, 
standardized weighted residuals revealed a random distribution around zero, within -2 
to +2 range indicative of an unbiased estimation (Figure 6C).
Model evaluation
A good agreement was found between parameter estimates of the final model and 
parameter estimates of the bootstrap analysis (Table 4). A visual predictive check was 
conducted by 1000 simulations based on the final model as shown in Figure 1. It con-
Table 5. Model equations describing the perioperative population PK model
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Figure 3. Graphical visualization of variability of the clearance and covariates
Visualization of variability of the clearance; a. as a function of blood group O versus blood group non O; b. 
as a function of risk of surgical procedure.
Figure 4. Clearance of FVIII in major and minor surgical procedures after stratification for age
Post-hoc estimates of FVIII clearance normalized for total body weight, and stratified for age (<4 years or 
>4 years) were categorized according to severity of surgical procedure. *A Spearman’s correlation test was 
performed to test for clearance differences between major and minor surgical procedures. The median 
age of children included in the study was used as cut-off value for analysis. This was supported by results 
of figure 5A.
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firmed, adequateness of the model, as seven percent of the measured concentrations 
were calculated above the 95th percentile of the simulated concentrations and nine 
percent of the measured concentrations were found to be below the 5th percentile of the 
simulated concentrations.
DISCUSSION
In this study, a population PK model was constructed describing the perioperative PK of 
several currently used FVIII concentrates. These factor VIII concentrates were in majority 
Figure 5. Clearance and elimination half-life as functions of age and body weight
a. Clearance of FVIII, normalized for total body weight, as a function of age; b. Clearance of FVIII as a function 
of body weight; c. The elimination half-life of FVIII as a function of age; d. The elimination half-life of FVIII as 
a function of body weight. Eta shrinkage was 10% and 20% respectively for the estimates of inter-individual 
variability of clearance and volume of the central compartment.
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FVIII recombinant products (77% of surgical procedures), of which 14% were a B-domain 
deleted FVIII concentrate, as well as plasma-derived FVIII concentrates (23% of surgical 
procedures). In the population PK model, a difference in results due to the B-domain 
deleted FVIII concentrate (Refacto AF®) was accounted for. No other differences were 
observed between products. As this difference is incorporated into the population PK 
model, this perioperative FVIII population PK model can be used for all described FVIII 
concentrates. The developed model will facilitate Bayesian adaptive dosing, allowing 
Figure 6. Observed and model-predicted FVIII plasma concentrations
Population predicted FVIII plasma concentrations (IUmL-1)
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Individualized predicted FVIII plasma concentrations (IUmL-1)
NONMEM model diagnostic plots, observed and model predicted FVIII plasma concentrations plotted 
against each other;
a. population predicted FVIII plasma concentrations;
b. individually predicted FVIII plasma concentrations;
c. conditionally weighted residuals versus time
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individualization of FVIII dosing during the entire perioperative period. Earlier, only a 
few studies have reported application of PK-guided dosing during the perioperative 
period. Unfortunately, in all studies only the FVIII loading dose was based on an indi-
vidual PK-profile derived several days before surgery.30-35 Iterative perioperative FVIII 
dosing-adjustments after first loading dose could not be performed as a population PK 
model was lacking. The perioperative population PK model presented, will now make 
Bayesian adaptive dosing in this setting possible. Moreover, it will take all important 
patient characteristics associated with clearance in the surgical setting into account.
The presented model consists of a two-compartment model with allometric scaling 
of the PK parameters for body weight. Both increasing age and increased severity of 
surgical procedure were overall significantly associated with a lower FVIII clearance, 
although individual clearance rates showed that patients with a major surgical proce-
dure did demonstrate higher clearance rates. This contradiction may be due to the fact 
that included covariates in the PK model were confounders e.g. older patients with a 
decreased CL of FVIII concentrate underwent major risk surgical procedures more often 
than younger patients. Also, increased consumption of concentrates due to blood loss 
and activation of coagulation are other possible modifying factors. In addition, blood 
group O was associated with higher FVIII clearance, which will be discussed in following 
sections. Although it should be underlined that this population PK model is an important 
development, it is important to realize that it does not account for pharmacodynamic 
outcome measures, as the occurrence of a bleeding complication could not be related to 
actual FVIII plasma concentrations due to scarcity of FVIII plasma concentrations during 
an acute bleeding.
As in most resource rich countries, current perioperative replacement therapy in hemo-
philia A in the Netherlands, consists of a FVIII loading dose followed by either continuous 
FVIII infusion or treatment with FVIII bolus infusions, while targeting predefined peak 
and trough FVIII plasma concentrations as stated in the National Hemophilia Consensus.3 
The retrospective study performed to collect data for this PK model, has been described 
earlier.9 Results show the challenges of current perioperative dosing of FVIII replacement 
therapy in daily clinical practice when targeting prescribed FVIII plasma concentrations 
as significant underdosing and overdosing were demonstrated. Moreover, it underlines 
the necessity of alternative, more individualized dosing strategies in the perioperative 
setting as is possible when PK-guided dosing based on a population PK model is applied.
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PK-guided dosing based on population PK models has mainly been studied in the long-
term prophylactic setting. However, to be able to apply Bayesian adaptive dosing, it is 
necessary to utilize a population PK model appropriate for the individual patient and 
the specific setting concerned. In analyses preceding the construction of this periopera-
tive population PK model, it was confirmed that the mean estimated PK parameters for 
prophylactic dosing, as reported by Björkman et al.12, did not reliably predict observed 
perioperative FVIII plasma concentrations. Using the prophylactic model, calculations 
showed an under prediction of perioperative FVIII concentrations <1.00 IUmL-1 as well 
as an overprediction of FVIII concentrations >1.00 IUmL-1. In other words, actual FVIII 
plasma concentrations were higher and respectively lower than predicted by prophylac-
tic population PK model (data not shown). Therefore, it was concluded that prophylactic 
population PK models cannot be applied in the perioperative setting. Use of the prophy-
lactic model in this setting would generate a bias of predicted perioperative FVIII plasma 
concentrations.
In the prophylactic setting, a similarly constructed population PK model has been ap-
plied earlier.12 CL, V1 and Q were actually in accordance when a comparison was made 
between perioperative and prophylactic PK population model (CL: 150 versus 222 mL/
hr/68 kg; V1: 2810 versus 3520 mL/68 kg; and Q: 160 versus 256 mL/h/68 kg, respectively). 
However, in the present perioperative model, a value of 1880 mL/68 kg was found for V2 
in contrast to a value of 240 mL/68 kg found in the prophylactic situation, suggesting a 
rapid redistribution of FVIII concentrate following intravenous administration.12 Due to 
increased V2, calculated distribution half-life and elimination half-life are significantly 
larger (as half-life is a derivative of the distribution volume) in the perioperative setting 
in comparison with the prophylactic state (respectively 4 hours and 25 hours versus 
0.6 hours and 12 hours). These calculated half-lifes are in accordance with previously 
described half-life observed immediately after surgery and half-life observed at steady 
state of 10 surgical patients described with a surgical model (respectively 9.6 and 17.8 
hours) in comparison to 10 surgical patients described with an estimated half-life of 10.1 
hours described with a non-surgical model.15 Unfortunately, the rapid redistribution was 
not quantifiable, due to minimal data of laboratory assessment after infusion. Previously, 
it has been suggested that V2 may reflect the FVIII distribution into extravascular spaces 
or within an intravascular compartment, more specifically as a reflection of adhesion 
to the vessel wall or that it may reflect the process of a rapid initial elimination.36, 37 We 
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hypothesized that an extra intravascular component resulting in a large V2, may be 
the result of the high affinity and stoichiometry of FVIII to VWF38, combined with the 
significant increase of VWF after surgery due to inflicted endothelial damage and its 
role in the acute phase reaction.39 In addition, Deitcher et al. have shown that volume of 
distribution increases after desmopressin administration, which of course results in an 
overall increase in VWF levels.40
Moreover, we believe that VWF may play a crucial role in the perioperative setting with 
regard to FVIII PK parameters, as previous studies have demonstrated a clear associa-
tion between VWF plasma concentrations and FVIII half-life.41, 42 This is not surprising, 
as VWF protects FVIII against proteolytic degradation by expression of ABH antigens 
on N-linked glycans and the uptake of the copper-binding protein ceruloplasmin.43, 44 
Additionally, it has been shown that in healthy individuals undergoing orthopedic sur-
gery, VWF decreases significantly intraoperatively and rises immediately after surgery.39 
Therefore, we suspected a time-dependent FVIII clearance in the presented PK model, 
with an increased clearance during the surgical procedure itself and a decrease in clear-
ance directly after surgery. However, no time-dependent clearance could be established. 
Unfortunately, it was not possible to investigate the role of VWF plasma concentrations 
in our analyses in more detail, as VWF measurements are currently not routine practice 
in the perioperative setting and only historically measured VWF plasma concentrations 
were available in half of the study population. However, a 26% higher clearance rate 
was observed in blood group O patients in the perioperative setting, underlining the 
potential importance of measurement of VWF plasma concentrations in the periopera-
tive setting if PK-guided dosing is implemented. This is supported by earlier reports that 
blood group O patients have around 25% lower VWF levels in comparison to patients 
with blood group non-O.43 Strikingly, this effect of blood group on clearance was not 
significant in the prophylactic population PK model as shown by Bjorkman et al.12 How-
ever, we are not informed if VWF levels were available for those analyses. Contrastingly, 
higher VWF levels may also help explain the unexpected overall lower clearance found 
in patients undergoing major surgical procedures. In the ongoing prospective random-
ized controlled “OPTI-CLOT” trial (RCT), which is described in more detail elsewhere45, 
insight will be gained into the pathophysiology of VWF in hemophilia patients during 
the perioperative setting and the relationship between VWF levels and estimates of 
FVIII PK parameters, among others. These data will further validate the now presented 
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perioperative PK population model, refining its applicability and further defining the 
influence of possible modifying factors of PK parameters. Moreover, extension of this 
population PK model, in combination with extended half-life (EHL) products in the near 
future, could be of great value. However, firstly, studies are needed to extensively docu-
ment associations between clearance of current FVIII products and EHL products within 
individuals.
Clinically in the perioperative setting, adaptive Bayesian dosing can be used to optimize 
and individualize dosing in order to obtain desired target FVIII plasma concentrations 
with increased certainty. Bayesian analysis combines individual PK information with 
information from an available population PK model. Such a population PK model is 
constructed from PK data of many individuals, and not only embodies defined patient 
characteristics known to influence clearance and other PK parameters, but also currently 
unidentified patient characteristics which cannot be quantified. Individual patient in-
formation that is entered into the model must include dose and time point of factor 
concentrate administration as well as achieved FVIII plasma concentrations. Incorpora-
tion of the patient’s weight, blood group, age and severity of surgical procedure will 
improve estimation of the individual clearance of factor concentrate. In clinical practice, 
individual clearance and other PK parameter estimates can be made by a clinical phar-
macologist with experience with this methodology and iteratively updated, leading to 
calculated dose adjustments. Currently, we are planning to develop a PK tool to imple-
ment this perioperative population PK model in daily clinical practice. The first dose of 
FVIII concentrate, still in steady state, will be based on individual PK parameters deducted 
from an individual PK profile constructed according to the prophylactic population PK 
model. As we were not able to demonstrate time dependent changes in PK parameters 
during the perioperative setting, the perioperative population PK model described here 
can be applied to the complete perioperative period with varying target FVIII plasma 
concentrations as described by National guidelines.
In conclusion, we have constructed a perioperative population PK model facilitating it-
erative dose-adjustments by Bayesian analysis. We believe this model will prove its value 
as it will lead to optimization of current dosing strategies by a decrease of underdosing 
and overdosing, and therefore both a decrease of bleeding risk and an expected overall 
reduction of factor concentrate consumption with concomitant cost reduction.
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Supplemental Table
Supplementary Table 1. Terminology and definitions used to develop population PK models
Terminology Definitions
NONMEM® Non-linear mixed-effects modelling software to construct a population analysis, where all 
plasma concentration time points are analyzed simultaneously
OFV Objective function value; a measurement of goodness of fit of the model. OFV is 
proportional to minus two times the logarithm of the likelihood (-2log likelihood) of the 
data
PK parameters Pharmacokinetic parameters (e.g. CL, V1, Q, V2)
CL Clearance
V1 Volume of distribution of the central compartment
Q Intercompartment clearance
V2 Volume of distribution of the peripheral compartment
Allometric scaling PK parameters are allometrically scaled to account for the wide range of body weights of 
both adults and pediatric patients
IIV Inter-individual variability; variability between patients
IOV Inter-occasion variability; variability within patients
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SUMMARy
Background Hemophilia B is an X-linked bleeding disorder characterized by a deficiency 
of coagulation factor IX (FIX). In the perioperative setting, patients receive replacement 
therapy with factor concentrate to normalize FIX activity levels (FIX) according to physi-
ological levels. Due to high inter-patient pharmacokinetic (PK) variability, PK-guided 
dosing can be used to individualize dosing of FIX.
Objective In this study, we aimed to construct a population PK model to describe FIX 
and inter-patient variability in the perioperative period, during FIX replacement therapy.
Methods Retrospective data of 118 patients (age/weight: median plus range) undergo-
ing 255 surgical procedures was available from ten hemophilia treatment centers in the 
Netherlands and the United Kingdom. Average PK parameters and their variability were 
estimated using nonlinear mixed effect modeling in NONMEM. Relationships between 
patient characteristics and PK parameters were evaluated to explain variability.
Results FIX versus time profiles were adequately described using a three-compartment 
model Average clearance (CL), inter-compartmental clearance (Q2, Q3), distribution 
volume of the central compartment (V1) and peripheral compartments (V2, V3), plus 
inter-patient variability (%) were: CL: 251 mLh-170kg-1 (13%), V1: 4950 mL70kg-1 (13%), 
Q2: 91.3 mLh-170kg-1 (99%), V2: 7900 mL70kg-1 (57%), Q3: 831 mLh-170kg-1, V3: 1600 
mL70kg-1. With increasing age, CL and V1 increased 1.2% and 1.9% per year, respectively, 
until the age of 32 years (p<0.001, p<0.01). Compared to patients treated in the United 
Kingdom, CL and V1 were 20.1% and 28.3% higher (p<0.01, p<0.01) than in patients 
treated in the Netherlands. Furthermore, a 9.8% decrease for V1 was associated with the 
use of tranexamic acid during a surgical procedure.
Conclusion Measured perioperative FIX were described adequately by the established 
population PK model. The estimated population PK parameters were significantly differ-
ent from those reported for prophylactic treatment. The present population PK analysis 
will be continued to develop a model that can be used prospectively to perform PK-
guided dosing of FIX concentrates during surgery.
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INTRODUCTION
Hemophilia B is an X-linked bleeding disorder characterized by a deficiency of coagulation 
factor IX (FIX). Severity is categorized according to a patient’s endogenous FIX coagulant 
activity level (FIX). Severe, moderate-severe and mild patients have an endogenous FIX 
of <0.01 IUmL-1, 0.01 to 0.05 IUmL-1 and >0.05 IUmL-1, respectively.1 Treatment consists 
of replacement therapy with plasma-derived or recombinant FIX concentrates.2, 3 These 
are administered ‘on demand’, in case of an acute bleed, or prophylactically, in patients 
with a severe bleeding phenotype, to prevent spontaneous joint bleedings. Prophylaxis 
is aimed at increasing trough FIX >0.01 IUmL-14, as moderate severe patients have sig-
nificantly less spontaneous bleeds than severely affected patients. However, to ensure 
hemostasis during a surgical procedure, trough FIX are prescribed which range from 
0.30 to 1.00 IUmL-1.5
Current guidelines specify FIX dosing according to body weight for prophylaxis, “on 
demand” treatment and in the perioperative setting. However, due to a heterogeneous 
treatment response and inter-patient variability in pharmacokinetics (PK), these doses 
are generally tailored to an individual’s need based on measured FIX levels. In situations 
of high risk of bleeding, monitoring is applied to ensure appropriate FIX. Fortunately, PK 
of plasma-derived FIX (pdFIX) and recombinant FIX (rFIX) is well documented.6, 7 Several 
population PK models, describing the PK of FIX concentrates for a cohort of patients 
rather than individual patients, have been reported.4, 8-10 So far, however, these models 
have all been constructed using data collected during prophylactic dosing of FIX. Dur-
ing the perioperative setting, it is suspected that the PK of FIX may be altered due to 
hemostatic challenges and consumption or loss of FIX.
In a retrospective study, Hazendonk et al.11 reported that 60% of hemophilia B patients 
have a FIX below specified target range during the first 24 hours of the surgical proce-
dure. Subsequently, six days after surgery 59% the of the patients have a FIX above the 
specified target range. In this study, it was suggested that dosing of FIX during surgery 
may be individualized by PK guidance of dosing. Using a Bayesian technique, PK of an 
individual patient can be calculated iteratively, as subsequent FIX are collected.12, 13 This 
Bayesian approach allows calculation of individual PK parameters by using a population 
PK model which also takes patient’s achieved plasma concentration after an adminis-
tered dose into account. By means of PK-guided dosing, target attainment can be opti-
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mized and bleeding risk, due to low inappropriate dosing, can be prevented. To date, no 
studies have been reported describing PK-guided dosing of FIX in hemophilia B patients 
undergoing elective surgical procedures.
In this study, we aimed to develop a population PK model describing perioperative FIX 
concentrations in hemophilia B patients using detailed retrospective perioperative FIX 
dosing data.11
METHODS
Patients and data
A multicenter observational cohort study was performed in which retrospective data 
was collected from 118 severe and moderate (defined as baseline FIX <0.05 IUmL-1) 
hemophilia B patients from five Hemophilia Treatment Centers in the Netherlands and 
five Hemophilia Treatment Centers in the United Kingdom. Patients of all ages, who had 
undergone a minor or major elective surgical procedure, were included. Details of the 
study have been reported previously.11
Clotting factor IX products
To ensure hemostasis during the surgical procedure, patients received replacement 
therapy with FIX concentrates. The following plasma-derived FIX products [AlphaNine® 
SD (Grifols Biologicals Inc., Los Angeles, USA), Replenine® (Bio Products Laboratory, 
Hertfordshire, UK), Haemonine® (Biotest Pharma GmbH, Dreierich, Germany), Mono-
nine® (CSL Behring GmbH, Marbourg, Germany), Nonafact® (Sanquin, Amsterdam, the 
Netherlands)] and the following recombinant FIX products [BeneFix® (Pfizer Wyeth 
Pharmaceuticals Inc., Kent, UK) and IXinity® (Aptevo BioTherapeutics LLC, Berwyn, US)] 
were administered.
Pharmacokinetic modeling
In population PK modeling, PK is assessed in a cohort of patients rather than in an 
individual patient.14 In the development of a population model, typical (average) PK 
parameter values and their intra- and inter-patient variability are estimated in combina-
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tion with residual variability. After this process, it is evaluated to what extent covariates 
explain these different kinds of variability.
In this study, a perioperative FIX population PK model was built by means of nonlinear 
mixed-effects modeling.15 Perioperative FIX dosing and FIX measurement data was ana-
lyzed simultaneously using NONMEM version 7.3 (ICON Development Solutions, Ellicott 
City, MD, USA).16 First-order conditional estimation (FOCE), in which the first-order Taylor 
expansion of the PK model is used, was applied to obtain all model parameter estimates. 
For PK parameters estimation, a transform-both-sides approach was used. Hereby, the 
FIX measurements from the data as well as the model predicted FIX are both logarithmi-
cally transformed.
PsN version 4.6.0 was used to aid model development and Pirana served as a model 
management tool. Data modification and model diagnostics were performed using R 
version 3.2.2 (R Development Core Team, 2015) with software-package Xpose version 
4.5.3.17-19
To evaluate the ability of the established models to describe the data, diagnostic evalu-
ation was performed using the obtained precision of the estimated model parameters, 
goodness-of-fit plots, condition number and visual predictive checks (VPC).20, 21 In the 
latter method, simulated concentrations from the established model are compared to 
the actual obtained plasma concentrations.
An objective function value (OFV), which depicts the fitting ability of the model, was 
calculated by minus two times the logarithm of the likelihood (-2LL) of the model to 
describe the data. To discriminate between hierarchical models, the difference of the 
OFVs (dOFV) was calculated. This value is known to be described by a c2 distribution, 
in which the degrees of freedom (df ) are calculated by the difference in the number of 
parameters between the evaluated (nested) models. Therefore, a dOFV of >3.84, >5.99 
and >7.81 corresponds to 1, 2, and 3 df, respectively, associated to an p-value of <0.05.
Structural model development
In literature, the population PK of FIX is mostly described by a three-compartment 
model.4, 8, 9, 22 In our study, however, it was uncertain whether the data would allow to es-
timate all parameters for a three-compartment model with adequate precision, since the 
precision of these estimates is determined by the timing of blood sampling. Therefore, 
development of the model was initiated by fitting a two-compartment model to the 
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data. Subsequently, it was evaluated if addition of an extra compartment to the model 
would improve the fit. Hereby, model building was performed in a stepwise manner.
For a two-compartment model, estimated PK parameters were clearance from the cen-
tral compartment (CL), inter-compartmental clearance (Q2), and volume of the central 
compartment (V1) and second peripheral compartment (V2). For a three-compartment 
model, inter-compartmental clearance between the central and the third peripheral 
compartment (Q3) and volume of the third peripheral compartment (V3) were added 
to the model. Inter-individual variability (IIV) was estimated using an exponential model 
(see equation 1 below). Furthermore, different residual error models were evaluated, 
including an additive, proportional and combined (additive and proportional) error 
model. In case a proportional or combined error model was applied to the model, inter-
action between residual and IIV was allowed for the FOCE method.
First, a structural model was developed, consisting of estimated population PK param-
eters, for which interpatient variability can be estimated as well, and residual variability. 
Because various patients underwent more than one surgical procedure, inter-occasion 
(between-surgery) variability (IOV) of the PK parameters was also estimated. An expo-
nential model was used to estimate IIV and IOV, as described by the following equation:
(1) θik = θTV x expηi+κik
in this expression, the subscripts i and k denote the number of the individual and oc-
casion, respectively, θTV is the estimated typical (average) value for a population PK 
parameter, θik is the estimated individual PK parameter, and η and κ are the random 
effects accounting for IIV and IOV, respectively. Both random effects describe individual 
deviation from the typical value and are assumed to follow a Gaussian distribution with 
a mean of zero and an estimated variance of ω2 and π2, respectively. In case dosing 
information was missing before the first FIX measurement, all model-compartments 
were initialized using this value. This would allow all model parameters to describe the 
disposition from this time-point onwards, instead of using only the terminal elimination 
half-life to correct for pre-dose measurements.23
PK parameters were allometrically scaled a priori (i.e. no evaluation of scaling perfor-
mance was conducted) using body weight, which is described by the following equation:
 
PK parameters w r  allom trically scal d a priori (i.e. no ev luati n of scali g performance was 
conducted) using body weight, which is described by the following equation: 
 =    (
70
)
in which θi is a population PK parameter, θTV is the typical value for this parameter, BW is body 
weight and θp is the allometric exponent. Allometric exponents were ﬁxed to 1 in case of a volume 
parameter (V1, V2, V3) and to 0.75 for all clearance parameters (CL, Q2, Q3). A median body weight 
of 70 kg was used to describe the PK parameter typical values. 
For every patient age was known at each surgical procedure. However, body weight was missing in 
40 surgical procedures (16%). Therefore, we developed a linear model in NONMEM to impute body 
weight using age as a predictor. First, by graphical exploration of distribution of age and body weight 
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in which θi is a population PK parameter, θTV is the typical value for this parameter, BW 
is body weight and θp is the allometric exponent. Allometric exponents were fixed to 1 
in case of a volume parameter (V1, V2, V3) and to 0.75 for all clearance parameters (CL, 
Q2, Q3). A median body weight of 70 kg was used to describe the PK parameter typical 
values.
For every patient age was known at each surgical procedure. However, body weight 
was missing in 40 surgical procedures (16%). Therefore, we developed a linear model in 
NONMEM to impute body weight using age as a predictor. First, by graphical exploration 
of distribution of age and body weight a piecewise linear model was selected to predict 
the missing values. The following equation was used to impute missing body weight:
 
 
PK parameters were allometrically scaled a priori (i.e. no evaluation of scaling performance was 
conducted) using body weight, which is described by the following equation: 
 =    (
70
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in which θi is a population PK parameter, θTV is the typical value for this parameter, BW is body 
weight and θp is the allometric exponent. Allometric exponents were ﬁxed to 1 in case of a volume 
parameter (V1, V2, V3) and to 0.75 for all clearance parameters (CL, Q2, Q3). A median body weight 
of 70 kg was used to describe the PK parameter typical values. 
For every patient age was known at each surgical procedure. How v r, body ight was missing in 
40 surgical procedures (16%). Therefore, we developed a linear model in NONMEM to impute body 
weight using age as a predictor. First, by graphical exploration of distribution of age and body weight 
a piecewise linear model was selected to predict the missing values. The following equation was used 
to impute missing body weight: 
 =  1 + 2 + 3 ( −  4)  5  {
≤  4: 5 = 0
>  4: 5 = 1
in which θBW is the imputed body weight, β1 is the estimated y-intercept of the linear model, β2 the 
estimated coeﬃcient of the predictor age for all ages, β3 the estimated coeﬃcient for the predictor 
age after the inﬂexion point estimated using β4. Since β3 only describes body weight after this 
inﬂexion point, β5 is 0 below this age and 1 in other cases. 
 
Covariate analysis 
After the ﬁnal structural model was established, relationships between covariates and PK parameters 
were evaluated. Based on clinical relevance, graphical evaluation and covariate correlations a pre-
selection on eligible relations was conducted. These relations were evaluated on their ability to 
explain the IIV of the PK parameters or residual variability. A stepwise covariate modeling (SCM) 
procedure from PsN was applied to evaluate pre-selected covariate relationships to the model 
parameters.24 In this procedure, the covariate relations are evaluated using a forward inclusion step, 
in which all eligible covariate relations are tested using a univariate analysis. After this step, the 
covariate relation with the lowest p-value (minimum of 0.05) is included in the (new) model in the 
consecutive step. This procedure is performed until all signiﬁcant covariate relations are included. 
Likewise, the backward elimination evaluates if the covariate relations, included by the ﬁnal forward 
step, retain in the model using a more conservative p-value of 0.01. 
 
 
Final model evaluation 
In the ﬁnal model, all covariate relations are included. By means of a bootstrap-analysis, the 
robustness of the ﬁnal model in terms of stability and estimation performance is evaluated.25 In the 
bootstrap-analysis, 1000 bootstrap data sets are created from the original data set in which the data 
from all patients are randomly sampled using permutation with replacement. From this procedure, 
in which θBW is the imputed body weight, β1 is the estimated y-intercept of the linear 
model, β2 the estimated coefficient of the pr dictor age for all age , β3 the estimated 
coefficient for the predictor age after the inflexion point estimated using β4. Since β3 
only describes body weight after this inflexion point, β5 is 0 below this age and 1 in other 
cases.
Covariate analysis
After the final structural mod l wa  est bli h d, relationships between covariates and 
PK parameters were evaluated. Based on clinical relevance, graphical evaluation and 
covariate correlations a pre-selection on eligible relations was conducted. These rela-
tions were valu t d on their ability to expl in the IIV of the PK parameters or residual 
variability. A stepwise covariate modeling (SCM) procedure from PsN was applied to 
evaluate pre-selected co ri te relationships to the mo el parameters.24 In this pro-
cedure, the covariate relations are evaluated using a forward inclusion step, in which 
all eligible covariate relations are tested using a univariate analysis. After this step, the 
covariate relation with the lowest p-value (minimum of 0.05) is included in the (new) 
model in the consecutive step. This procedure is performed until all significant covariate 
relations are included. Likewise, the backward elimination evaluates if the covariate rela-
tions, included by the final forward step, retain in the model using a more conservative 
p-value of 0.01.
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Final model evaluation
In the final model, all covariate relations are included. By means of a bootstrap-analysis, 
the robustness of the final model in terms of stability and estimation performance is 
evaluated.25 In the bootstrap-analysis, 1000 bootstrap data sets are created from the 
original data set in which the data from all patients are randomly sampled using per-
mutation with replacement. From this procedure, standard errors can be calculated 
amongst all obtained estimates from all bootstrap datasets. These standard errors depict 
the influence of the input data on the obtained model parameter estimates.
RESULTS
Patients and data
In total, 118 severe and moderate-severe hemophilia B patients were included in the 
cohort undergoing 255 surgical procedures. Surgical and patient characteristics are 
shown in Table 1.
Body weight was not recorded in 16% of all occasions. Therefore, a piecewise linear 
model was developed, from which body weight could be calculated using age. Param-
eter estimates for the piecewise linear model, describing the relationship between age 
and body weight, are shown in Supplementary Table 1. The relationship between age 
and body weight is shown in Supplementary Figure 1; the line depicts the predictions 
from the model used to calculate values for missing body weight.
Pharmacokinetic modeling
A three-compartment population PK model provided a better fit to the data than a 
two-compartment model, according to the drop in OFV (Table 2). In Figure 1, a general 
presentation of a three-compartment model is shown. NONMEM subroutine ADVAN11 
with TRANS4 was applied, comprising estimates for CL, V1, Q2, V2, Q3 and V3. Model 
building was conducted using a stepwise approach and models were evaluated sepa-
rately for their ability to describe the data. In Table 2, the decrease in OFV is shown for 
several building steps. The individual residual endogenous FIX were obtained from the 
patient’s chart and were subtracted from each observed FIX.
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6In the structural model, the typical PK parameters were allometrically scaled a priori. All PK parameters were scaled to a body weight of 70 kg and were estimated with high precision (<25% relative standard error). In comparison with an additive residual error model, application of a proportional residual error or combined residual error model did 
not improve the fit of the structural model to the data.
In the final base model, inter-patient variability for CL, V1, V2 and Q2 could be estimated, 
as shown in Table 2. Furthermore, covariance between inter-patient and inter-occasion 
variability was evaluated. Correlation between inter-patient variability for CL and 
V1 was high (100%), which negatively influenced model convergence. Therefore, we 
constrained the inter-patient variability estimates on CL and V1 to be the same using 
following equations:
 
 , = , ∗ ( 1 + )
 1, = 1, ∗ ( 1  + )
in which i and k denote the number of individual and occasion, respectively, η1 describes the IIV of 
parameters CL as well as V1, and θη is used to estimate the ratio between the (shared) IIV of CL and 
V1. Hereby, correlation of IIV for CL and V1 was constrained to 100%. 
 
The ﬁt of the established structural model to the data was evaluated by using goodness-of-ﬁt plots, 
as shown in Figure 2. Figure 2B shows a slight overprediction of the highest FIX. However, few data is 
present in this concentration region. For the largest part of the concentration region, data are 
randomly distributed around the y=x axis. Figure 2A demonstrates that the model is able to describe 
the measured FIX for all individuals. Nevertheless, this ﬁgure should be considered with caution, 
because the described IIV showed marked shrinkage (IIVCL: 35%, IIVV1: 31%, IIVQ2: 38%, IIVV2: 66%) for 
all estimates, whereas the ε-shrinkage was small (10.5%). High shrinkage indicates that values for 
individual PK parameters cannot be estimated accurately. As a consequence, these individual 
26
in which i and k denote the number of individual and occa ion, respectively, η1 describes 
the IIV of parameters CL as well as V1, and θη is used to estimate the ratio between the 
(shared) IIV of CL and V1. Hereby, correlation of IIV for CL and V1 was constrained to 
100%.
Figure 1. Depiction of a three-compartment population PK model
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Intravenous doses of clotting factor are administered into the central compartment. From this compart-
ment disposition occurs to the other compartments. In the pharmacokinetic model, FIX:C represents the 
plasma levels of FIX in the central compartment (V1). CL: clearance from central compartment; Q2: inter-
compartmental clearance between central en second compartment; V2: distribution volume of second 
(peripheral) compartment; Q3: inter-compartmental clearance between central en third compartment; V3: 
distribution volume of third (peripheral) compartment.
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Table 1. General characteristics of the study population
Total cohort Adults Children
No. (%); or Median [IQR]
Patient characteristics
No. of patients 118 82 36
Age (years) 40 [22-58] 46 [34-59] 6 [2-11]
Body weight (kg) 79 [65-92] 85 [73-95] 19 [13-39]
Severe hemophilia B (<0.01 IUmL-1) 85 (72) 57 (70) 28 (78)
On prophylaxis 36 (31) 28 (34) 8 (22)
Blood group O* 33 (28) 24 (29) 9 (25)
Neutralizing antibodies (historically) 6 (5) 5 (6) 1 (3)
Chronic hepatitis C 47 (40) 46 (56) 1 (3)
Surgical characteristics
No. of surgical procedures 255 201 54
Total no. of patients undergoing:
1 55 33 33 22
2 31 21 21 10
≥3 42 28 28 4
Major surgical procedure 120 (47) 105 (52) 15 (28)
Type of surgical procedure
General 19 (7) 16 (8) 3 (6)
Colorectal 16 (6) 14 (7) 2 (4)
Vascular 9 (4) 9 (4) 0 (0)
Cardio-thoracic 3 (1) 2 (1) 1 (2)
Orthopedic 99 (39) 92 (46) 7 (13)
Urological 11 (4) 11 (5) 0 (0)
Maxillofacial 1 (0) 1 (0) 0 (0)
Ear-Nose-Throat 9 (4) 5 (2) 4 (7)
Neurosurgery 1 (0) 1 (0) 0 (0)
Eye surgery 2 (1) 2 (1) 0 (0)
(Re)placement central intravenous catheters 27 (11) 2 (1) 25 (46)
Dental extractions 31 (12) 25 (12) 6 (11)
Miscellaneous 27 (11) 21 (10) 6 (11)
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The fit of the established structural model to the data was evaluated by using goodness-
of-fit plots, as shown in Figure 2. Figure 2B shows a slight overprediction of the highest 
FIX. However, few data is present in this concentration region. For the largest part of 
the concentration region, data are randomly distributed around the y=x axis. Figure 2A 
demonstrates that the model is able to describe the measured FIX for all individuals. 
Nevertheless, this figure should be considered with caution, because the described IIV 
showed marked shrinkage (IIVCL: 35%, IIVV1: 31%, IIVQ2: 38%, IIVV2: 66%) for all estimates, 
whereas the ε-shrinkage was small (10.5%). High shrinkage indicates that values for 
individual PK parameters cannot be estimated accurately. As a consequence, these 
individual estimates are closer to their average value than in reality.26
Table 1. General characteristics of the study population (continued)
Total cohort Adults Children
No. (%); or Median [IQR]
Replacement therapy with factor concentrate, hospitalization and blood loss
Mode of infusion
Continuous 56 (22) 54 (27) 2 (4)
Bolus 199 (78) 147 (73) 52 (96)
Product type
Recombinant$ 201 (79) 150 (75) 51 (91)
Plasma derived# 54 (21) 51 (25) 3 (6)
Duration of hospitalization (days) 4 [2-9] 5 [2-11] 4 [2-5]
Complications during perioperative period
No. of patients suffering from a complication
Bleeding
Re-operation 2 (2) 2 (2) 0 (0)
Hemoglobin drop >1,24 mmolL-1 23 (19) 17 (21) 6 (17)
Red blood cell transfusion 1 (1) 1 (1) 0 (0)
Thrombosis 0 (0) 0 (0) 0 (0)
No. = number; IQR = inter-quartile range; kg = kilogram; IUmL-1 = international units per milliliter; * Blood 
group available in 80 patients; $ including BeneFix (Pfizer Wyeth Pharmaceuticals Inc., Kent, UK); # Including 
AlphaNine (Grifols Biologicals Inc. Los Angeles, USA); Replenine (Bio Products Laboratory, Hertfordshire, 
UK); Haemonine (Biotest Pharma GmbH, Dreierich, Germany); Mononine (CSL Behring GmbH, Marbourg, 
Germany); Nonafact (Sanquin, Amsterdam, the Netherlands).
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Covariate analysis
In the pre-selection of covariate relationships, the distinction between severe or moderate 
hemophilia, age, the use of tranexamic acid during surgery, the use of recombinant versus 
plasma-derived products, country of treatment and brand of product were evaluated on 
CL and V1. For V1, a difference between treatment centers was evaluated as well. For V2, 
age, the use of tranexamic acid and the distinction between severe and moderate hemo-
philia, and for Q2, the use of plasma-derived versus recombinant products, age, the use of 
tranexamic acid, the presence of hepatitis C, the country of treatment and the severity of 
the surgical procedure (see Table 1, Major surgical procedures) were evaluated.
Using the SCM method, age was found to be significantly associated to the population 
PK parameters CL and V1, as shown in Table 3. In Figure 3, age versus individual param-
eter values for CL and V1 are shown. In both cases, a piecewise-linear model was chosen 
to describe the relationship between age and the PK parameter:
 
 , = , ∗ ( 1 + )
 1, = 1, ∗ ( 1  + )
in which i and k denote the number of individual and occasion, respectively, η1 describes the IIV of 
parameters CL as well as V1, and θη is used to estimate the ratio between the (shared) IIV of CL and 
V1. Hereby, correlation of IIV for CL and V1 was constrained to 100%. 
 
The ﬁt of the established structural model to the data was evaluated by using goodness-of-ﬁt plots, 
as shown in Figure 2. Figure 2B shows a slight overprediction of the highest FIX. However, few data is 
present in this concentration region. For the largest part of the concentration region, data are 
randomly distributed around the y=x axis. Figure 2A demonstrates that the model is able to describe 
the measured FIX for all individuals. Nevertheless, this ﬁgure should be considered with caution, 
because the described IIV showed marked shrinkage (IIVCL: 35%, IIVV1: 31%, IIVQ2: 38%, IIVV2: 66%) for 
all estimates, whereas the ε-shrinkage was small (10.5%). High shrinkage indicates that values for 
individual PK parameters cannot be estimated accurately. As a consequence, these individual 
estimates are closer to their average value than in reality.26 
 
Covariate an lysis 
In the pre-selection of covariate relationships, the distinction between severe or moderate 
hemophilia, age, the use of tranexamic acid during surgery, the use of recombinant versus plasma-
derived products, country of treatment and brand of product were evaluated on CL and V1. For V1, a 
diﬀerence between treatment centers was evaluated as well. For V2, age, the use of tranexamic acid 
and the distinction between severe and moderate hemophilia, and for Q2, the use of plasma-derived 
versus recombinant products, age, the use f tranexamic acid, the presence of hepatitis C, the 
country of treatment and the severity of the surgical procedure (see Table 1, Major surgical 
procedures) were evaluated. 
Using the SCM method, age was found to be signiﬁcantly associated to the population PK parameters 
CL and V1, as shown in Table 3. In Figure 3, age versus individual parameter values for CL and V1 are 
shown. In both cases, a piecewise-linear model was chosen to describe the relationship b tween ag  
and the PK parameter: 
 = ∗ (( 1 ∗ ( − ))
2 + ( 3 ∗ ( − ))
(1− 2))
in this expression, θ2 is 1 if age of an individual is less than or equal to its population median and 0 
otherwise, θ1 and θ3 are the coeﬃcients for age below or equal to its population median and above, 
respectively, θTV the parameter typical mean value and θi the individual PK parameter. Median age 
calculated for this population was 32.2 years. 
Other signiﬁcant covariate relationships provided by the SCM method were country and the use of 
tranexamic acid during a surgical procedure. Both covariate relations were additively associated to CL 
Table 2. Model-building steps
NOP OFV
Structural model
1 Two-compartment model with IIV on V1 and CL 7 -2313.7
2 Baseline FIX:C measurements added to model 1 7 -2343.1
3 IOV for both CL and V1 added to model 2 9 -2522.5
4 IIV for both V2 and Q2 added to model 3 11 -2612.3
5 Three-compartment model with IIV on CL, V1, V2, and Q2 and Baseline 13 -2657.8
Univariate relationships (covariates added to model 5)
4 AGE on V1 14a -2667.2
5 Country on V1 15 -2673.7
6 Tranexamic acid on V1 16 -2679.6
7 Country on CL 17 -2686.9
8 AGE on CL 18a -2713.8
NOP = number of estimated parameters; OFV = objective function value; IIV = inter-individual variability; CL 
= Clearance; V1 = distribution volume of the central compartment; V2 = distribution of the second compart-
ment; Q2 = inter-compartmental clearance between central and second compartment. a For these models, 
the coefficients for covariate age on both CL and 1 were estimated using a hockey-stick m del. However, the 
coefficients for ll ages above medi n age were fixed to 0. Therefore, the NOP is only lowered by 1.
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in this expression, θ2 is 1 if age of an individual is less than or equal to its population 
median and 0 otherwise, θ1 and θ3 are the coefficients for age below or equal to its 
population median and above, respectively, θTV the parameter typical mean value and θi 
the individual PK parameter. Median age calculated for this population was 32.2 years.
Other significant covariate relationships provided by the SCM method were country and 
the use of tranexamic acid during a surgical procedure. Both covariate relations were 
additively associated to CL or V1, which was described by the following equation:
 
 , = , ∗ ( 1 + )
 1, = 1, ∗ ( 1  + )
in which i and k denote the number of individual and occasion, respectively, η1 describes the IIV of 
parameters CL as well as V1, and θη is used to estimate the ratio between the (shared) IIV of CL and 
V1. Hereby, correlation of IIV for CL and V1 was constrained to 100%. 
 
The ﬁt of the established structural model to the data was evaluated by using goodness-of-ﬁt plots, 
as shown in Figure 2. Figure 2B shows a slight overprediction of the highest FIX. However, few data is 
present in this concentration region. For the largest part of the concentration region, data are 
randomly distributed around the y=x axis. Figure 2A demonstrates that the model is able to describe 
the measured FIX for all individuals. Nevertheless, this ﬁgure should be considered with caution, 
because the described IIV showed marked shrinkage (IIVCL: 35%, IIVV1: 31%, IIVQ2: 38%, IIVV2: 66%) for 
all estimates, whereas the ε-shrinkage was small (10.5%). High shrinkage indicates that values for 
individual PK parameters cannot be estimated accurately. As a consequence, these individual 
estimates are closer to their average value than in reality.26 
 
Covariate analysis 
In the pre-selection of covariate relationships, the distinction between severe or moderate 
hemophilia, age, the use of tranexamic acid during surgery, the use of recombinant versus plasma-
derived products, country of treatment and brand of product were evaluated on CL and V1. For V1, a 
diﬀerence between treatment centers was evaluated as well. For V2, age, the use of tranexamic acid 
and the distinction between severe and moderate hemophilia, and for Q2, the use of plasma-derived 
versus recombinant products, age, the use of tranexamic acid, the presence of hepatitis C, the 
country of treatment and the severity of the surgical procedure (see Table 1, Major surgical 
procedures) were evaluated. 
Using the SCM method, age was found to be signiﬁcantly associated to the population PK parameters 
CL and V1, as shown in Table 3. In Figure 3, age versus individual parameter values for CL and V1 are 
shown. In both cases, a piecewise-linear model was chosen to describe the relationship between age 
and the PK parameter: 
 = ∗ (( 1 ∗ ( − ))
2 + ( 3 ∗ ( − ))
(1− 2))
in this expression, θ2 is 1 if age of an individual is less than or equal to its population median and 0 
otherwise, θ1 and θ3 are the coeﬃcients for age below or equal to its popul tion median and above, 
respectively, θTV the parameter typical mean value and θi the individual PK parameter. Median age 
calculated for this population was 32.2 years. 
Other signiﬁcant covariate relationships provided by the SCM method were country and the use of 
tranexamic acid during a surgical procedure. Both covariate relations were additively associated to CL 
or V1, which was de cribed by the following equation: 
 = ∗ (1 + )
in which θcov is the fraction of the typical PK parameter θTV, which was calculated in case a patient 
was treated in the Netherlands or used tranexamic acid during a surgical procedure, respectively. In in which θcov is the fraction of the typical PK parameter θTV, which was calculated in 
case a patient was treated in the Netherlands or used tranexamic acid during a surgical 
procedure, respectively. In other cases θcov was 0, meaning θTV was not altered. V1 was 
9.8% higher than the associated population typical value in case tranexamic acid was 
Figure 2. Goodness-of-fit of plot for the base model
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FIX:C = FIX activity level. 3A. Individual predicted versus measured FIX:C. 3B. Population predicted versus 
measured FIX:C. 3C. Conditi nal weighted residuals (CWRES) versus population predict d FIX:C. 3D. CWRES 
versus time, in which time is defined as the time of first measured or first dosing, whichever occurs first.
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Table 3. Estimated population PK parameters for the structural model, final model and bootstrap analysis
Structural model Final model Bootstrap analysis
Estimate (%RSE) Estimate (%RSE) Estimate (%RSE)a
Structural model
Clearance (CL; mLh-170kg-1) 286 3 251 3 251 4
Volume of central compartment (V1; 
mL70kg-1)
5550 4 4950 3 4935 3
Distribution CL to compartment 2 (Q2; 
mLh-170kg-1)
92.7 14 91.3 11 92.2 14
Volume of compartment 2 (V2; mL70kg-1) 7880 21 7900 14 7756 29
Distribution CL to compartment 3 (Q3; 
mLh-170kg-1)
1580 54 831 8 847 72
Volume of compartment 3 (V3; mL70kg-1) 1810 17 1600 12 1659 17
Inter-individual variability (%CV)
IIV on CL 17.4 12 12.5 19 12.2 39
IIV on V1Δ 19.6 14 13.3 21 12.9 25
IIV on Q2 84.9 14 98.9 12 98.6 30
IIV on V2 48.7 27 56.8 27 51.1 83
Inter-occasion variability (%CV)
IOV CL 18.9 11 18.8 11 18.6 23
IOV V1 16.5 14 15.8 13 15.9 29
Covariance between IOV on CL and V1 68.3 14 68.6 13 70.2 27
Residual variability
Additive residual error (SD; IUmL-1)§ 0.192 5 0.192 5 0.192 5
Covariate relations
CL – Age (change with increasing age for age 
<32 years)
-0.012 21 -0.012 22
CL – Country 0.202 31 0.204 31
V1 – Age (change with increasing age for age 
<32 years)
-0.019 18 -0.019 17
V1 – Country 0.283 23 0.280 24
V1 – Tranexamic acid use during surgical 
procedure
-0.098 49 -0.093 50
† IIV: Inter-individual variability; ‡ RSE: relative standard error; § Additive error estimated on log-scale; Δ Pa-
rameter was estimated using a ratio estimator on shared inter-individual variability parameter; CV: coeffi-
cient of variation. SD: standard deviation. a Relative standard errors for parameter estimates obtained from 
bootstrap analysis.
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used during the surgical procedure. In case a patient was treated in the Netherlands, CL 
and V1 were 20.1% and 28.3% higher, respectively, than their corresponding population 
typical values (Table 3).
Product brand was evaluated as a categorical covariate and found to be significantly 
associated to V1. However, when associated to the model parameters using equation 
7 for each specific brand, high uncertainty for the estimated coefficients were found. 
Moreover, due to a high condition number (>1000), indicating over-parameterization, 
product brand was not used as a covariate relationship on V1.
Figure 3. Age versus distribution volume and clearance
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In both plots the empirical Bayesian estimates for distribution volume (V1) and clearance (CL) versus age 
is shown. It can be seen that there is a steep increase for ages below 32 years. Likewise, for ages above 32 
years there is (on average) no change in the parameter values. Therefore, age was associated using a piece-
wise linear model (equation 6). In both graphs, trend lines were added using a linear model for ages below 
32 years and a (separate) linear model describing age above 32 years.
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Using all covariate relations from the SCM method, except for product, IIV for CL and V1 
decreased from 17.5% to 12.5% and from 19.6% to 13.3%, respectively, in comparison 
with the structural model.
Final model evaluation
To evaluate the final model, a visual predictive check was performed using 1000 Monte 
Carlo simulations from the established model, as shown in Figure 4. The simulated 
concentrations described the median of the observed data well. The observed median 
(solid red line) and 5th quantile (lower red dashed line) were within their respective 95% 
prediction intervals (grey area), whereas the 95th quantile of the observed FIX (upper red 
dashed line) is slightly below its prediction interval. This suggests that the model slightly 
over-predicts variability.
A bootstrap analysis was performed to evaluate the stability of the model regarding pa-
rameter estimation. Using this method, 1000 bootstrapped datasets were created, from 
which 78% converged. Obtained parameter estimates were similar to the estimates from 
Figure 4. Prediction-corrected visual predictive check of the final model
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Time is defined as the time after first FIX activity levels (FIX:C) measurement or first dose administration, 
whatever comes first, each surgical procedure of a patient. Dashed red lines depict the 5th and 95th quan-
tiles of the measured FIX:C and the solid red line the 50th quantile. The grey areas surrounding the red 
quantile lines depict the 95% prediction interval for the simulated values from the final model.
A perioperative population pharmacokinetic model for FIX concentrates • 145
6
Table 4. Population PK parameter estimates from published models
Model 1a Model 2b Model 3c
Estimate (%RSE) Estimate (%RSE) Estimate (%RSE)
Structural model
Clearance (CL; mLh-170kg-1) 319.8 7.2 290 3.7 560 3.1
Volume of central compartment (V1; 
mL70kg-1)
5922 7.0 5710 3.6 6090 14
Distribution CL to compartment 2 (Q2; 
mLh-170kg-1)
1049 20.3 1990 35 22400 28
Volume of compartment 2 (V2; mL70kg-1) 828.9 50.7 810 19 4160 17
Distribution CL to compartment 3 (Q3; 
mLh-170kg-1)
160.4 8.1 170 6.7 430 15
Volume of compartment 3 (V3; mL70kg-1) 2234 73.9 2890 10 3900 7.7
Inter-individual variability (%CV)Δ
IIV on CL 36.8 36.8 23 64 19 18
IIV on V1 41.2 34.2 19 37 46 36
IIV on V2 97.4 72.6 63 30 28 44
IIV on V3 133.2 34.5 78 81 19 71
Inter-occasion variability (%CV)
IOV CL 48.8 10.1 15 36 - -
IOV V1 47.2 17.8 12 24 - -
Residual variability
Additive residual variability (SD; IUmL-1) 0.0067 3.1 0.0037 10 0.0064 12
Proportional residual variability (CV; %) 6.95 1.5 9.2 11 8.7 4.9
Calculated half-life⌐
First phase (t1/2,α, h) 0.48 0.25 0.08
Second phase (t1/2,β, h) 6.2 6.7 4.1
Elimination phase (t1/2,γ, h) 23 28 20
a Brekkan, 2016. b Björkman, 2012. c Björkman, 2013. Δ Calculated for FOCE with interaction. ⌐ Half-life was 
calculated (without precision) using a closed-form solution for three compartments, using the population 
PK parameter typical values. Since only the structural part of the models with the random-effects were 
compared, allometric coefficients and covariate relations are not shown. Furthermore, correlations for IIV 
and IOV are not shown.
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the final model, as shown in Table 3. Comparing the relative standard errors obtained 
from the bootstrap analysis, values for PK parameter Q3 and IIV for V2 were large (72% 
and 83%). This indicates these parameters can vary amongst the bootstrapped datasets 
and therefore are suspected to be more unstable estimates.
DISCUSSION
In this study, a population PK model was established which describes the time profile of 
FIX in hemophilia B patients during surgery. Inter-patient and inter-occasion variability 
was modest and could be explained on basis of patient characteristics.
A three-compartment model adequately fitted the data, which is in agreement with pre-
viously published population PK models.8, 9, 22 However, these models were constructed 
using data from the prophylactic (non-surgical) setting. Population parameter estimates 
for these models are summarized in Table 4. In this study, an elimination half-life of 88 
hour and a second phase half-life of 12.7 hours were calculated. These are markedly 
higher compared to the elimination half-life for each of the models in Table 4. These 
differences are caused mainly due to the differences in PK parameters estimates of first 
peripheral compartment (Q2, V2). In Figure 5, the performance to predict the periopera-
tive FIX is shown and underprediction is seen for each model. This finding is counter 
intuitively, since it was expected that perioperative FIX would be overpredicted by each 
model due to lower FIX resulting from endogenous consumption. These findings clearly 
show that perioperative FIX PK is different from regular prophylaxis.
FIX is believed to distribute rapidly to the interstitial fluids due to its small molecular 
size7, which is supported by the estimates for the peripheral clearance terms in Table 4. 
However, the estimate for Q2 in this study was markedly lower, suggesting a less rapid 
first phase disposition to the interstitial fluids during the perioperative period. A tenta-
tive explanation for this finding is that endogenous consumption and complexation of 
FIX with FVIII during hemostatic challenge causes a lower distribution towards the in-
terstitial fluids. Therefore, a dedicated population PK model is needed when PK-guided 
dosing is performed in the perioperative period.
As body weight is known to be correlated with age, especially for children, estimation of 
an allometric exponent would interfere with estimation of the association between age 
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6and the PK parameters. In this study, however, allometric exponents were fixed to 0.75 (CL, Q2, Q3) and 1 (V1, V2, V3).27 Therefore, the relation between age and PK parameters, which were normalized using body weight, was investigated. In our study, an increase 
in age was associated to a decrease in CL as well as V1 until an age of 32 years. These 
findings are in accordance with a study with only adult patients, in which this relation-
ship was absent9. In Björkman et al.28, a similar piecewise linear relation was obtained 
compared to our findings (see Figure 4). In their results, clearance and (steady-state) 
distribution volume increased per rising age, for ages below 20 years. Above 20 years, 
there was virtually no change in clearance or distribution volume. In our study, covariate 
coefficients for ages above 32 years were fixed to 0, as virtually no change in parameter 
value was observed.
In previous studies, differences in PK were reported between plasma-derived and re-
combinant FIX products.4, 29, 30 The clearance of recombinant FIX products is found to be 
higher compared to plasma-derived products.4 In this study, a dichotomous covariate 
was used to evaluated the relationship between these product types and the estimated 
PK parameters. However, this covariate relationship was not retained in the final model 
using SCM. Therefore, further investigations should be focused towards confounding 
Figure 5. Predictions of perioperative FIX:C using population PK models for the prophylactic setting
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Population predictions, obtained using Bayesian analysis, for the perioperative data using three different 
models from literature. If a model was constructed using recombinant FIX data, the predictions were ob-
tained only for perioperative recombinant FIX data and likewise for plasma-derived FIX data. A: Predictions 
using model [Björkman, 2013]. B: Predictions using model [Björkman, 2012]. C: Predictions using model 
[Brekkan, 2016]. Black line is the line of identity (y=x). Blue line depicts the loess line. In each case, an under-
prediction of the perioperative FIX:C is shown for the models constructed using solely prophylactic data.
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factors for this covariate relationship, since findings from literature suggests a relation-
ship for clearance terms should be detected.
The final model indicated that CL and V1 differed between countries. CL and V1 were 
found to be 20.1% and 28.3% higher, respectively, when a patient was treated in the 
Netherlands. Due to preferences in choice of clotting factor concentrate brands be-
tween countries, further investigations should be focused towards the interference of 
combined or masked covariate effects of product and country on the mentioned PK 
parameters. However, the final backward model from the SCM method contained both 
covariate effects associated to CL, suggesting both covariate relations can be estimated 
simultaneously. Furthermore, the use of tranexamic acid decreased V1 by 9.8% and thus 
obtaining a lower V1. This corresponds to achieving higher FIX directly after dosing, 
when tranexamic acid is applied during a surgical procedure. However, to date there 
are no studies which demonstrate this pharmacodynamic effect. Besides, a decrease of 
10% would not be marked as clinically relevant. Therefore, further study is necessary to 
demonstrate this covariate relationship is established by a true covariate relationship 
instead of an association due to confounding.
A prerequisite for PK-guided dosing during regular prophylaxis is a low inter-occasion 
variability compared to the inter-individual variability. In this study, the estimates for 
IIV and IOV were similar. Compared to the perioperative PK of FVIII, IIV was comparable 
when IOV was also taken into account for describing the total variability of CL and V1 in 
the patient population.31 However, in the perioperative setting the variability described 
within an individual (between occasions) may be influenced by the types of surgical 
procedure. For all occasions of a specific individual, these types can vary between minor 
and major surgical interventions. Nevertheless, no relationship between type of surgery 
and the PK parameters estimated was found in this study.
In all efforts to prevent the occurrence of bleeding events in hemophilia B using doses 
of factor IX concentrates, the exact relationship between hemostasis and achieved 
FIX is unknown. During perioperative treatment, patients are ‘normalized’ towards 
physiological concentrations for FIX to ensure hemostasis. While irrefutable evidence for 
perioperative target concentrations is missing, PK-guided dosing may be used to obtain 
the desired FIX. In this study, a population PK model was developed, which can be used 
to individualize and optimize FIX dosing using a Bayesian approach. In this approach, 
individual information (dose, concentration) is combined with population information 
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(fixed, random-effects) to estimate individual PK parameters. Using these parameters, 
doses can be tailored to achieve target concentration attainment for a specific individual.
Using Bayesian analysis, this model can be used to individualize FIX replacement 
therapy in the perioperative setting. Application of perioperative PK-guided FIX dosing 
allows more optimal and adequate FIX dosing. Hazendonk et al. have demonstrated 
that improvement is possible as 60% of achieved trough and steady-state FIX were 
below required target concentration range during the first 24 hours after the start of the 
surgical procedure.11 However, these ranges were not evidently associated to bleeding 
complications. Therefore, it was suggested that target attainment during the periopera-
tive period is complex and target ranges may potentially be lowered.11 Nevertheless, 
PK-guided dosing may enable to reliably lower perioperative doses for hemophilia B 
patients without raising risk of bleeding.
CONCLUSIONS
This study provides a preliminary PK analysis of FIX dosing for hemophilia B patients 
undergoing surgery. A three-compartment perioperative population PK model was 
established using FIX levels obtained during the perioperative period. Age, country of 
treatment and the use of tranexamic acid during a surgical procedure were associated 
to the model as covariate relations. A relationship between the PK parameters from the 
model and the different brand of product could not be established. However, the model 
was constructed using both pdFIX and rFIX dosing information. Therefore, the model is 
suitable to describe both mentioned types of FIX concentrates.
Inter-patient differences in FIX PK should be taken into account when optimizing treat-
ment regimens. These differences are accounted for by means of patient tailored dosing, 
in which individual PK parameters obtained from an appropriate population PK model 
is essential.
PK parameter estimates for the established final model clearly demonstrates that the PK 
of FIX in the perioperative period is different from dosing during the regular prophylac-
tic setting. Therefore, it has been advocated that attainment of target plasma activity 
levels should be considered using iterative Bayesian adaptive dosing, which comprises 
the use of a population PK model in lieu of body weight for calculation of individualized 
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doses. Since this is a preliminary study, the established structural model and associated 
covariate relations should be further investigated.
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Supplemental Table/Figure
Supplemental Table 1. Model for body weight imputation using age
Parameter Unit Mean (%RSE)‡
β1 – y-intercept kg 6.3 (7)
β2 – coefficient for all ages kg year-1 3.6 (5)
β3 – coefficient for age > β4 kg year-1 -3.73 (7)
β4 – Inflexion point year 23.5 (8)
Residual variability
Proportional error (CV)§ % 19.1 (6)
‡ RSE: relative standard error; Kg = kilogram; § measured on normal scale; CV: coefficient of variation.
Supplemental Figure 1. Imputed weight based on age from all individuals
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Black dots are individual body weights plotted versus age for all patients. The black line depicts the predict-
ed body weight with age as predictor, described by the piecewise linear model (equation 3 in the method 
section).
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SUMMARy
Background Hemophilia A is an X-linked inherited, rare bleeding disorder, caused by a 
deficiency of coagulation factor VIII (FVIII). Previous studies in prophylactic dosing have 
demonstrated that FVIII consumption can be significantly reduced by individualizing 
dosing based on combined analysis of individual pharmacokinetic (PK) profiling and 
population PK data (Bayesian analysis). So far, no studies have been performed that ad-
dress perioperative concentrate consumption using iterative PK-guided dosing based 
on a PK population model.
Methods The “OPTI-CLOT” trial is an open-label, prospective, multicenter randomized 
controlled superiority trial (RCT), aiming to detect a 25% difference in perioperative 
FVIII concentrate consumption with iterative Bayesian PK-guided dosing in comparison 
to the standard dosing procedure. Sixty hemophilia A patients ≥ 12 years of age, with 
FVIII plasma levels ≤ 0.05 IUmL-1 will be included requiring FVIII replacement therapy 
administered either by continuous or bolus infusion for an elective, low or medium risk 
surgical procedure.
Discussion The proposed study aims to investigate a novel perioperative iterative PK-
guided dosing strategy, based on a recently constructed perioperative PK population 
model. This model will potentially decrease underdosing and overdosing of clotting 
factor concentrate and is expected to overall reduce FVIII consumption by minimally 
25%. Moreover, participating hospitals will gain experience with PK-guided dosing, 
facilitating future implementation of this intervention which is expected to optimize 
current care and reduce costs of treatment.
Trial registration: NTR4121
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INTRODUCTION
Hemophilia A is an X-linked inherited bleeding disorder, caused by a deficiency of 
coagulation factor VIII (FVIII). Patients with severe (FVIII <0.01 IUmL-1) and moderate 
severe (FVIII 0.01-0.05 IUmL-1) hemophiliac A experience spontaneous bleeding, mainly 
in muscles and joints, or bleeding after minor trauma. Prophylactic substitution of FVIII 
concentrate intravenously, several times a week, aiming for a trough level of above 0.01 
IUmL-1, generally prevents severe joint damage and subsequent long term disability. 
Surgery necessitates an intensive regimen of factor replacement therapy, as factor levels 
are normalized for 7-14 days. Therefore, overall in the perioperative period, a patient 
may consume up to 15% of his regular annual use of clotting factor concentrate. An-
nually, overall costs of hemophilia treatment In the Netherlands are estimated at €130 
million, of which more than 90% consists of costs for concentrates.1-3
In the perioperative period, target trough levels dictated by National and International 
Guidelines are exceeded in the perioperative setting. This seems due to difficulties in tar-
geting these levels but also due to the fact that doctors are inclined to dose generously 
in order to avoid low factor activity levels and subsequent bleeding risk.4-6 Treatment is 
extremely effective as perioperative bleeding is rare in hemophilia patients in countries 
where concentrates are adequately available. Refining of perioperative dosing strategies 
seems warranted to optimize replacement therapy in the individual hemophilia patient 
and to increase quality of care by avoiding both under dosing and overdosing.
Rationale: Pharmacokinetic-guided dosing may be cost-reductive
Large inter-individual differences in the pharmacokinetics (PK) of FVIII concentrates 
have been demonstrated, making PK-guided dosing a potential strategy to improve 
clinical outcome and possibly cost-effectiveness of dosing in prophylactic, on demand 
and perioperative settings.7 Bayesian PK-guided dosing is the combined analysis of 
individual PK parameters in regard to the population parameters. Using this approach 
only three samples are needed to describe a complete PK curve.8
Using a Bayesian approach in the prophylactic setting, Carlsson et al.9 reported a dose 
reduction of 30% without an increase in bleeding in a randomized cross-over study of 
two six months’ periods, comparing PK-guided dosing with standard dosing. However, 
prophylactic population PK models cannot be extrapolated to the perioperative situa-
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tion, as surgery forms an incomparable hemostatic challenge. Moreover, Longo et al. 
reported excessive FVIII consumption and clearance in 50% of surgical hemophilia 
patients due to unidentified factors.10
Current perioperative management in hemophilia
In surgery, earlier studies on perioperative management in hemophilia have compared 
continuous infusion with intermittent bolus infusions. Batorova et al.11 reviewed eleven 
case series and concluded that continuous infusion of FVIII and factor IX is safe and 
effective in situations requiring intensive replacement therapy such as surgery and 
major bleedings. Strikingly, there was a wide variation in targeted hemostatic levels, 
dosage regimens, modes and duration of therapy. Eight of these studies concluded 
that continuous infusion is more cost-effective than intermittent bolus administration 
by reduction of total clotting factor consumption.12-19 In two studies, bolus injections 
were prospectively compared to adjusted continuous infusions, demonstrating 30-36% 
reduction of FVIII consumption in the latter.12, 19 Preoperative PK profiling was reported 
in 3 out of 8 hemophilia A case series, but was not specified.13-15, 17, 19, 20 A perioperative 
study by Batorova and Martinowitz12 showed that if targeted FVIII levels are actually 
maintained, a reduction of consumption and therefore costs of up to 70% may be at-
tained. Mulcahy et al.15 retrospectively evaluated adjusted continuous FVIII infusions in a 
single center study and concluded that close monitoring of FVIII levels in itself with strict 
regulation of infusion rate alone, may significantly reduce FVIII consumption.
So far, iterative Bayesian PK-guided perioperative dosing has not been performed as 
perioperative PK population models for clotting disorders have not been available. 
Recently, we have however constructed a population PK model from retrospective 
perioperative FVIII data21, facilitating Bayesian adaptive dosing of FVIII in the periopera-
tive setting. We hypothesize that application of this approach may improve quality of 
hemophilia care as both underdosing and overdosing are avoided. Potentially, it will 
also decrease FVIII consumption and lower costs of treatment.
The “OPTI-CLOT” trial • 163
7
OBjECTIVE
The objective of this study is to investigate whether perioperative PK-guided dosing 
of FVIII concentrate in hemophilia A patients receiving FVIII replacement therapy using 
a Bayesian approach, leads to a significant reduction in perioperative clotting factor 
consumption.
METHODS
Trial design
The “OPTI-CLOT” trial is a prospective, multicenter randomized controlled superiority 
trial (RCT), aiming to detect a difference in perioperative FVIII consumption with iterative 
PK-guided dosing in comparison to the standard dosing procedure, the latter primarily 
based on body weight. FVIII levels will be targeted in the middle of each target range 
defined in the perioperative guidelines of the National Hemophilia Consensus, unless 
stated otherwise by treating physician.
In all patients six weeks before surgery, a preoperative PK profile will be constructed 
using only three blood samples without a wash out period but with exact notation of 
prior doses in the week before PK profiling; individual PK parameters will be assessed by 
Bayesian analysis (Figure 1). Subsequently, patients will be randomized after stratifica-
tion according to mode of FVIII administration (continuous or bolus), type of surgical 
procedure (minor or major) and treatment center as is usual in a multicenter trial and 
subsequently allocated to one of two perioperative treatment arms: (A) the intervention 
arm in which dosing is adjusted on basis of the individual preoperative PK parameter 
estimates and iterative perioperative Bayesian analysis; or (B) the standard treatment 
arm in which dosing regimen is established by the physician according to the standard 
dosing regimen. At least 60 patients will be needed to detect a difference of minimally 
25% in consumption of FVIII concentrate during the perioperative period between 
treatment arms. Safety is guarded by generally daily monitoring of FVIII levels, as is 
now standard procedure. Perioperative hemostasis will be assessed during the entire 
perioperative period.
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Study population
Patients will be included from six large Academic Hemophilia Treatment Centers in the 
Netherlands: Erasmus University Medical Center Rotterdam, Academic Medical Center 
Amsterdam, Radboud university medical center, University Medical Center Utrecht, 
University Medical Center Groningen and Leiden University Medical Center.
Figure 1. Flowchart
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After inclusion a PK profi le will be constructed preoperatively prior to stratifi ed randomization; individual 
PK parameters will be assessed using Bayesian analysis. In the intervention arm dosing will be administered 
based on the individual PK parameter estimates. With daily FVIII levels available the Bayesian approach will 
be used to iteratively adjust the daily dose. In the standard treatment arm dosing will be set by the treating 
physician according to the standard dosing regimen described in the National Hemophilia Consensus in 
the Netherlands based primarily on bodyweight with target plasma FVIII values as set in the Consensus, 
unless otherwise specifi ed. Adjustments will be performed by the treating physician without knowledge of 
the preoperative profi le of the patient.
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Inclusion criteria:
– Severe and moderate hemophilia A patients with FVIII levels ≤0.05 IUmL-1;
– ≥ 12 years of age at inclusion date;
– Undergoing elective, minor or major surgery as defi ned by surgical risk score (Koshy 
et al.22);
– Under replacement therapy with FVIII concentrate, (plasma derived or recombinant) 
by continuous or bolus infusion;
– Written informed consent, according to METC guidelines.
Exclusion criteria:
– Patient with other congenital or acquired hemostatic abnormalities.
– Withdrawal of (parental) informed consent.
– Due to additional eff ect on FVIII clearance: detectable FVIII inhibiting antibodies 
(>0.2 Bethesda Units) at study inclusion.
– General medical conditions which may interfere with participation in the study.
Outcome measures
Primary endpoints are:
1. Total amount of infused FVIII concentrate (IU per kilogram) during the periopera-
tive period per postoperative day (from 72 hours before surgery up to 14 days after 
surgery);
2. Achieved FVIII levels (IUmL-1) after FVIII infusion.
Secondary endpoints are:
1. Duration of hospitalization (day of release - day of surgery/ start of continuous or 
bolus FVIII infusion);
2. Perioperative hemostasis as quantifi ed by standardized form;
3. Eff ects of baseline VWF antigen, propeptide values and blood type on FVIII clearance 
and identifi cation of other potential modifi ers;
4. Economic analysis of costs in both treatment arms.
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Interventions
Overall treatment protocol in all patients, independent of treatment arm
In all patients, a PK profile will be constructed six weeks before surgery prior to stratified 
randomization. After a standard bolus of FVIII of 50 IU per kilogram, FVIII levels will be 
measured in three blood samples of 1.8 mL citrate blood, withdrawn at t=4, t=24 and 
t=48 hours after FVIII clotting factor concentrate infusion, according to Björkman et al.8 
The individual PK parameters are assessed by Bayesian analysis. During PK profiling, 
exact information on three prior FVIII doses before the standardized FVIII infusion will 
be gathered to predict residual FVIII level in each individual patient. Treating physicians 
and nurses will be blinded for PK profile results in both arms.
In both treatment arms, target ranges for FVIII values will be applied as set by the National 
Hemophilia Consensus aiming for the middle of each range, unless stated otherwise by 
treating physician (Table 1)4. In all patients in both treatment arms, FVIII levels will be 
monitored as is momentarily standard clinical practice, which is generally daily, during 
the perioperative period.
Specification of treatment arms
Trial/ Intervention arm:
The FVIII dose prior to the start of the surgery will be based on the required FVIII target 
level according to the National Consensus and individual PK parameters as obtained 
from the preoperative PK profile according to Björkman et al.8 and exact information of 
three prior doses of FVIII concentrate preceding the date of surgery. Subsequent doses 
will be adjusted iteratively using Bayesian analysis on basis of daily therapeutic monitor-
Table 1. Target trough levels of FVIII in the perioperative period according to the National Hemophilia 
Consensus4
Time postoperative Target range FVIII levels 
(IUmL-1)
OPTI-CLOT Target FVIII 
level (IUmL-1)
Day 1 0-24 hours 0.80-1.00 0.90
Day 2-5 24-120 hours 0.50-0.80 0.65
Day >6 > 120 hours 0.30-0.50 0.40
FVIII values as set in the Consensus, unless otherwise specified. Adjustments will be performed by the treat-
ing physician without knowledge of the preoperative profile of the patient.
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ing of FVIII using our own perioperative population PK model based on retrospective 
data of severe and moderate severe hemophilia patients undergoing surgery.21
Daily therapeutic monitoring of FVIII is part of current standard clinical care and FVIII val-
ues will be analyzed locally. Results will be blinded for the treating physician and nurses. 
The FVIII levels and administered FVIII doses will be communicated by the laboratories of 
each specific site with the clinical pharmacologist. The clinical pharmacologist is respon-
sible for the calculation of the individual dose using the Bayesian approach. The clinical 
pharmacologist will send the FVIII dosing recommendations to the treating physician, 
who will subsequently adjust dosing. Target levels according to Consensus or otherwise 
set by the treating physician will be safeguarded by an unblinded hematologist with 
experience in hemophilia treatment.
Trial/ Standard treatment arm:
The standard perioperative dosing regimen, as described by the Consensus, consists of 
a FVIII bolus dose directly prior to surgery of 50 IUkg-1, followed by either continuous 
infusion or intermittent daily bolus infusions. The rate of infusion (IU hour-1) is obtained 
by multiplying the patient’s bodyweight (kg) with clearance (3-4 mL kg-1 hour-1) and 
target FVIII level (IUmL-1). Subsequent FVIII clotting factor concentrate dosing will be 
based on daily monitoring of FVIII levels and adjusted according to doctor’s opinion, 
based on a standard clearance of 3-4 mL kg-1 hour-1 and FVIII levels are targeted in the 
middle of each target range as set by the National Hemophilia Consensus, which de-
crease per postoperative day (Table 1).4 Dosing adjustments will be performed by the 
treating physician on basis of the daily monitored FVIII levels, without knowledge of PK 
parameters collected in the individual preoperative PK profile.
Bayesian-analysis
In the treatment arm individual PK parameters will be assessed iteratively by application 
of Bayesian analysis as implemented in the NONMEM® software (Icon, Dublin, Ireland). 
For Bayesian analysis a population PK model will be used constructed on the basis of 
the PK data from an earlier retrospective perioperative study.21 Based on the derived 
individual Bayesian PK parameters an optimal dosing scheme will be calculated during 
perioperative use, taking mode of administration of concentrates (continuous or bolus 
infusion) and desired target FVIII value into account. As for continuous infusions, indi-
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vidual estimates for clearance are needed. With regard to intermittent bolus infusions, 
estimates for both clearance and volume of distribution are needed.
Sample size
Based on earlier data and economic relevance, we aim to detect a difference in mean 
FVIII concentrate use in IUkg-1 which equals 150 IUkg-1 or a 25% reduction in use of clot-
ting factor. To study this with a power of 80% and a two-sided α of 0.05, a sample size 
of minimally 60 patients is necessary. To allow for dropouts, 65 patients will be included 
in the total study. One patient per center, except Erasmus MC (n=5) will be treated ac-
cording to protocol to test local logistical processes. These patients will not be evaluated 
with regard to primary endpoints, only with regard to secondary endpoints.
Economic analysis will be performed from a health care perspective taking all health care 
costs into account. We will calculate and compare the costs of PK profiling consisting of: 
bolus of 50 IUkg-1 FVIII minus prophylactic doses required, time invested by hemophilia 
caretakers, two and three FVIII test samples (in standard clinical practice, usually one in 
vivo recovery FVIII level is performed), generation of PK profile by Bayesian analysis and 
perioperative iterative Bayesian analysis to the standard dosing procedure consisting of: 
establishment of treatment protocol by hemophilia expert, and perioperative dosing 
adjustment calculations by hemophilia expert. Theoretical consequences of PK profiling 
on prophylactic dosing regimen in the following years, at one year after surgery, both 
reduction and increase of dosing, will also be taken into account in this economic evalu-
ation. Actual medical costs will be calculated by multiplying volume of health care use 
with corresponding unit prices. Costs will be valued using the National guidelines for 
economic evaluation studies.23
CONCLUSION
The proposed study aims to investigate an innovative individualized perioperative PK-
guided dosing strategy, which is expected to reduce FVIII consumption and therefore 
costs by minimally 25%. Strengths of the study are the number of participating centers 
and study design. The application of both perioperative Bayesian guided dosing and a 
specific perioperative population PK model has not been performed before. Further-
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more, the inclusion of children is important, as inter-individual clearance of clotting 
factor is exceptionally variable at younger ages. As a direct consequence of the study, 
participating hospitals will gain experience with PK-guided dosing facilitating future 
implementation of this promising intervention.
Ethical considerations
The study protocol was approved by the Medical Ethics Board of the Erasmus University 
Medical Center Rotterdam, the Netherlands and approved by all boards of participating 
hospitals.
Registration
The trial is registered at the Dutch Trial registry, number NTR4121 (www.trialregister.nl)
This research is funded by ZonMW (grant number 80-83600-98-10098), the Dutch 
organization for Health Research and Development, and an unrestricted investigator 
initiated research grant from Baxter. The funding source has no involvement in the study 
and the author’s work is independent.
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SUMMARy
Background Treatment in hemophilia A is based on body weight and an in vivo recov-
ery (IVR) of 2.0 which equals an increase of 2.0 IUdL-1 per unit of factor VIII (FVIII) per 
kilogram. Overweight/obese patients have significantly higher IVR values, resulting in 
overestimation of FVIII doses.
Objective To explore the potential of PK-guided dosing of factor VIII concentrate in 
overweight/obese hemophilia A patients and to evaluate the use of alternative body 
size descriptors for dose calculation, e.g. ideal-, adjusted- and lean body weight.
Methods Twenty-two hemophilia A patients (baseline FVIII <0.05 IUmL-1) were classi-
fied according to body mass index (BMI), normal: < 25kgm-2(n=5), overweight: 25-30 
kgm-2(n=12) and obese: > 30 kgm-2(n=5). All patients received ±50 IUkg-1 FVIII, with FVIII 
sampling after 4, 24 and 48 hours. Population PK models were applied to calculate FVIII 
plasma concentration over time.
Results The population PK model by Bjorkman et al. did not correctly predict FVIII levels 
in the overweight/obese. A modified model was constructed, describing PK parameters 
and FVIII levels adequately. Median IVR was significantly higher in overweight (2.65) 
and obese (3.00) patients when compared to those with a normal BMI (2.17) (p<0.05). 
IVR was independent of BMI when ideal body weight was applied. IVR-based dosing 
resulted in FVIII trough levels below set target levels for bleeding events.
Conclusion When PK-guided dosing of factor VIII concentrate is performed, the popu-
lation PK model should represent the specific patient population, in this case: obese/
overweight patients. In contrast to what is generally hypothesized, alternative body size 
descriptors are not able to substitute PK-guided dosing.
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INTRODUCTION
Hemophilia A is an X-linked inherited bleeding disorder characterized by a deficiency in 
coagulation factor VIII (FVIII). Treatment with FVIII concentrate replacement therapy is 
administered prophylactically or “on demand”, in case of bleeding or in the perioperative 
setting. Various guidelines prescribe specified target levels for different circumstances1-3, 
for example a bolus infusion of 50 IUkg-1 followed by twice a day 25 IUkg-1 in case of 
a life-threatening bleeding event. To achieve the prescribed target plasma level the 
required dose is calculated based on baseline FVIII, actual body weight in kilograms 
(kg), and a crude estimation of clearance. In these calculations FVIII in vivo recovery 
(IVR) is assumed to be 2.0, defined as an increase of 2.0 IUdL-1 per unit of infused FVIII 
concentrate per kilogram (kg) body weight.4 The crude FVIII half-life, generally assumed 
to be 12 hours, is subsequently applied to predict FVIII trough levels. As large interindi-
vidual variation in IVR and half-life exist, the lack of precision of these estimates can be 
overcome by frequent monitoring of FVIII plasma concentrations in critical situations. In 
order to predict FVIII plasma concentrations over time, it may be more efficient to dose 
based on a population PK model.
Both overweight and obesity are highly prevalent in the hemophilia population with 
a prevalence of respectively 35% and 8%.5 Previous studies have shown that obese 
patients have significantly higher IVR values when dosed according to body weight, 
suggesting that these doses can be decreased.6-8 This is probably due to the fact that the 
intravascular plasma volume (in which factor concentrate is infused) does not linearly 
increase with body weight.9 The increased IVR in overweight and obese hemophilia A 
patients has led to hypotheses that alternative parameters for dose calculations such as 
ideal body weight (kg) or lean body mass (kg) instead of actual body weight (kg) may be 
more adequate.6, 7, 10, 11 Until now, the effect of the use of these alternative parameters 
on adequate prediction of trough FVIII plasma concentrations has not been evaluated.
Therefore, we aimed to explore the potential of PK-guided dosing based on FVIII popula-
tion PK models in overweight and obese hemophilia A patients and to evaluate the use 
of alternative body size descriptors instead of actual body weight for dose calculation.
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PATIENTS AND METHODS
Patients
In this cross-sectional study, severe and moderate hemophilia A patients were included 
(baseline FVIII <0.05 IUmL-1) from four Academic Hemophilia Treatment Centers in the 
Netherlands (Erasmus University Medical Center Rotterdam, University Medical Center 
Groningen, Radboud university medical center Nijmegen, Leids University Medical Cen-
ter). Patients with FVIII neutralizing antibodies were excluded. Written informed consent 
was obtained from all patients according to the declaration of Helsinki.
Methods
Patient characteristics were collected; including baseline FVIII plasma concentration, 
DNA mutation, inhibitor status, age (years), actual body weight (kg), and height (cm). 
These parameters were used to calculate the following body size descriptors for each 
patient: body mass index (BMI, kgm-2), ideal body weight (kg), adjusted body weight 
(kg), and lean body weight (kg) (Table 1).8, 12, 13 These body size descriptors are believed 
to take percentages of fat mass into account and therefore may be more precise de-
scriptors of body size in association with clearance and volume of distribution when 
compared to actual body weight. FVIII plasma concentrations were measured by means 
of an one-stage clotting assay, using FVIII-deficient plasma (Siemens Healthcare, Mar-
burg, Germany) and reference plasma (Cryocheck, Precision Biologic, Kordia, Leiden, The 
Netherlands) on an automated coagulation analyzer (Sysmex CA1500, Siemens, Breda, 
The Netherlands).
Table 1. Calculation of body size descriptors
Body size descriptor Formula
Ideal body weight (IBW) (kg) Devine et al. 1974 0.9 * H -88
Adjusted body weight (ABW) (kg) Devine et al. 1974 IBW + 0.4 (BW-IBW)
Lean body weight (LBW) (kg) Janmahasatian et al. 2005 (9.27 *103 * BW)/(6.68*103+(216*BMI))
Body mass index (BMI) (kgm-2) Garrow et al. 1985 BW / (HT2)
kg= kilogram; H= height in centimeter; BW = body weight in kilograms; BMI= body mass index; HT= height 
in meter
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Pharmacokinetic modeling
All patients received a FVIII bolus infusion of approximately 50 IUkg-1 with FVIII blood 
sampling at baseline, t=4, t=24 and t=48 hours. Individual PK profiles were constructed 
by Bayesian analysis using the FVIII population PK model, developed for the prophylac-
tic setting, as published by Björkman et al.14 Actual FVIII plasma concentrations were 
compared to predicted FVIII plasma concentrations obtained using this model.14
Furthermore, a novel modified FVIII population PK model was developed for this study 
population using nonlinear mixed-effects modeling software (NONMEM version 7.3.0, 
Globomax LLC, Ellicott City, Maryland, USA)15, including both the normal, overweight 
and obese study patients. A two-compartment model was constructed. The endogenous 
baseline FVIII plasma concentration, collected for each individual, was incorporated 
into the model. The following PK parameters were estimated: clearance (CL), intercom-
partmental clearance (Q), central volume of distribution (V1) and peripheral volume of 
distribution (V2). PK parameters were not scaled allometrically, allowing evaluation of 
the relationship with various body size descriptors. Inter-individual variability (IIV) and 
their correlation was estimated for clearance and central volume of distribution using an 
exponential function. Residual variability in FVIII plasma concentration was described 
by an additive error model. In order to perform these calculations, R version 3.2.22 (The 
R Foundation for Statistical Computing) and R-package Xpose version 4.5.316 were used 
for data check-out, exploration and model diagnostics. In addition, Pirana software was 
used as an interface between NONMEM, R and Xpose.17
Estimated individual PK parameters from the modified FVIII population PK model were 
used to simulate FVIII plasma concentration-time curves using the four body size de-
scriptors e.g. actual body weight, ideal body weight, adjusted body weight and lean 
body mass (Table 1). Moreover, the simulated FVIII peak plasma concentrations were 
used to recalculate IVR according to the formula: body size descriptor (kg) x observed 
FVIII increase (%) / FVIII dose (IU).4 In addition, simulated FVIII trough levels achieved 
with FVIII doses based on the different the body size descriptors were compared to 
predefined FVIII target trough levels for a life threatening bleeding event (Table 2).
Statistical analysis
Hemophilia patients were divided into three subgroups according to BMI; <25 kgm-2, 
overweight: 25-30 kgm-2, and obese: >30 kgm-2. Descriptive statistics are presented as 
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median and interquartile range [IQR] for continuous variables and as number (No.) and 
percentages (%) for categorical variables.
The relationship of IVR with body size descriptors was evaluated. To test differences 
between groups and significant trends, the Kruskal Wallis-test and Jonckheere Terpstra 
test were used, which are non-parametric independent tests using SPSS statistics for 
Windows, version 21.0 (IBM Corp, Armonk, NY, USA). A p-value of <0.05 was considered 
statistically significant.
RESULTS
In total, we included 22 severe and moderate hemophilia patients (median body weight 
87 kg [IQR 73-96]; median age 51 years [IQR 33-65]). Twelve patients (54.5%) were over-
weight (BMI 25-30 kgm-2) and five (22.7%) were obese (BMI >30 kgm-2). General patient 
characteristics and individual PK parameters are depicted in Table 3. Comparison of 
measured and predicted FVIII plasma concentrations, calculated using the FVIII popula-
tion PK model developed by Björkman et al.14, demonstrated underprediction of FVIII 
measurements at t=4 hours (with concentrations greater than 0.8 IUmL-1) in overweight 
and obese hemophilia patients (Figure 1A). Therefore, it was concluded that individual 
PK parameters using this model could not describe FVIII plasma concentrations versus 
time curves adequately.
Average parameter estimates of the newly constructed modified FVIII population PK 
model were: CL: 258 mLhr-1, Q: 89 mLhr-1, V1: 3898 mL and V2 799 mL. Inter-patient vari-
ability in CL and V1 was 44% and 34%, respectively. Residual variability was 14%. The 
modified FVIII population PK model was able to describe PK parameters of all study pa-
tients adequately, and to correctly predict observed FVIII plasma concentrations (Figure 
Table 3. Dose recommendations and specified FVIII target levels for a life-threatening bleeding event
FVIII bolus FVIII target
Consensus* Initial: 50 IUkg-1
bd: 25 IUkg-1
1.00 IUmL-1(peak)
>0.50 IUmL-1(trough)
* according to the National guideline of the Netherlands3; bd= twice daily
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1B). No differences were observed for clearance and volume of the central compartment 
between different subgroups when classified according to BMI (p=0.40 and p=0.66 
respectively, Table 2).
For each patient with individual PK parameters obtained from the modified population 
PK model, FVIII concentration versus time profiles were simulated. Four time profiles 
Figure 1. Goodness of fit plot with both measured and individual predicted FVIII plasma concentrations
*According to the population pharmacokinetic model of A. Bjorkman et al. and B. the modified model in-
cluding overweight and obese patients; in all figures patients are categorized to body mass index (BMI), in 
green patients with a BMI <25 kgm-2, in black BMI 25-30 kgm-2, and red BMI >30 kgm-2.
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were simulated following a dose of 50 IUkg-1, using the four body size descriptors e.g. 
body weight, ideal body weight, adjusted body weight, and lean body weight (Table 
1). Subsequently, IVR was calculated using these simulated FVIII plasma concentrations 
generated according to body size descriptor (Figure 2). A significant trend was observed 
towards higher IVR with increasing BMI when dosing was performed according to body 
weight (p=0.049). When ideal body weight was used as a body size descriptor, IVR was 
independent of BMI, as expected. In contrast, dosing according to adjusted body weight 
and lean body weight showed a non-significant trend of increasing IVR for subgroups 
with increasing BMI (Figure 2).
Prediction of FVIII peak and trough levels in case of a life threatening bleeding 
event
As treatment for a life threatening bleeding event requires both minimal FVIII peak val-
ues as well as minimal FVIII trough levels (Table 3), we used the individual PK parameter 
estimates from the modified FVIII population PK model to simulate FVIII peak values and 
FVIII trough levels.
As expected, high peak FVIII plasma concentrations were observed for overweight 
and obese patients dosed according to body weight, with mean peak FVIII plasma 
Figure 2. In vivo recovery and body size descriptors
In vivo recovery according to body mass index (BMI) for each body size descriptor; BMI <25 kgm-2; BMI 25-30 
kgm-2; BMI >30 kgm-2; IVR= in vivo recovery; IUdL-1= International units per deciliter; IUkg-1= International 
units per kilogram; BW= actual body weight; IBW= ideal body weight; ABW= adjusted body weight; LBW= 
lean body weight. Comparison and ordered pattern between groups was analyzed by the non-parametric 
Jonckheere-Terpstra test.
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concentrations of 1.60 and 1.80 IUmL-1 respectively (Figure 3). However, predictions of 
FVIII plasma concentrations resulted in trough FVIII levels below specified minimal FVIII 
target plasma concentration of 0.50 IUmL-1 in both normal and obese patients. The simu-
lated peak FVIII plasma concentrations were significantly lower after dosing according 
Figure 3. Individual estimations of FVIII plasma concentrations when dosing for a life threatening bleeding 
event
 
  



"$
	"$
	"$
&) %&( %*&&-, *"



 $&+()


'#
)$

&%

%*(
* 
&%

$


 
  



"$
	"$	"$
&) %&( %*& #&-, *"



 $&+()

'
#)
$
&
%
%
*(
* &
%

$


 
  



"$
	"$ 	"$
&) %&( %*&!+)*&-, *"



 $&+()

'
#)
$
&
%
%
*(
* &
%

$


 
  



"$

	"$ 
	"$
&) %&( %*&#%&-, *"



 $&+()

'
#)
$
&
%
%
*(
* &
%

$


Individual estimations of FVIII plasma concentrations after dosing according to different body size descrip-
tors in case of a life threatening bleed; BMI=body mass index; A. Dosing according to body weight (kg), 
which resulted in high peak FVIII plasma concentrations, but also trough levels below specified target FVIII 
ranges; B. Dosing according to ideal body weight (kg); C. Dosing according to adjusted body weight (kg); D. 
Dosing according to lean body weight (kg); Dosing according to ideal body weight, adjusted body weight 
and lean body weight, results in FVIII trough levels below specified minimal FVIII target plasma concentra-
tion. Data presented as median of all groups, BMI <25 kgm-2, BMI 25-30 kgm-2, BMI >30 kgm-2.
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to ideal body weight in all patients (all BMI subgroups). However, corresponding FVIII 
trough plasma concentrations were below specified target ranges. Furthermore, dosing 
according to the other body size descriptors e.g. adjusted body weight and lean body 
weight showed similar results (Figure 3).
DISCUSSION
This cross-sectional study including overweight and obese hemophilia A patients con-
firms that current body weight-based dosing strategies are inadequate in these patient 
groups. As expected, a significant higher IVR was observed with increased BMI, as has 
been published by Henrard et al. and Blanchette et al.6-8, 11 Furthermore, the FVIII popula-
tion PK model by Bjorkman et al. did not correctly predict FVIII plasma concentrations in 
overweight and obese patients.
The data collected for this study was used to construct a modified FVIII population PK 
model which was able to adequately predict achieved FVIII levels for all patients. The 
inadequacy of the current prophylactic FVIII population PK model underlines the fact 
that these models should be representative for the hemophilia population as a whole. 
The necessity of such enriched population PK models, in this case including sufficient 
overweight and obese patients, is underlined by the growing number of overweight and 
obese hemophilia patients.5
A Bayesian approach was used, in which observations from individual patients and the 
modified population PK model were combined, in order to obtain individual PK param-
eter estimates. These parameter estimates were subsequently used to simulate FVIII 
plasma concentration-time dosing curves according to four body size descriptors e.g. 
actual body weight, ideal body weight, adjusted body weight and lean body mass. IVR 
was independent of BMI when ideal body weight was applied as a body size descriptor. 
Nevertheless, calculations according to IVR-based dosing resulted in FVIII values below 
prescribed FVIII trough values for bleeding events. This suggests that individualized dos-
ing cannot be achieved by application of body size descriptors. Moreover, that dosing by 
PK-guidance using a representative population PK model seems best practice.
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Study strengths and limitations
The strength of this study is the inclusion of patients with a wide range of body 
weights, including overweight and obese patients, with corresponding BMI values. 
The prophylactic population PK model by Bjorkman et al. was allometrically scaled to 
account for the wide ranges of body weight (17-124 kg) of the 50 included patients.14 
Nonetheless, the distribution of overweight and obese patients in this dataset is unclear. 
In addition in our study, a modified population PK model was developed which was able 
to describe the specific patients included in this study group.
Previously Graham et al. treated six obese hemophilia patients (BMI >30 kgm-2) accord-
ing to ideal body weight.18 A significant reduction of infused concentrates and a good 
clinical outcome was observed. However, no information was available on FVIII trough 
levels 48 hours after infusion. In a study by Collins et al. in 143 severe hemophilia A 
patients treated prophylactically with a follow-up period of a minimum of 75 exposures, 
time spent with FVIII levels below trough levels were associated with an increased risk 
of bleeding.19 In our study, we showed that dosing based on ideal body weight results in 
FVIII trough plasma concentrations below specified FVIII target ranges for a life threaten-
ing bleeding event and thus leads to a potential increased risk of severe bleeding. Earlier 
reports, have also observed poor correlations between IVR and FVIII trough levels.20, 21 
In our opinion, this inability to predict trough levels makes IVR-based dosing undoubt-
edly less useful in both prophylactic and “on demand” settings. Therefore, PK-guided 
dosing is preferred as it takes both targeted peak and trough levels into account when 
establishing necessary dosing and frequency of dosing. In addition, in daily practice 
interindividual differences in FVIII clearance may occur with significant consequences 
for trough FVIII plasma concentrations and dosing without an effect on IVR.22
In conclusion, we believe that PK-guided dosing for overweight and obese hemophilia 
A patients based on Bayesian analysis using an enriched FVIII population PK model is 
superior to IVR-based dosing as it adequately predicts both required peak and trough 
levels of FVIII. Although, other body size descriptors such as ideal body weight have 
been suggested to optimize IVR-based dosing, our simulations show that this approach 
does not guarantee adequate targeting of FVIII. Future studies are needed to validate 
current findings, which will lead to optimization of current treatment strategies for both 
overweight and obese patients.
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Pharmacokinetic-guided dosing of 
factor VIII concentrate in a patient with 
hemophilia during renal transplantation
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SUMMARy
A 29 year old man with severe hemophilia A and end-stage renal disease underwent a re-
nal transplantation. To prevent bleeding, patient was treated with replacement therapy 
using factor VIII (FVIII) concentrate, according to National guidelines. Bayesian analysis 
was performed by combining observed FVIII concentrations with a population pharma-
cokinetic (PK) model for patients with severe hemophilia A in a perioperative setting. 
Application of Bayesian analysis led to accurate prediction of observed concentrations 
after prescribing dosing advice. We believe PK-guided dosing of factor concentrates is 
a valuable step towards further individualization of treatment in patients with bleeding 
disorders. Especially in those patients requiring precise targeting of coagulation factor 
levels due to high risk of either bleeding or thrombosis, as illustrated by this patient 
undergoing a major surgical procedure.
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BACKGROUND
Hemophilia A is an X-linked inherited deficiency of coagulation factor VIII (FVIII), 
characterized by bleeding in muscles and joints. Patients are classified according to 
residual coagulation factor concentrations e.g. severe (FVIII<0.01 IUmL-1), moderate 
(FVIII:0.01-0.05 IUmL-1) and mild disease (FVIII:0.06-0.40 IUmL-1).1 Replacement therapy 
with factor concentrates is prescribed both “on demand” in case of acute bleeding or for 
surgical and dental procedures or “prophylactically” to prevent spontaneous bleeding in 
patients with a severe bleeding phenotype.
Hemophilia A patients are currently dosed with FVIII concentrate according to body 
weight, clinical phenotype, residual FVIII levels, severity of bleed or surgical bleeding 
risk, and crude estimations of clearance.1 In case of surgical procedures or bleeding, 
minimal FVIII target levels are maintained according to National guidelines to safeguard 
haemostasis.2 FVIII clearance is influenced by various factors, such as age, body weight 
and von Willebrand factor (VWF). The latter prevents FVIII clearance by protecting it from 
proteolysis and cellular uptake in the circulation. The liver is primarily responsible for 
FVIII clearance by mechanisms of cellular clearance. Due to high molecular weight of 
FVIII, clearance by the kidney does not play a role.3, 4
Previously, we demonstrated that novel dosing methods are necessary to minimalize 
under- and overdosing in the perioperative period.5 In this study, 45% of trough and 
steady state FVIII plasma concentrations within 24 hours after surgery were lower than 
specified target ranges, while 75% of these plasma concentrations were above target 
more than six days after hospitalization.5 Moreover, we developed a perioperative popu-
lation PK dosing model for (moderate) severe hemophilia A patients to optimize dosing 
(Table 1).6 In this case report, we applied Bayesian analysis using this model in order to 
individualize perioperative dosing. Important as this patient required precise targeting 
of coagulation factor levels due to a high risk of both bleeding and thrombosis. Hereby, 
we show feasibility of individualized PK-guided iterative dosing.
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CASE PRESENTATION
A 29 year old man with severe hemophilia A presented with end-stage renal disease due 
to a proliferative familial IgA nephropathy and severe symptoms of nephrotic syndrome. 
Medical history also included a period of acute renal failure due to post infectious 
glomerulonephritis, which was treated conservatively. Renal treatment consisted of 
peritoneal dialysis, and prednisolone. Prophylactic treatment for hemophilia A consisted 
of 2000 IU FVIII concentrate three times a week. Further patient characteristics are de-
picted in Table 2. Patient underwent a renal transplantation with perioperative iterative 
FVIII concentrate dosing guided by application of Bayesian analysis using individual FVIII 
plasma concentrations in combination with information from the perioperative popula-
tion PK model.
Table 1. Model equations describing the perioperative population PK model*
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INVESTIGATIONS
Renal function tests prior and after surgery are depicted in Table 2. Peak and trough FVIII 
plasma concentrations were measured daily by a one-stage clotting factor assay, using 
FVIII-deficient plasma (Siemens healthcare, Marburg, Germany) and reference plasma 
(Cryocheck, Precision Biologic, Kordia, Leiden, The Netherlands) on an automated co-
agulation analyser (Sysmex CA1500, Siemens, Breda, The Netherlands). PK analysis was 
performed using nonlinear mixed-effects modelling (NONMEM (version 7.2.0), Globo-
max LLC, Ellicott City, Maryland, USA). Individual PK parameter estimates were obtained 
from Bayesian analysis after performance of an individual FVIII PK-profile (Figure 1). 
Application of Bayesian analysis using measured FVIII plasma concentrations resulted in 
iterative dose-adjustments.
Table 2. Patient characteristics and laboratory measurements
Age (years) 29
Body weight (kilograms) 93
Blood group O
Prophylactic treatment 2000 IU FVIII (Helixate®) 3 times/week
Individual pharmacokinetic parameters*
Clearance (mLkg-1) 180
Central volume of distribution (mL) 3260
Intercompartmental clearance (mLkg-1) 186
Peripheral distribution volume (mL) 2750
Prior surgery After surgery
GFR (mLmin-1) <10 73
Creatinine (umolL-1) 1427 105
Urea (mmolL-1) 50 6.9
* Derived from perioperative population PK model (Hazendonk et al. 2016)6
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TREATMENT
During the perioperative period, patient was treated with FVIII concentrate by bolus 
infusions, with specific FVIII trough target plasma concentrations >0.65 IUmL-1 during 
the first 24 hours and between 0.50 and 0.80 IUmL-1 during the next five days in accor-
dance to protocol defined by the treating haematologist, who adapted standard treat-
ment due to high risk of the intervention.2 As shown in Figure 1, predicted trough FVIII 
plasma concentrations were in accordance with measured FVIII plasma concentrations. 
Moreover, trough FVIII plasma concentrations of >0.50 IUmL-1 were achieved during five 
consecutive days following surgery.
Figure 1. Individual pharmacokinetic profile and individual prediction of factor VIII plasma concentrations
An individual PK profile is constructed based upon measurement of three FVIII plasma concentrations ac-
cording to the prophylactic population PK model by Björkman et al. In the perioperative setting, FVIII was 
targeted at >0.65 IUmL-1 in the first 24 hours following surgery followed by target trough FVIII plasma con-
centrations of >0.50 IUmL-1. Application of Bayesian analysis using a perioperative population PK model 
resulted in iterative FVIII concentrate dose-adjustments.
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OUTCOME AND FOLLOW-UP
Perioperative hemostasis was evaluated as adequate by the surgical team and no post-
surgical bleeding or thrombosis was observed. At twelve weeks post-surgical evaluation, 
renal graft was functioning well.
DISCUSSION
This is the first publication of a patient treated using PK-guided dosing during the total 
perioperative period based on a perioperative population PK model. We show that 
iterative adaptive dosing by Bayesian analysis is possible and feasible for major surgical 
interventions.
Renal transplant surgery is often complicated by adverse haematological events such 
as bleeding but also intravesical thrombosis, both with a risk of renal allograft rejec-
tion.7 One earlier report described a renal transplantation in a mild hemophilia patient 
that was complicated by occurrence of an intravesicular bleed resulting in an allograft 
rejection.8 In another case report, FVIII plasma concentrations were kept > 0.70 IUmL-1 
for more than 2 weeks and afterwards >0.20 IUmL-1 with long-term successful transplan-
tation of the allograft.9 To prevent adverse events, maintenance of predefined trough 
levels is important. We have shown that it is possible to guide FVIII dosing by iterative 
application of Bayesian analysis using a recently developed perioperative population 
PK model in a major surgical procedure prone for complications such as bleeding and 
thrombosis.
Strikingly, actual peak and trough FVIII plasma concentrations after surgery were some-
what higher than predicted by the model. Most probably this under prediction is caused 
by high postsurgical VWF levels due to inflicted endothelial damage due to the intensity 
of the surgical procedure. VWF prolongs FVIII presence in the circulation, due to the 
decrease in clearance by protection from proteolysis, resulting in higher FVIII plasma 
concentrations.4, 10, 11 In the ongoing prospective randomized controlled “OPTI-CLOT” 
trial (RCT), which is described in more detail elsewhere12, we hope to gain more insight 
into the relationship between VWF levels and PK parameter estimates. It is expected that 
future incorporation of VWF into the population PK model will minimalize discrepancies. 
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A proposal for when and how often to measure VWF can then be provided, which will 
further improve individualized treatment.
Bayesian analysis is already routine practice for dosing of certain antibiotics, cyclospo-
rine, and some chemotherapeutics. Therefore, we believe that implementation of this 
approach in the current routine practice of hemophilia will increase quality of care and 
help achieve individualization of treatment.
LEARNING POINTS
– Individualized treatment of perioperative hemophilia A patients is possible by appli-
cation of a Bayesian approach using a recently developed FVIII population PK model 
as predefined target ranges were adequately maintained.
– Future individualized PK-guided dosing of factor concentrates may minimalize 
underdosing and overdosing, leading to improvement of quality of care.
– Especially in surgical procedures requiring strict maintenance of FVIII concentrations, 
PK-guided dosing may be of additional value.
PATIENT’S PERSPECTIVE
As a patient with hemophilia and comorbidity, I have often experienced anxiety with 
regard to hemostatic complications around the various surgical procedures I have 
undergone. Now that I have experienced the advantages and minimal disadvantages 
of PK-guided dosing, I realize that this methodology provides a real opportunity to im-
prove suboptimal targeting of coagulation factor levels in the perioperative setting. My 
recent renal transplantation, which was associated with both a high risk of bleeding as 
well as thrombosis illustrates this nicely. Moreover, I realize that in general, minimization 
of overdosing will decrease thrombotic risk but also minimize health care costs by po-
tential decrease of overall consumption of factor concentrates. Inversely, minimization 
of underdosing is important to decrease bleeding risk. To conclude, I gladly support this 
treatment innovation as it optimizes quality of care and leads to individualization of 
hemophilia treatment.
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SUMMARy
Replacement therapy with clotting factor concentrates (CFC) is the mainstay of treatment 
in hemophilia. It’s widespread application has led to a dramatic decrease in morbidity 
and mortality in patients, with concomitant improvement of quality of life. However, 
dosing is challenging and costs are high. This review discusses benefits and limitations 
of pharmacokinetic (PK)-guided dosing of replacement therapy as an alternative for cur-
rent dosing regimens. Dosing of CFC is now primarily based on body weight and based 
on its in vivo recovery (IVR). Benefits of PK-guided dosing include individualization of 
treatment with better targeting, more flexible blood sampling, increased insight into 
association of coagulation factor levels and bleeding, and potential overall lowering 
of overall costs. Limitations include a slight burden for the patient, and availability of 
closely collaborating, experienced clinical pharmacologists.
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HEMOPHILIA AND CURRENT TREATMENT
Background of the disease
Hemophilia A and B are X-linked inherited bleeding disorders characterized by deficien-
cies of factor VIII (FVIII) and factor IX (FIX), respectively. Prevalence is estimated at 1 in 
5,000 male births for hemophilia A and 1 in 30,000 male births for hemophilia B.1, 2 FVIII 
and FIX enhance formation of thrombin and consequently stabilize the hemostatic clot 
by increased fibrin formation. Disease severity is classified according to residual FVIII or 
FIX coagulation activity in plasma (FVIII:C or FIX:C).3 Mild hemophilia patients have FVIII:C 
or FIX:C levels of 0.05-0.40 IUmL-1, moderate patients FVIII:C or FIX:C levels of 0.01-0.05 
IUmL-1 and severe patients FVIII:C or FIX:C levels of less than 0.01 IUmL-1. Mild hemophilia 
is characterized by an increased risk of bleeding after trauma or surgery. Moreover, se-
vere as well as moderate hemophilia patients suffer from spontaneous bleeding or 
bleeding after minimal trauma in muscles and/or joints, potentially resulting in disabling 
arthropathy.4 Strikingly, bleeding phenotype differs between hemophilia patients with 
identical baseline FVIII:C or FIX:C levels and is probably influenced by inter-individual 
variation in patient characteristics such as age, body weight, modifying factors within 
the hemostatic system, behavioral factors and daily (sporting) activities and other yet 
unidentified factors.5-10 In addition, it may be influenced by inter-individual variation of 
half-life of clotting factor concentrates (CFC) administered either prophylactically or on 
demand (Table 1).
Current treatment with replacement therapy
Replacement therapy with CFC can be given to prevent spontaneous or repetitive 
bleeding (prophylaxis), or “on demand” to treat acute bleeding and prevent bleeding 
at the time of dental or surgical procedures. Current CFCs are either of recombinant or 
plasma-derived origin. Prophylaxis is the mainstay of treatment in hemophilia. Its intro-
duction has dramatically changed the lives of many hemophilia patients. Consequently, 
hemophilia has evolved from a crippling disease due to frequent bleeding in joints and 
muscles with a life expectancy of about 20 years due to often lethal severe bleeding, into 
a disease with a normal life expectancy, reduced prevalence of joint arthropathy and 
acceptable quality of life.11, 12
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Prophylaxis
Prophylaxis was introduced in 1965 by Ahlberg and is based on the observation that 
moderate hemophilia patients with FVIII:C or FIX:C levels above 0.01 IUmL-1 have far 
fewer joint bleeds and less subsequent arthropathy.13 Therefore, it was reasoned that 
joint bleedings could be prevented in severe hemophilia by keeping FVIII:C and FIX:C 
levels above 0.01 IUmL-1. To achieve this, CFCs must be regularly infused generally two 
to four times a week in hemophilia A and one to three times a week in hemophilia B.14-17 
Prophylactic treatment profoundly reduces frequency of bleeding and improves joint 
status as demonstrated by Manco Johnson et al. in a randomized controlled trial.11 Vari-
ous guidelines for prophylaxis are available of which Table 2 shows a selection of those 
most often applied. The efficacy of prophylaxis in preventing joint bleedings is largely 
dependent on maintaining minimal FVIII:C and FIX:C trough levels of 0.01 IUmL-1 in the 
patient. Moreover, time spent below trough levels is associated with number of bleed-
ing events.18 However, in standard clinical practice, trough levels are hardly measured 
and dose and frequency of prophylactic infusions are only adjusted when spontaneous 
or frequent bleeding occurs.
Table 1. Factors influencing bleeding phenotype in hemophilia patients
 
Table 1. Factors influencing bleeding phenotype in hemophilia patients  
 
 
 
 
 
 
 
 
 
 
 
Patient characteristics Hemostatic factors Pharmacokinetics of treatment  
Age  FVIII and FIX plasma levels Clearance (Cl) 
Body weight  FVIII and FIX gene mutation  Volume of distribution (Vd) 
Other morphometric variables Blood group  Half-life (T1/2) 
Joint status von Willebrand factor  In vivo recovery (IVR) 
General (muscle) condition Thrombin generation and 
fibrinolysis 
 
Daily (sporting) activities Unidentified hemostatic factors  
Behavioral factors   
Adherence to treatment    
Miscellaneous   
 
 
 
 
Table 2. Prophylactic dosing regimens for hemophilia A and B.  
Prophylaxis Hemophilia A Hemophilia B 
 Dose  
 
(IUkg-1) 
Frequency dosing 
(n/ week) 
Dose  
 
(IUkg-1) 
Frequency dosing 
(n/ week) 
Utrecht protocol-Dutch 
(Low dose prophylacti  
regimen) 14  
15-30  three  15-30  two  
Malmö protocol – Nordic  
(High dose prophylactic 
regimen) 17  
25-40  three  25-40  two  
FV
III
/F
IX
  
(IU
/m
L)
Time (hours)
 
Table 1. Factors influenci g bleeding phenotype in hemophilia patients  
 
 
 
 
 
 
 
 
 
 
 
Patient characteristics Hemostatic factors Pharmacokinetics of treatment  
Age  FVIII and FIX plasma levels Clearance (Cl) 
Body weight  FVIII and FIX gen  mutation  Volume of distribution (Vd) 
Other morphometric vari bles Blood group  Half-li e (T1/2) 
Joint status von Willebrand factor  In vivo recovery (IVR) 
Gen ral (muscle) condition Thrombin gen ration a d 
fibr nolysis 
 
Daily (sporting) activi ies Unidentified hemostatic factors  
Behavioral f ctors   
Adherence to reatment    
Miscellaneous   
 
 
 
 
Table 2. Prophylacti  dosing regimens for hemophilia A and B.  
Prophylaxis Hemophilia A Hem philia B 
 Dose  
 
(IUkg-1) 
Frequency dosing 
(n/ week) 
Dose  
 
(IUkg-1) 
Frequency dosing 
(n/ week) 
Utrecht protocol-Dutch 
(Low dose prophylactic 
regimen) 14 
15-30  three  15-30  two  
Malmö protocol – Nordic  
(High dose prophylactic 
regimen) 17  
25-40  three  25-40  two  
FV
III
/F
IX
  
(IU
/m
L)
Time (hours)
 
Table 1. Factors influenci g bleeding phenotype in h mophilia t ents  
 
 
 
 
 
 
 
 
 
 
 
Patient characteristic  Hemostatic fa ors Pharmacokinetics of treatment  
Age  FVIII and FIX plasma evels Clearance (Cl) 
Body weight  FVIII and FIX gene mutation  Volume of distr bution (Vd) 
Other morphometric variables Blood gr up  Half-life (T1/2) 
Joint status von Willebrand factor  In vivo recovery (IVR) 
General (muscle) conditi  Thrombin generation a d 
fibrinolysis 
 
Daily (sporting) activities Unidentified hemostatic fa ors  
Behavioral f ctors   
Adherenc  to tr atment    
Miscellaneous   
 
 
 
 
Table 2. Prophylactic dos ng regimens for hemophilia A and B. 
Prophylaxis Hemophilia A Hemophilia B 
 Dose  
 
(IUkg-1) 
Frequency dosing 
(n/ week) 
Dose  
 
(IUkg-1) 
Frequency dosing 
(n/ week) 
Utrecht protocol-Dutch 
(Low ose pr hylactic 
regimen) 14  
15-30  three  15-30  two  
Malmö protocol – N rdic  
(High dose pr hylactic 
regimen) 17  
25-40  three  25-40  two  
FV
III
/F
IX
  
(IU
/m
L)
Time (hours)
Patient characteristics Hemostatic factors Pharmacokinetics of treatment 
Age FVIII and FIX plasma level Clearance (Cl)
Body weight FVIII and FIX gene mutation Volume of distribution (Vd)
Other morphometric variables Blood group Half-life (T1/2)
Joint status von Willebrand factor In vivo recovery (IVR)
General (muscle) condition Thrombin generation and fibrinolysis
Daily (sporting) activities Unide tified hemost tic factors
Behavioral factors
Adherence to treatment 
Miscellaneous
Individualized therapy and role of pharmacokinetics • 205
10
On demand treatment
When patients are treated “on demand” either for acute bleeding or in a dental and/or 
surgical setting, dosing of CFC is aimed to achieve FVIII:C and FIX levels above a certain 
threshold/ trough and below a certain maximum to avoid waste of CFC and high costs 
without clinical effect according to various guidelines (Table 3).
More specifically, when acute bleeding occurs FVIII:C and FIX:C peak levels are generally 
considered particularly important, although they are rarely monitored. Targeted peak 
levels are dependent on both severity and location of bleeding. In Dutch guidelines14, 
FVIII:C or FIX:C peak levels of 0.30 IUmL-1 for minor bleeds, 0.50 IUmL-1 for severe bleeds 
and 1.00 IUmL-1 for life threatening bleeds are targeted. In severe or life threatening 
bleeds, it is more important to take trough levels into account. These FVIII:C and FIX lev-
els are sometimes monitored but often merely estimated, and maintained based on the 
opinions of the treating physician. In the perioperative setting, mainly trough levels are 
considered important although at initiation of surgery a specific peak FVIII:C and FIX:C 
range is targeted according to all guidelines. Overall, targeted perioperative FVIII:C and 
FIX:C trough levels depend on the invasiveness of the dental and/or surgical procedure 
and postoperative day, with e.g. Dutch guidelines prescribing FVIII:C or FIX trough levels 
of 0.80-1.00 IUmL-1 during the first 24 hours after surgery; 0.50-0.80 IUmL-1 1 to 5 days 
(24-120 hours) after surgery; and 0.30-0.50 IUmL-1 >5 days after surgery (Table 3).
Table 2. Prophylactic dosing regimens for hemophilia A and B
Prophylaxis Hemophilia A Hemophilia B
Dose (IUkg-1) Frequency 
dosing (n/ week)
Dose (IUkg-1) Frequency 
dosing (n/ week)
Utrecht protocol-Dutch (Low dose 
prophylactic regimen) 14
15-30 three 15-30 two
Malmö protocol– Nordic (High dose 
prophylactic regimen) 17
25-40 three 25-40 two
UKHCDO16 25-50 four Not provided*
WFH15 According 
to Utrecht or 
Malmö protocol
According 
to Utrecht or 
Malmö protocol
*Recommendations for patients with hemophilia B are not provided given the paucity of published evi-
dence.
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Table 3. Target ranges with peak and trough FVIII:C and FIX levels and duration of administration accord-
ing to a selection of available guidelines
Hemophilia A Hemophilia B
Predefined target 
ranges (IUmL-1)
Duration (days) Predefined target 
ranges (IUmL-1)
Duration (days)
Dutch14
Major surgery
Preoperative 0.80-1.00 0.80-1.00
Postoperative 0.80-1.00 1 0.80-1.00 1
0.50-0.80 2-5 0.50-0.80 2-5
0.30-0.50 >6 0.30-0.50 >6
Minor surgery
Preoperative 0.80-1.00 0.80-1.00
Postoperative >0.50 Depending on 
procedure
>0.50 Depending on 
procedure
Nordic17
Major surgery
Preoperative 0.70-1.00 0.70-1.00
Postoperative 0.60-0.80 1-3 0.60-0.80 1-3
0.40-0.60 4-6 0.40-0.60 4-6
0.30-0.40 7-9 0.30-0.40 7-9
Minor surgery
Preoperative >0.50 >0.50
Postoperative 1-5 depending on 
procedure
1-5 depending on 
procedure
WFH15 No significant resource constraints
Major surgery
Preoperative 0.80-1.00 0.60-0.80
Postoperative 0.60-0.80 1 - 3 0.40-0.60 1 - 3
0.40-0.60 4 - 6 0.30-0.50 4 - 6
0.30-0.50 7 - 14 0.20-0.40 7 -14
Minor surgery
Preoperative 0.50-0.80 0.50-0.80
Postoperative 0.30-0.80 1 - 5 0.30-0.80 1 - 5
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Peak FVIII:C and FIX levels are estimated based on average in vivo recovery (IVR) of 
FVIII or FIX concentrates and amounts of CFC (IU) infused per kilogram body weight. 
This IVR-based dosing originates from studies that show that each infused unit of 
CFC per kilogram results in a mean increase of 0.02 IUmL-1 for FVIII:C and 0.01 IUmL-1 
for FIX.9, 19 Application of this formula only provides a rough estimate of the maximum 
plasma concentration of FVIII:C and FIX after infusion. More explicitly, it does not take 
the pharmacokinetics (PK) of administered CFC of the individual patient into account, 
e.g., clearance, volume of distribution, and half-life. Application of these PK parameters 
results in a more precise estimate of peak FVIII:C and FIX but also enables calculation of 
FVIII:C or FIX levels and the formulation of recommendations on frequency and timing 
of dosing of FVIII and FIX concentrates.
When describing PK of the various CFC in hemophilia, differences are apparent between 
products. In both recombinant and plasma-derived FVIII concentrates, average half-life 
is estimated at 10.4 hours [95% CI 7.5-16.5] in adults and 9.4 hours [95%CI 7.4-13.1] in 
children.20 Contrastingly, no relationship between age and terminal half-life is observed 
for FIX concentrates.21 Differences in PK of current FVIII and FIX concentrates are signifi-
cant, with a longer half-life of FIX in comparison to FVIII (18-34 hours and 11-16 hours, 
respectively).22 Furthermore, FVIII clearance is lower than FIX clearance (2.4-3.4mL h-1 kg-1 
versus 3.8-8.4 mL h-1 kg-1)22, due to the binding of FVIII to its carrier protein VWF which 
Table 3. Target ranges with peak and trough FVIII:C and FIX levels and duration of administration accord-
ing to a selection of available guidelines (continued)
Hemophilia A Hemophilia B
Predefined target 
ranges (IUmL-1)
Duration (days) Predefined target 
ranges (IUmL-1)
Duration (days)
WFH15 Significant resource constraints
Major surgery
Preoperative 0.60-0.80 0.50-0.70
Postoperative 0.30-0.40 1 - 3 0.30-0.40 1 - 3
0.20-0.30 4 - 6 0.20-0.30 4 - 6
0.10-0.20 7 - 14 0.10-0.20 7 -14
Minor surgery
Preoperative 0.40-0.80 0.40-0.80
Postoperative 0.20-0.50 1 - 5 0.20-0.50 1 - 5
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protects FVIII from proteolytic degradation.23, 24 Although, FVIII has a lower clearance in 
comparison to FIX the longer half-life of FIX is explained by its much larger volume of 
distribution, as roughly t1/2 = 0.693*Volume of distribution (Vd)/ clearance (CL). This 
larger volume of distribution of FIX is due to FIX binding to the vascular endothelium 
and diffusion into interstitial fluid on account of its lower molecular weight when com-
pared to FVIII (FIX: 57 kDa ; FVIII: 280 kDa).25, 26
Limitations of current treatment guidelines
Underlying the presently used dosing calculations is the assumption that all patients 
demonstrate similar PK of administered CFCs. However unfortunately, this is not the 
case. Bjorkman et al. were the first to report the significant inter-individual variations 
in PK after the administration of a standard bolus of FVIII or FIX concentrate in a large 
population. Significant differences were observed with regard to in vivo recovery (IVR), 
clearance and half-life8, 20,27, 28 with FVIII half-life varying from 6-25 hours and FIX half-life 
from 25-56 hours between individuals. Collins et al. showed that the efficacy of pro-
phylactic treatment is based on time spent above certain FVIII trough levels29 and that 
therefore half-life and frequency of CFC dosing are more important than IVR of CFCs. 
Despite these findings, current treatment guidelines for replacement therapy are still 
based on IVR-based dosing regimens, which do not take the inter-individual variation of 
pharmacokinetics of CFCs into account.
Furthermore, as is observed in the general population, obesity also increasingly occurs 
in hemophilia patients.30 This will result in in higher FVIII and FIX consumption if prophy-
lactic and on demand treatment is persistently based on body weight and IVR-based 
dosing regimens. Importantly, increasing body weight is not linearly associated with 
increasing volume of distribution as assumed by IVR-based dosing regimens.31 There-
fore, these higher costs of treatment may not be necessary to safeguard hemostasis. 
Obviously, current global constraints of health care budgets, obligates hemophilia com-
munities worldwide to generate dosing algorithms in hemophilia with optimal results 
for patients and minimal costs for society.
Moreover in the perioperative setting, we recently demonstrated that current dosing 
leads to significantly lower and higher FVIII and FIX levels than targeted in hemophilia 
A and B.32, 33 In moderate and severe hemophilia A patients, a large proportion of trough 
and steady state FVIII:C levels were found to be below or above predefined target ranges. 
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Specifically, 45% of FVIII:C measurements were below the FVIII target range within first 
24 hours after surgery and 75% above the target range during hospitalization more 
than six days after surgery.32 Potentially, more optimal maintenance of perioperative 
target ranges could result in a reduction of 44% of CFC consumption, when ignoring 
logistical aspects of care.32 In a recent retrospective study on perioperative management 
in moderate and severe hemophilia B patients, 60% of FIX measurements were below 
target and 59% FIX levels above target during hospitalization more than six days after 
surgery.33 Although the terminology of under- and overdosing suggests putting the 
patient at risk which is not the case as perioperative complications were minimal, these 
data do underline the limitations of current dosing algorithms primarily based on body 
weight using IVR-based dosing. As well as potential cost-effectiveness of alternative 
algorithms.
PHARMACOKINETIC (PK)-GUIDED DOSING IN HEMOPHILIA
Principles of PK-guided dosing
To address interindividual differences in PK of CFC and to employ more effective dos-
ing, PK-guided dosing is a potential strategy. PK-guided dose-calculations are based on 
individual PK parameters in relationship to the population PK model and obtained by 
Bayesian analysis using statistical software (NONMEM®). In a population PK model for 
CFC, relationships between dose and achieved FVIII:C or FIX:C levels are described by 
PK parameters of all individuals in the population under review. This makes it possible 
to describe both inter-individual and intra-individual variability within this population 
dataset. In general, an important condition for implementing PK-guided dosing, is that 
intra-individual variability is smaller than inter-individual variability. Identified covari-
ates explaining variability can be used to further improve constructed models, while 
unknown factors are labeled as residual errors. The principal strength of PK-guided dos-
ing is that a population PK model not only represents identified covariates influencing 
PK parameters, but also takes the unknown modifiers of PK into account as they are 
described by the population data included in the model.
Importantly, Bayesian adaptive dosing is only possible when population PK models are 
representative of the individual patient and her or his specific clinical setting. Construct-
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ed models should therefore comprise a wide variation in patient-related (age, body 
weight, endogenous baseline FVIII/FIX, blood group) and circumstance-related factors 
(prophylaxis, on demand dosing during hemostatic challenges such as acute bleeding 
and surgery). For example, the recently published perioperative FVIII population PK 
model showed a significantly larger peripheral volume of distribution in comparison to 
the prophylactic PK model by Bjorkman et al. (1180 mL/68 kg versus 240 mL/68 kg).8, 34 
Further, to optimize current population models it is important to include often under-
represented patient populations, such as children and overweight/obese patients since 
PK parameters in these populations may differ significantly.
Construction of individual PK profiles and population PK models
Extensive work performed by Bjorkman et al. has made PK-guided prophylactic dosing 
with limited blood sampling in hemophilia possible.35 Prior to the construction of these 
population PK models, individual PK curves were constructed through extensive blood 
sampling (>10 samples), with an obligatory wash-out period, leaving the patient at po-
tential risk of bleeding. Currently, individual PK profiles for FVIII and FIX can fortunately 
be constructed with limited blood sampling and without a wash out period (Table 4).35-37 
Using Bayesian analysis and a representative population PK model, individual PK esti-
mates can be iteratively updated, providing prophylactic dosing advice and prediction 
of achieved FVIII:C and FIX:C levels.38
Perioperatively, several research groups have estimated preoperative loading doses of 
FVIII and FIX after constructing individual PK profiles.39-43 However, until recently it was 
not possible to iteratively dose patients in the perioperative setting owing to the lack of 
population PK models for this specific setting. Construction of perioperative PK popula-
tion models for both moderate and severe hemophilia A34 and B, mild hemophilia A44 
and in the near future for von Willebrand disease34 will eventually make this possible for 
several bleeding disorders.
The most important covariate in FVIII population PK models for hemophilia A patients, 
will most likely be von Willebrand factor (VWF). This is supported by findings that blood 
group O versus non-O is a significant covariate of clearance in the perioperative setting, 
with 26% higher clearance rates for patients with blood group O.34 It is generally known 
that patients with blood group O have lower VWF levels due to influence of ABO anti-
gens on the rate of synthesis or proteolysis of VWF.45 However, this effect of blood group 
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O was not previously observed in a steady state prophylactic setting.46 Most likely, this 
diff erence can be explained by an increase of VWF due to infl icted endothelial damage 
and its role in the acute phase reaction after surgery.47
Benefi ts of PK-guided treatment
As early as 1997, Carlsson et al. showed benefi ts of a PK-guided dosing approach for 
prophylaxis.7 This small study was designed as a randomized cross-over study compar-
ing PK-guided dosing of prophylaxis with standard prophylactic dosing in 14 individuals 
during a period of two times six months. Strikingly, a reduction of CFC administration 
of 30% was achieved. The number of reported bleedings was similar in both treatment 
arms.7 Such a reduction can have a signifi cant fi nancial impact, since annual costs for 
replacement therapy in the Netherlands amount to more than 126 million euros.48 Be-
fore drawing conclusions, however, it is important to prospectively evaluate these out-
comes of PK-guided dosing in adequately designed and powered studies.49 Currently, 
a randomized controlled trial comparing PK-guided perioperative treatment of CFC in 
moderate and severe hemophilia A patients is in place to analyze the amount of CFC 
Table 4. Limited blood sampling strategies to construct individual PK curves. 
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Bolus infusion 
(IUkg-1) 
FVIII:C or FIX measurements 
Factor VIII (FVIII) 
(Björkman et al.35) 
50 T=4, T=24, T=48 hours 
 
Plasma derived Factor IX (FIX) 
(Brekkan et al.36)  
 
50 
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Recombina t Factor IX (FIX) 
(Preijers et al.37)  
 
100 
 
One sample post infusion, two samples 
between T=72 and T=80 hours.  
The upper panel shows a graphic example of a Factor VIII (FVIII) concentrate PK profile. A FVIII 
concentrate bolus is administrated followed by FVIII:C measurements (red points). Using a 
population PK model, FVIII pl sma levels (red line) are calculated using individual PK arameter 
estimates derived from Bayesian analysis. To estimate FIX PK, similar principles are applied, although 
FIX blood sampling occurs at different longer time points as FIX concentrate half-life is longer.  
 
 
 
 
 
  
Bolus infusion
(IUkg-1)
FVIII:C or FIX measurements
Factor VIII (FVIII)
(Björkman et al.35)
50 T=4, T=24, T=48 hours
Plasma derived Factor IX (FIX)
(Brekkan et al.36) 
50 T=48, T=72 hours ór T=54, T=78 hours
Recombinant Factor IX (FIX)
(Preijers et al.37) 
100 One sample post infusion, two samples between 
T=72 and T=80 hours. 
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administered, time spent to achieve targeted FVIII levels, as well as staff investment and 
costs, all in accordance with the economic health principles established by Hakkaart-van 
Rooijen.49, 50 This study may result in clear conclusions regarding the cost effectiveness 
of PK-guided dosing.
Another benefit of PK-guided dosing is that both prophylactic and “on demand” dosing 
will be based on actual FVIII:C and FIX:C trough and peak levels or FVIII and FIX levels 
predicted by population PK models, instead of current FVIII:C and FIX estimates based 
on IVR-based dosing. Furthermore, FVIII and FIX sampling can be made flexible and not 
necessarily fixed at certain time points before or after infusion, once models are in place. 
Moreover, PK-guidance will optimize dosing as knowledge will increase with regard to 
relationship between FVIII:C and FIX:C levels and bleeding in individual patients and pa-
tient groups. In addition, an increase in dosing will not only depend on actual bleeding 
and a reduction of dosing can be considered by the treating professional in consultation 
with patients and parents. Importantly, the dose and frequency of CFC of patients on 
prophylaxis should only be reduced if clinically justified and impact should be moni-
tored with regard to bleeding events, bleeding pattern and joint status (Table 5).
Over time, more exact targeting of FVIII:C and FIX levels may also lead to reliably lower-
ing of target levels of treatment. Especially in hemophilia B, studies and clinical experi-
ence suggest that lower target levels may be acceptable.15, 51 In a recent retrospective 
study on perioperative management in moderate and severe hemophilia B patients, 
60% of FIX measurements were below target, without clinical relevant bleeding and 
independent of the severity of surgical procedures.33 Srivastava et al. showed that 
lower trough FVIII:C (0.20-0.40 IUmL-1) and FIX:C (0.15-0.30 IUmL-1) levels 0-72 hours 
after surgery were not accompanied by bleeding complications since only one patient 
experienced bleeding due to a lack of surgical hemostasis.51 Furthermore, International 
WFH guidelines for perioperative treatment in hemophilia A and B patients recommend 
FIX levels 0.20 IUmL-1 lower than FVIII:C levels (Table 3).15 In countries with significant 
financial constraints, even lower FIX target ranges are suggested.15 Interestingly, various 
European guidelines do not differ regarding perioperative target ranges for hemophilia 
A and B14, 17, 52 as reported in a survey by the European Therapy Standardization Board 
in 2009.53
PK-guided dosing will also facilitate individualization of dosing according to individual 
lifestyle and activities, therefore achieving true personalization of treatment. When 
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targeting weekly FVIII:C and FIX:C levels, personal activities and preferences should be 
taken into account, as bleeding risk is closely related to these factors.54-56 Moreover, non-
adherence should be discussed as implementation of minimal dosing schemes may lead 
to an increased risk of bleeding.57-59 Patients and families should be aware of time points 
when factor concentrate levels are low or high and consider additional dosing when 
bleeding risk is significant.
All benefits of PK-guided dosing are also applicable with regard to upcoming enhanced 
half-life (EHL) products. Moreover, costs of treatment will directly depend on the dose 
and frequency of treatment and therefore on individual PK and population PK param-
Table 5. Benefits and limitations of PK-guided dosing based on population PK models as alternative for 
body weight and IVR-based dosing regimens
Advantages Conditions and remarks
1.  Better targeting of FVIII:C and FIX levels with 
minimal burden to patients.
Although limited blood sampling decreases frequency 
of blood sampling, two/three samples for individual 
PK profile are still obligatory.
Population PK models should however be 
representative of population and specific setting.
2. More flexible blood sampling Once PK-guided dosing is in place.
3.  Insight into association of FVIII:C and FIX trough 
and peak levels and bleeding Future possibilities 
to construct both PK and pharmacodynamics (PD) 
models and to further understand pathophysiology 
of hemostasis
Further development of global hemostatic assays 
measuring hemostatic potential also essential.
4.  Possibility to potentially lower FVIII:C and FIX target 
values, due to more reliable targeting
Intensive collaboration between experienced 
clinical pharmacologist and (pediatric) hematologist 
necessary. Realization of risks and intensive 
monitoring of clinical impact of lowering of FVIII and 
FIX levels obligatory.
5.  Facilitation of actual personalization of treatment 
according to lifestyle
Continuous adaptation of dosing regimen according 
to lifestyle also necessary. Individual PK profiles must 
be potentially repeated every 3-4 years. Adherence 
must be discussed.
6. Potential reduction of overall treatment costs Prospective studies to evaluate actual impact on costs 
are obligatory.
7. Further enrichment of population PK models Intensive collaboration between experienced 
clinical pharmacologist and (pediatric) hematologist 
necessary.
214 • Chapter 10
eters. Furthermore, the ongoing discussion of the association of trough levels and 
the role of peak levels with regard to bleeding will be made more transparent. This is 
especially relevant in EHL products as higher troughs will be possible and treatment 
peaks will be less frequent.60
Limitations of PK-guided treatment
Important limitations with regard to PK-guided dosing include the requirement of close 
collaboration with a clinical pharmacologist with expertise in PK modeling. Furthermore, 
time investments by patients, parents and medical professionals may be substantial as 
individual PK profiles must be performed regularly (every three to four years depending 
on patient characteristics) and perioperative PK-guided iterative dosing requires daily 
dosing recommendations. Solutions to overcome these limitations are the availability of 
web portal-based consultancies for PK-guided dosing advice, as established by Iorio61, for 
instance, and as developed by a pharmaceutical company for the prophylactic setting.62 
Both initiatives to implement a closer collaboration and to educate both professionals 
and patients are valuable for future patient care. Transparency and reliability of the data 
used to construct underlying population models are of course of crucial importance in 
such settings.
FUTURE ROLE FOR PK-GUIDED DOSING OF FACTOR CONCENTRATES IN 
HEMOPHILIA CARE AND RESEARCH PERSPECTIVE
Replacement therapy has led to the high standard of hemophilia care in high-income 
countries. However, recent studies show that treatment is suboptimal; although bleed-
ing is rare, both under- and overdosing of CFC occur. We believe that PK-guided dosing 
as alternative to body weight and IVR-based dosing, will play an important role in fur-
ther individualization of therapy. We have summarized the anticipated improvements 
in Table 5.
Future research should include studies prospectively validating constructed population 
PK models but also combining PK with pharmacodynamic data (e.g. bleeding events, 
global hemostatic test results) and simulations to objectify minimal FVIII:C and FIX levels 
required for adequate hemostasis in the individual patient and in populations. These 
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data may subsequently support studies aiming at lower target levels in specific bleeding 
disorders.
CONCLUSION
We believe that PK-guided dosing deserves attention as a means of ensuring the indi-
vidualization of treatment in hemophilia since benefits are significant and limitations 
can be overcome. The burden for patients and parents appears to be minimal. Accord-
ingly, we call on patients, medical professionals, clinical pharmacologists, hemostatic 
laboratories and pharmaceutical companies to join hands in applying this approach for 
all CFCs, in hemophilia and other bleeding disorders requiring CFC replacement therapy.
PRACTICE POINTS
– Replacement therapy with clotting factor concentrates (CFC) is the mainstay of treat-
ment in hemophilia.
– However, dosing is challenging and costs are high.
– Current dosing is based on body weight and in vivo recovery (IVR) of CFC.
– PK-guided dosing will enable individualization of treatment with better targeting of 
coagulation factor levels.
RESEARCH AGENDA
– Prospective studies are warranted validating constructed population PK models
– Future studies combining PK with pharmacodynamic data (e.g. bleeding events, 
global hemostatic test results)
– Simulation analyses to objectify minimal FVIII:C and FIX:C levels required for ad-
equate hemostasis in individual patients and specific patient populations.
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SUMMARy
All studies described in this thesis are part of the “OPTI-CLOT” research program on 
patient tailOred PharmacokineTIc (PK)-guided dosing of CLOTting factor concentrate in 
bleeding disorders. These are (inter)national multicenter studies which aim to imple-
ment PK-guided dosing of clotting factor replacement therapy by initiation of studies to 
prove the implications of PK-guided dosing, to construct perioperative and prophylactic 
population PK models and to evaluate the cost-effectiveness of a PK-guided approach.
This thesis focuses on the evaluation of current dosing strategies and the feasibility of 
alternative, more individualized dosing based on PK-guidance using Bayesian analysis.
In chapter 1, a short introduction to this thesis is presented which includes an overview 
of current treatment of inherited bleeding disorders and introduces the terminology 
used to describe pharmacokinetic (PK) principles. As replacement therapy with fac-
tor concentrates is administered intravenously, especially volume of distribution and 
clearance are important factors when determining the dosage of factor concentrate 
necessary to achieve a certain coagulation factor level. Moreover, mainly volume of 
distribution is of importance in case of bolus infusion therapy and the administration of 
a loading dose while clearance of the factor concentrate is most relevant when continu-
ous infusion is the mode of administration of factor concentrate.
In part I, the current management of patients with an inherited bleeding disorder 
undergoing a surgical procedure is evaluated with the aim to identify the extent and 
predictors of levels under target range and above target range as prescribed by National 
guidelines.
In chapter 2, perioperative treatment of hemophilia A patients was evaluated with 
special attention to the extent and predictors of factor VIII (FVIII) values under and below 
target values as set by National guidelines. We demonstrated that targeting of factor 
VIII (FVIII) values is challenging in the periperative setting in a study which included 
119 hemophilia A patients undergoing 198 elective minor or major surgical procedures. 
Remarkably, in the first 24 hours after surgery, 45% of achieved trough and steady 
state FVIII levels were under predefined target ranges. Depending on postoperative 
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day, 33-75% of FVIII levels were above predefined target ranges. Strikingly, a potential 
reduction of FVIII consumption of 44% would have been attained if FVIII levels had been 
maintained within target ranges. Blood group O and major surgery were predictive of 
underdosing (OR=6.3; 95%CI [2.7-14.9];OR=3.3; 95%CI [1.4-7.9]). Also, blood group O 
patients had more bleeding complications in comparison to patients with blood group 
non-O (OR=2.02 95%CI[1.00-4.09]). Patients with blood group non-O were at higher risk 
of overdosing (OR=1.5 95%CI[1.1-1.9]). Most probably, this is explained by higher VWF 
levels and therefore higher FVIII levels, as VWF protects FVIII against proteolytic degrada-
tion in the circulation. Additionally, patients treated with bolus infusions were at higher 
risk of excessive overdosing (OR=1.8 95%CI[1.3-2.4]). It was concluded that refinement 
of dosing strategies based on individual patient characteristics such as blood group and 
mode of infusion can potentially lead to improved quality of care and cost-effectiveness.
The perioperative treatment of hemophilia B patients is evaluated in chapter 3. In this 
retrospective international multicenter study, a total of 118 patients were included that 
underwent 255 surgical procedures. The aim of the study was to investigate the periop-
erative management and to assess predictors of low and high FIX levels. Patients were 
included from a total of ten Hemophilia Treatment Centers situated in the Netherlands 
and United Kingdom. Sixty percent of factor IX (FIX) levels ≤ 24 hours after surgery were 
under target level with a median deviation of 0.22 IUmL-1 [IQR 0.12-0.36]; while 59% of 
FIX levels were above target level >six days after surgery with a median deviation of 
0.19 IUmL-1 [IQR 0.10-0.39]. However, in only three procedures (1.2%), clinically relevant 
bleeding complications occurred, defined as procedures requiring a second surgical 
intervention or necessity of a red blood cell transfusion. These events were not associ-
ated with lowFIX levels. This study shows that targeting of prescribed FIX levels in the 
perioperative setting is complex and results are suboptimal, but bleeding is minimal. 
Therefore, this may indicate that current target ranges may be debatable. Moreover, that 
PK-guided dosing may not only make it possible to target FIX ranges more optimally, 
but also to reliably target lower FIX ranges to minimalize bleeding risk.
In chapter 4, the perioperative management of patients with von Willebrand disease 
(VWD) treated with von Willebrand factor (VWF)/ FVIII concentrate was evaluated to 
investigate whether current strategies not based on PK are sufficient to reach the target 
levels of coagulation factors perioperatively. Achieved VWF activity (VWF:Act) and FVIII:C 
activity (FVIII) levels during FVIII-based treatment regimens were compared to pre-
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defined VWF:Act and FVIII target levels stated in National guidelines. In total, 103 VWD 
patients undergoing 148 surgical procedures were included: 54 type 1 (73 surgeries), 43 
type 2 (67 surgeries) and 6 type 3 (8 surgeries). Overall during treatment, VWF:Act and 
FVIII levels were measured, and were defined as high when plasma levels were ≥ 0.20 
IUmL-1 above predefined target levels. In type 1 VWD patients, respectively 65% and 91% 
of trough VWF:Act and FVIII levels were classified as high. In type 2 VWD and type 3 re-
spectively, 53% and 57% of trough VWF:Act and 72% and 73% of trough FVIII levels were 
classified as high. In addition, as expected accumulation of FVIII levels was observed 
after perioperative FVIII-based replacement therapy in VWD patients. Prevalence of 
FVIII and VWF:Act levels >0.20 IUmL-1 lower than target levels was rare. When analyzing 
predictors of high and low levels, in type 1 VWD, during the total postoperative period, 
only blood group O was predictive of high VWF:Act levels (VWF:Act levels ≥0.20 IUmL-1 
above target) (OR 2.9; 95%CI [1.3-6.6]). Most probably this is explained by lower endog-
enous baseline VWF:Act and FVIII:C levels resulting in administration of higher dosages 
of VWF/FVIII concentrates. No other predictors were found for low and high VWF:Act 
and FVIII levels in both type 1 and type 2 VWD patients. It was concluded, that more 
efficient therapy as well as further individualization is possible in VWD patients requiring 
replacement therapy. PK-guided dosing may be a potential strategy to optimize and 
individualize dosing in VWD. The complexity of the disease with great variation in VWD 
types, mutations and endothelial activation, e.g. production, secretion, and clearance of 
VWF however makes this a challenging prospect.
In part II, we used the retrospectively collected data of the observational studies 
described in part I to construct population PK models using nonlinear mixed-effects 
modeling.
In chapter 5, we describe the construction of a perioperative population PK model for 
patients with hemophilia A which depicts the perioperative PK of various currently used 
FVIII concentrates in order to optimize dosing based on this PK model. Population PK pa-
rameters were estimated in 119 patients of which 75 were adults (median age: 48 years, 
median weight: 80 kg) and 44 were children (median age: 4.3 years, median weight: 
18.5 kg) undergoing respectively 140 and 58 surgical procedures. PK profiles were best 
described by a two-compartment model. Typical values for clearance, inter-compart-
mental clearance, central and peripheral volume were 0.15 L/h/68 kg, 0.16 L/h/68 kg, 
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2.81 L/68 kg and 1.90 L/68 kg. Inter-patient variability in clearance and central volume 
was 37% and 27%. Clearance decreased with increasing age (p<0.01) and increased in 
case of blood group O (26%, p<0.01). In addition, a minor decrease in clearance was 
observed when a major surgical procedure was performed (7%, p<0.01). In comparison 
to the population PK model constructed for the prophylactic setting, a large peripheral 
volume was observed. We hypothesized, that this may be explained by the periopera-
tive increase of VWF which protects FVIII from elimination, thereby reducing clearance 
of FVIII. Prospective studies are however needed to evaluate this relationship in the 
perioperative setting. Moreover, this will be investigated in the randomized controlled 
“OPTI-CLOT” trial, described in chapter 7. The development of the described model in 
chapter 5 will allow individualization of perioperative FVIII dosing in severe and moder-
ate severe hemophilia A patients by Bayesian adaptive dosing.
In chapter 6, we also constructed such a perioperative population PK model for severe 
and moderate severe hemophilia B patients with the aim to describe FIX concentrations 
and interpatient variability in the perioperative period, during FIX replacement therapy, 
ultimately leading to more individualized therapy. A total of 118 hemophilia B patients 
were included (median age 40 years, median body weight 79 kilogram) who under-
went a total of 255 surgical procedures. In contrast to the model constructed for FVIII 
concentrate, FIX:C versus time profiles were now adequately described using a three-
compartment model. Average clearance (CL), inter-compartmental clearance (Q2, Q3), 
distribution volume of the central compartment (V1) and peripheral compartments (V2, 
V3), plus inter-patient variability (%) were: CL: 251 mLh-170kg-1 (13%), V1: 4950 mL70kg-1 
(13%), Q2: 91.3 mLh-170kg-1 (99%), V2: 7900 mL70kg-1 (57%), Q3: 831 mLh-170kg-1, V3: 
1600 mL70kg-1 for a 32 year old patient. The estimated population PK parameters were 
different from those reported for prophylactic treatment, suggesting a less rapid first 
phase disposition to the interstitial fluids during the perioperative period. A tentative 
explanation for this finding is that endogenous consumption and complexation of FIX 
with FVIII during hemostatic challenge causes a lower distribution towards the inter-
stitial fluids. Therefore, a dedicated population PK model is needed when PK-guided 
dosing is performed during surgery. With increasing age, CL and V1 increased 1.2% and 
1.9% per year, respectively, until the age of 32 years (p<0.001, p<0.01). Strikingly, the 
final model showed that CL and V1 differed between countries. CL and V1 were 20.1% 
and 28.3% higher when a patient was treated in the Netherlands. Further investigations 
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should focus on preferences of factor concentrate brands between countries, which 
may explain this variation. Furthermore, the use of tranexamic acid decreased V1 by 
9.8%, thus leading to a lower V1. This suggests that tranexamic acid leads to higher FIX:C 
directly after dosing of tranexamic acid. However, to date this pharmacodynamic effect 
has never been described and should be further investigated before drawing conclu-
sions.
In part III, the feasibility and validation of PK-guided dosing of factor concentrates in 
patients with bleeding disorders is investigated. In chapter 7, the design of the “OPTI-
CLOT trial is described. The “OPTI-CLOT” trial is an open-label, prospective, multicenter 
randomized controlled superiority trial (RCT), which compares standard dosing pro-
cedure with iterative Bayesian PK-guided dosing, aiming to detect a 25% difference in 
perioperative FVIII concentrate consumption. Patients are stratified according to mode 
of administration of FVIII (continuous or bolus infusion) and severity of the surgical 
procedure. At least sixty hemophilia A patients ≥ 12 years of age, with FVIII levels ≤ 
0.05 IUml-1 will be included, requiring FVIII replacement therapy for an elective, minor or 
major surgical procedure. In this RCT, the perioperative population PK model, discussed 
in chapter 5, will be prospectively validated. In addition, concomitantly during the RCT 
participating Hemophilia Treatment centers will gain experience with PK-guided dos-
ing, facilitating future implementation of this intervention.
Because some previous studies showed that PK parameters may be different in children 
compared to adults and in obese versus normal weight individuals we analyzed in chap-
ter 8, alternative dosing strategies based on body size descriptors in overweight and 
obese hemophilia A patients and compared them to individualized treatment based 
on PK guidance. Current replacement therapy in hemophilia is based on residual FVIII 
levels, body weight in kilograms, and influenced by clinical phenotype, crude clear-
ance estimations and severity of (risk of ) bleeding. Historically, guidelines for dosing 
of hemophilia A are based on an in vivo recovery (IVR) of 2.0 which equals an increase 
of 2.0 IUdL-1 per unit of infused FVIII concentrate per kilogram. Obese patients have 
significantly higher IVR values, potentially leading to overdosing of factor concentrate. 
Therefore, alternative dosing strategies using ideal body weight or lean body weight 
have been proposed by several groups. We discuss the benefits and limitations of alter-
native dosing strategies using body size descriptors in the obese hemophilia patient. In 
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the study, 22 severe and moderate severe hemophilia A patients were included (baseline 
FVIII <0.05 IUml-1) and categorized according to body mass index (BMI), normal: <25 
kgm-2 (n=5) overweight: 25-30 kgm-2 (n=12) and obese: >30 kgm-2 (n=5). All patients 
received ± 50 IUkg-1 FVIII, with FVIII sampling after 4, 24 and 48 hours. Population PK 
models were applied to calculate FVIII plasma concentration over time. The population 
PK model by Bjorkman et al. did not correctly predict FVIII levels in the overweight/
obese. A modified model was constructed, describing PK parameters and FVIII levels 
adequately in this overweight and obese patient group. Median IVR was significantly 
higher in overweight (2.65) and obese (3.00) patients when compared to those with a 
normal BMI (2.17) (p<0.05). IVR was independent of BMI when ideal body weight was 
applied. Nevertheless, for all body size descriptors IVR-based dosing (IVR of 2.0) resulted 
in FVIII trough levels below set target levels for bleeding events. It was concluded that, 
in contrast to what is generally hypothesized, alternative body size descriptors are not 
able to substitute PK-guided dosing. We conclude that when PK-guided dosing of factor 
VIII concentrate is performed, the population PK model should be representative of the 
specific patient population, in this case e.g.obese/overweight patients.
In chapter 9 it is illustrated how an individual PK profile and a perioperative population 
PK model can be utilized to individualize treatment in a single patient undergoing a 
renal transplantation. During the perioperative period, we were able to maintain pre-
defined target ranges and to reliably predict FVIII dosing requirements by a Bayesian 
analysis approach using the constructed perioperative FVIII population PK model from 
chapter 5. This case report of a complex patient shows the role this innovation can play, 
especially in patients requiring precise targeting of coagulation factor levels due to a 
high risk of either bleeding or thrombosis during a major surgical procedure.
In chapter 10, the benefits and limitations of PK-guided dosing are discussed. Benefits 
of PK-guided dosing include individualization of treatment with better targeting, more 
flexible blood sampling, increased insight into association of coagulation factor levels 
and bleeding, and potential lowering of overall costs. Limitations include a slight burden 
for the patient due to somewhat more blood sampling, and the necessity of closely col-
laborating, experienced clinical pharmacologists.
Overall, the studies performed and included in this thesis show that laboriously col-
lected retrospective data can lead to construction of high quality population PK 
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models (Figure 1). The internal validation performed shows a good performance of the 
developed population PK models. Prospective studies are needed to further externally 
validate these population PK models and to further improve the constructed population 
PK models.
Figure 1. Different steps towards individualized PK-guided dosing of clotting factor concentrates (“OPTI-
CLOT” studies)
I
II III
IV
I Data collection regarding current management
II Construction of population PK models
III External validation and implementation of PK guided dosing
IV Individualized treatment
Different steps towards individualized PK-guided dosing of factor concentrates include data collection of 
replacement therapy followed by the construction of population PK models. These should be externally 
validated and implemented in clinical practice leading to more individualized treatment.
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De studies beschreven in dit proefschrift maken allen onderdeel uit van de “OPTI-CLOT” 
onderzoekslijn die nastreeft patiënten met een stollingsstoornis geïndividualiseerder 
te behandelen met stollingsfactorconcentraten door implementatie van het farma-
cokinetisch (PK) gestuurd doseren van stollingsfactorconcentraten. De “OPTI-CLOT” 
onderzoeksgroep bestaat uit hemofiliebehandelaren werkzaam in alle Nederlandse 
Hemofiliebehandelcentra als ook behandelcentra in Groot Brittannië.
De studies beschreven in dit proefschrift evalueren de huidige behandeling met stol-
lingsfactorconcentraten in de verschillende stollingsstoornissen en de haalbaarheid 
van alternatieve, meer geïndividualiseerde behandeling op basis van farmacokinetisch 
gestuurd doseren aan de hand van Bayesiaanse analyse.
In hoofdstuk 1 wordt een korte inleiding van dit proefschrift gegeven met een gedetail-
leerde beschrijving van de huidige behandeling met stollingsfactorconcentraten van 
patiënten met een stollingsstoornis. Dit hoofdstuk beschrijft de terminologie om farma-
cokinetiek (PK) te beschrijven. Omdat stollingsfactorconcentraten intraveneus worden 
toegediend zijn verdelingsvolume en klaring belangrijke factoren die mede de dosering 
bepalen. Bij bolus infusietherapie is met name het verdelingsvolume van belang, terwijl 
bij continue toediening van stollingsfactorconcentraten klaring de belangrijkste deter-
minant is.
In deel I wordt de huidige behandeling geëvalueerd van patiënten met een erfelijke 
stollingsstoornis die een chirurgische ingreep ondergaan met het doel de prevalentie en 
voorspellers van plasma spiegels van stollingsfactoren onder en boven de streefwaarde 
te identificeren zoals beschreven door de Nationale richtlijn.
In hoofdstuk 2 werd de behandeling van hemofilie A patiënten ten tijde van een 
chirurgische ingreep in de perioperatieve periode geëvalueerd. Er werden predictoren 
geïdentificeerd van onder- en overbehandeling ten aanzien van streefwaarde zoals 
vastgesteld door de Nationale richtlijn. In de studie waarbij 119 hemofilie A patiënten 
198 electieve kleine of grote chirurgische ingrepen ondergingen, toonden we aan dat 
het bereiken van FVIII streefwaarden moeilijk is. Opmerkelijk was dat in de eerste 24 uur 
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na de operatie, 45% van de dal of ‘steady state’ FVIII waarden die bereikt waren onder de 
streefwaarde waren. Afhankelijk van de hoeveelheid dagen na operatie, waren 33-75% 
van de FVIII spiegels boven de streefwaarde. Er werd berekend dat een reductie van 44% 
van FVIII concentraat mogelijk zou zijn geweest indien er zodanig was gedoseerd dat 
FVIII spiegels binnen de streefwaarden waren geweest. Bloedgroep O en een grotere 
operatie waren predictoren voor lagere bereikte FVIII spiegels (OR = 6.3; 95% CI [2.7-
14.9]; OR = 3.3; 95% CI [1.4-7.9]). Daarnaast hadden patiënten met bloedgroep O ook 
meer bloedingscomplicaties in vergelijking met patiënten met bloedgroep non-O (OR 
= 2.02 95% CI [1.00-4.09]). Bij patiënten met bloedgroep non-O werden ook vaker FVIII 
waardes boven streefwaarde gevonden (OR = 1.5 95% CI [1.1-1.9]). Een verklaring voor 
deze bevinding is dat bloedgroep non-O patiënten hogere spiegels van VWF hebben en 
daarbij een hogere spiegel FVIII in het plasma, doordat VWF de proteolytische afbraak 
van FVIII voorkomt door binding aan FVIII. Er werd tevens vastgesteld dat patiënten die 
behandeld werden met bolus infusie therapie een grotere kans hadden op excessief 
hogere FVIII waardes (OR = 1.8 95% CI [1.3-2.4]). Geconcludeerd werd dat verfijning van 
doseerstrategieën gebaseerd op individuele patiënt kenmerken zoals bloedgroep en 
wijze van infusie mogelijk kan leiden tot een betere kwaliteit van zorg en kosteneffecti-
viteit van de behandeling.
De perioperatieve behandeling van hemofilie B patiënten werd geëvalueerd in hoofd-
stuk 3. In deze retrospectieve, internationale, multicenter studie werden 118 patiënten 
die 255 chirurgische ingrepen ondergingen geïncludeerd. Het doel van de studie was 
de behandeling te evalueren en predictoren van lage en hoge factor IX (FIX) spiegels te 
identificeren. Data werd verzameld in totaal tien hemofiliebehandelcentra in Nederland 
en het Verenigd Koninkrijk. Zestig procent van de FIX spiegels binnen 24 uur na de 
operatie waren onder de streefwaarde met een mediane afwijking van 0.22 IUmL-1[IQR 
0.12-0.36]; terwijl 59% van de FIX spiegels boven de streefwaarde waren meer dan zes 
dagen na de operatie met een gemiddelde afwijking van 0.19 IUmL-1 [IQR 0.10-0.39]. In 
slechts drie chirurgische ingrepen (1.2%) waren er klinisch relevante bloedingscompli-
caties opgetreden, gedefinieerd als ingrepen die een tweede chirurgische ingreep of 
een bloedtransfusie behoeften. Deze gebeurtenissen waren niet geassocieerd met lage 
FIX spiegels. Deze studie toont aan dat behandeling met behalen van FIX streefwaar-
den complex is en FIX spiegels in de huidige therapie suboptimaal zijn, maar met een 
minimaal bloedingsrisico. Dit kan erop wijzen dat de huidige streefwaarden discutabel 
Samenvatting • 235
11
zijn. Farmacokinetisch gestuurd doseren kan mogelijk gebruikt worden om lagere FIX 
streefwaarde te identificeren in combinatie met een minimaal risico op bloedingen.
In hoofdstuk 4 werd de perioperatieve behandeling met van Willebrand factor (VWF)/
factor VIII (FVIII) concentraten van patiënten met de ziekte van von Willebrand (VWD) 
geëvalueerd. Dit met als doel om te onderzoeken of de huidige doseerstrategieën ade-
quaat zijn om de voorgestelde streefwaarden te bereiken. De bereikte VWF-activiteit 
(VWF:Act) en FVIII:C-activiteit (FVIII) spiegels werden vergeleken met de VWF:Act en 
FVIII streefwaarden zoals beschreven in de Nationale richtlijn. In totaal werden 103 
VWD patiënten die 148 chirurgische ingrepen ondergingen geïncludeerd: 54 type 1 (73 
operaties), 43 type 2 (67 operaties) en 6 type 3 (8 operaties). VWF:Act en FVIII spiegels 
werden postoperatief meerdere keren gemeten. Spiegels > 0.20 IUmL-1 boven de ver-
melde streefwaarden werden gedefinieerd als hoog. In type 1 VWD patiënten, waren 
respectievelijk 65% en 91% van alle dalspiegels van VWF:Act en FVIII hoog. In type 2 
VWD en type 3 VWD waren respectievelijk 53% en 57% van de dalspiegels van VWF:Act 
en 72% en 73% van de dalspiegels van FVIII te hoog. Zoals verwacht werd er een ac-
cumulatie van FVIII dalspiegels geobserveerd door behandeling gebaseerd op FVIII spie-
gels. Prevalentie van FVIII en VWF:Act spiegels > 0.20 IUmL-1 onder de streefwaarde was 
zeldzaam. Bij het analyseren van predictoren van spiegels > 0.20 IUmL-1 boven en onder 
de streefwaarde werd alleen bloedgroep O als predictor voor hoge spiegels gevonden 
in type 1 VWD patiënten (OR 2.9; 95 % CI [1.3-6.6]). Waarschijnlijk is dit te verklaren door 
lagere endogene spiegels van VWF:Act en FVIII resulterend in het toedienen van hogere 
doseringen van stollingsfactorconcentraten. Geen andere predictoren werden gevon-
den voor lage en hoge VWF:Act en FVIII spiegels in type 1 en type 2 VWD patiënten. 
Geconcludeerd werd dat een efficiëntere behandeling en verdere individualisering van 
behandeling mogelijk is in VWD patiënten. Farmacokinetisch gestuurd doseren kan een 
potentiele strategie zijn. Echter, de complexiteit van VWD met een grote variatie in VWD 
type, mutaties en endotheel activatie, b.v. in verschillen in productie, secretie en klaring 
van VWF maakt dit een uitdaging.
In deel II werden op basis van de retrospectief verzamelde gegevens van de observa-
tionele studies in deel I populatie farmacokinetische (PK) modellen geconstrueerd met 
behulp van non-linear mixed-effects modelling (NONMEM) software.
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In hoofdstuk 5 beschrijven we de constructie van een perioperatief FVIII populatie PK 
model voor patiënten met hemofilie A. Dit model kan gebruikt worden in de periope-
ratieve periode om de behandeling te individualiseren en daarmee te optimaliseren. 
Populatie PK parameters werden beschreven van 119 patiënten; 75 volwassenen (ge-
middelde leeftijd: 48 jaar, mediaan gewicht: 80 kg) en 44 kinderen (gemiddelde leeftijd: 
4.3 jaar, mediaan gewicht: 18.5 kg) die respectievelijk 140 en 58 chirurgische ingrepen 
ondergingen. FVIII concentratie-tijd curven werden het best beschreven door een twee-
compartimenten model. Populatie waarden voor klaring, intercompartimentele klaring, 
centraal en perifere verdelingsvolume waren 0.15 L/uur/68 kg, 0.16 L/uur/68 kg, 2.81 
L/68 kg en 1.90 L/68 kg. Interpatiënt variabiliteit in klaring en het centrale verdelings-
volume waren 37% en 27%. Klaring neemt af met toenemende leeftijd (p <0,01) en is 
groter van patiënten met bloedgroep O (26%, p <0,01). Daarnaast werd een kleine af-
name van de klaring waargenomen als een grote chirurgische ingreep werd uitgevoerd 
(7%, p <0,01). In vergelijking met het bestaande populatie PK model van Björkman et al. 
voor de profylactische behandeling, werd een groter perifeer verdelingsvolume waarge-
nomen. Gehypothetiseerd werd dat de toename van VWF postoperatief zorgt voor een 
verminderde klaring van FVIII. Prospectieve studies zijn echter nodig om deze relatie in 
de perioperatieve setting te evalueren. Dit zal verder worden onderzocht in de “OPTI-
CLOT” trial, beschreven in hoofdstuk 7. De ontwikkeling van het model beschreven in 
hoofdstuk 5 zal individualisering van de perioperatieve FVIII dosering bij ernstige en 
matig ernstige hemofilie A patiënten mogelijk maken door middel van doseren aan de 
hand van Bayesiaanse analyse.
In hoofdstuk 6 wordt de constructie van een perioperatief populatie PK model voor 
ernstige en matig-ernstige hemofilie B patiënten beschreven. Het doel was om geme-
ten FIX spiegels en de variabiliteit tussen patiënten in de perioperatieve periode te 
beschrijven tijdens de behandeling met stollingsfactorconcentraat. Er werden in totaal 
118 hemofilie B patiënten geïncludeerd (mediane leeftijd 40 jaar, mediaan gewicht 79 
kilogram) die gezamenlijk 255 chirurgische ingrepen ondergingen. In tegenstelling 
tot het model voor FVIII, werden FIX spiegels versus tijd curven het beste beschreven 
door een drie compartimenten model. Hierbij werden de volgende PK parameters 
beschreven: Klaring (CL), inter-compartimentale klaring (Q2, Q3), distributievolume 
van het centrale compartiment (V1) en perifere compartimenten (V2, V3), plus inter-
patiënt variabiliteit (%) met de volgende populatiegemiddelden: CL: 251 mLh-170kg-1 
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(13%), V1: 4950 mL70kg-1 (13%), Q2: 91.3 mLh-170kg-1 (99%), V2: 7900 mL70kg-1 (57%), 
Q3: 831 mLh-170kg-1, V3: 1600 mL70kg-1 voor een 32 jaar oude patiënt. Deze populatie 
PK parameters zijn verschillend ten opzichte van de waarden beschreven op basis van 
het profylaxe populatie PK model met een minder snelle eerste fase distributie naar het 
interstitium in de perioperatieve periode. Een mogelijke verklaring is endogene con-
sumptie tijdens de perioperatieve periode en het vormen van FIX/FVIII complex met als 
gevolg een verminderde distributie naar het interstitium. Om deze reden is een specifiek 
populatie PK model nodig voor de perioperatieve periode. Bij toename van de leeftijd 
nemen CL en V1 toe met respectievelijk 1,2% en 1,9% per jaar tot een leeftijd van 32 jaar 
(p<0.001, p<0.01). Opvallend genoeg bleken CL en V1 verschillend tussen Nederland en 
het Verenigd Koninkrijk. Verder onderzoek is nodig om een verklaring voor deze associ-
atie te vinden. Dit verschil zou kunnen zijn veroorzaakt door voorkeur voor bepaalde 
stollingsfactorconcentraten en het geven van comedicatie. Opvallenderwijs, bleek 
tranexaminezuur geassocieerd te zijn met een afname van V1 (9.8%). Dit suggereert dat 
tranexaminezuur leidt tot hogere FIX:C direct na de toediening van tranexaminezuur. 
Dit farmacodynamisch effect is niet eerder beschreven en moet verder onderzocht 
worden voordat hier conclusies aan verbonden kunnen worden.
In Deel III werd de haalbaarheid en validatie van het PK gestuurd doseren van stol-
lingsfactoren in patiënten met stollingsstoornissen in kaart gebracht.
In hoofdstuk 7 wordt de opzet van de “OPTI-CLOT” trial beschreven. Dit is een open-
label, prospectieve, multicenter, gerandomiseerde trial (RCT) die een vergelijking 
maakt tussen de standaard manier van doseren en een iteratief Bayesiaans PK-gestuurd 
doseren met als doel het aantonen van een reductie van 25% in FVIII consumptie als 
ook het sneller behalen van de specifieke streefwaardes. Patiënten worden verdeeld 
over beide behandelarmen op basis van de manier van toedienen van FVIII (continu 
of bolus) en de ernst van de chirurgische ingreep. Er zullen minimaal zestig hemofilie 
A patiënten met baseline FVIII spiegels ≤ 0,05 IUmL-1, ≥12 jaar, geïncludeerd worden 
die een electieve, kleine of grote chirurgische ingreep moeten ondergaan. In deze 
RCT, wordt het perioperatieve populatie PK model, zoals beschreven in hoofdstuk 5, 
prospectief gevalideerd. Tegelijkertijd zullen participerende Hemofiliebehandelcentra 
ervaring opdoen met PK-gestuurd doseren waardoor latere implementatie van deze 
behandelstrategie gemakkelijker maakt.
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Eerdere studies hebben aangetoond dat PK parameters van kinderen en obese patiënten 
verschillen van volwassenen met een normaal gewicht. In hoofdstuk 8 zijn alternatieve 
doseerstrategieën op basis van verschillende definities die lichaamsgrootte beschrijven 
“body size descriptors” vergeleken met een geïndividualiseerde PK gestuurde behande-
ling in hemofilie A patiënten met overgewicht of obesitas. De huidige behandeling van 
hemofilie patiënten is gebaseerd op baseline FVIII spiegels, lichaamsgewicht per kilo-
gram, klinisch fenotype, inschatting van klaring en grootte/kans op een bloeding. Van 
oudsher zijn de richtlijnen voor de dosering gebaseerd op in een vivo recovery (IVR) van 
2.0, wat overeenkomt met een toename van 2.0 lUdL-1 per IU FVIII per kilogram lichaams-
gewicht. Obese patiënten hebben significant hogere IVR waarden wat potentieel kan lei-
den tot overdosering. Om deze reden hebben diverse onderzoeksgroepen voorgesteld 
om alternatieve doseerstrategieën te gebruiken op basis van ideaal lichaamsgewicht 
of lean body weight. De voordelen en beperkingen van alternatieve doseerstrategieën 
bij obese hemofilie A patiënten werden onderzocht. In de studie werden 22 ernstige en 
matig-ernstige hemofilie A patiënten geïncludeerd (baseline FVIII <0.05 IUmL-1) en geca-
tegoriseerd op basis van body mass index (BMI), normaal: <25 kgm-2 (n=5) overgewicht: 
25-30 kgm-2 (n=12) en obesitas: >30 kgm-2 (n=5). Alle patiënten kregen ± 50 IUkg-1 FVIII 
toegediend, waarna FVIII werd gemeten op 4, 24 en 48 uur. Op basis van populatie PK 
modellen werden individuele FVIII versus tijd curven geconstrueerd. Het populatie PK 
model van Björkman et al. voorspelde niet de correcte FVIII spiegels bij patiënten met 
overgewicht en/of obesitas. Er werd een aangepast populatie PK model geconstrueerd 
welke PK parameters en FVIII spiegels correct beschreven van deze patiëntengroep. De 
mediane IVR was significant hoger van patiënten met overgewicht (2.65) en obesitas 
(3.00) ten opzichte van patiënten met een normale BMI (2.17) (p<0,05). IVR was onafhan-
kelijk van BMI bij gebruik van ideaal lichaamsgewicht. Desondanks gold voor alle body 
size descriptors dat IVR gebaseerd doseren (IVR van 2.0) resulteerde in FVIII dalspiegels 
onder de gewenste streefwaarden voor behandeling van bloedingen. In tegenstelling 
tot de algemene hypothese, concluderen wij dat alternatieve body size descriptors niet 
als surrogaat gebruikt kunnen worden dan wel PK gestuurd doseren kunnen vervangen. 
Om PK gestuurd te kunnen doseren dient het populatie PK model representatief te zijn 
voor de specifieke patiëntenpopulatie; in dit geval dus patiënten met overgewicht en 
obesitas.
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In hoofdstuk 9 wordt geïllustreerd hoe aan de hand van een individueel PK profiel en 
een perioperatief populatie PK model de behandeling geïndividualiseerd kan worden in 
een hemofilie A patiënt die een niertransplantatie ondergaat. Gedurende de periope-
ratieve periode, was het mogelijk door toepassing van het ontwikkelde populatie PK 
model binnen de vooraf vastgestelde streefwaarden te blijven. Er kon een betrouwbare 
voorspelling gedaan worden van de benodigde FVIII doseringen met behulp van een 
Bayesiaanse analyse, gebruikmakend van het geconstrueerde perioperatieve FVIII po-
pulatie PK model uit hoofdstuk 5. Deze casus toont aan welke rol deze innovatie kan 
spelen, zeker bij patiënten waarbij het van groot belang is dat de stollingsfactorwaarden 
dicht bij de streefwaarden liggen, omdat zij een hoge kans op bloedingen of trombose 
hebben.
Figuur 1. Verschillende stappen op weg naar geïndividualiseerde behandeling (“OPTI-CLOT” studies)
I
II III
IV
I Data verzamelen ten aanzien van de huidige behandeling
II Constructie van populatie PK modellen
III Externe validatie en implementatie van PK gestuurd doseren
IV Geïndividualiseerde behandeling
Verschillende stappen in de richting van geïndividualiseerde behandeling van stollingsfactorconcentraten 
zijn onder meer het verzamelen van gegevens van behandeling gevolgd door de constructie van popu-
latie PK modellen. Externe validatie en implementatie van PK gestuurd doseren zijn nodig om te leiden tot 
geïndividualiseerde behandeling.
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In hoofdstuk 10, worden de voordelen en beperkingen van PK gestuurd doseren bedis-
cussieerd. De voordelen van PK gestuurd doseren zijn individualisatie van behandeling 
met meer mogelijkheden om streefwaarden na te streven, flexibele bloedafnames, 
verhoogd inzicht in het verband tussen stollingsfactorspiegels en bloedingen, en po-
tentieel een verlaging van de kosten van behandeling. Beperkingen zijn een kleine extra 
last voor de patiënt omdat er vaker bloed afgenomen dient te worden, en de noodzaak 
van een nauwe samenwerking met een ervaren klinisch farmacoloog.
Over het geheel genomen geldt dat de studies uit dit proefschrift aantonen dat het 
verzamelen van retrospectieve data kan leiden tot kwalitatief hoogstaande populatie PK 
modellen (Figuur 1). Interne validatie van het ontwikkelde populatie PK model laat zien 
dat deze goede resultaten oplevert. Er zijn prospectieve studies nodig om de modellen 
extern te valideren en verder te verbeteren.
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IIV Inter-Individual Variability; variability between patients
IOV Inter-Occasion Variabilitiy; variability within patients
IQR Interquartile Range
ISTH International Society of Thrombosis and Hemostasis
IU International Units
IVR In Vivo Recovery
LBM Lean Body Mass
MEC Medical Ethical Committee
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Vd Volume of Distribution
VWD Von Willebrand Disease
VWF Von Willebrand Factor
VWF:Act Von Willebrand Factor Activity
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DANKWOORD
Al lerende leren wij. Samen steeds een stapje verder. Wat een enorme eer om de afgelo-
pen jaren met zoveel mensen samen te kunnen werken. Ik wil iedereen die bijgedragen 
heeft aan dit spannende avontuur hartelijk bedanken.  
Allereerst alle patiënten die met onze studies hebben meegedaan. Zonder jullie enthou-
siasme en het open staan voor wetenschappelijk onderzoek zou het niet mogelijk zijn 
om nieuwe stappen en verbeteringen in de zorg te maken. 
Ik wil graag mijn promotoren bedanken, prof. dr. F.W.G. Leebeek en prof. dr. R.A.A. 
Mathôt. 
Beste prof. dr. F.W.G. Leebeek, beste Frank, dank voor jouw waardevolle begeleiding, 
kritische blik, je steun en vertrouwen tijdens het onderzoek. Ik bewonder je gedreven-
heid en passie voor de kliniek en wetenschap. 
Beste prof. dr. R.A.A. Mathôt, beste Ron, hartelijk dank voor jouw enthousiasme en de 
mogelijkheid om mij het modelleren met NONMEM te leren. Nooit gedacht dat ik nog 
eens in een soort van oud zwart DOS-schermpje zou werken. Maar jij liet me zien hoe je 
daar prachtige dingen uit tevoorschijn kan toveren. Er valt nog heel veel meer te leren, 
maar de mogelijkheden en de klinische toepassingen van het modelleren zie ik inmid-
dels overal terug.
Beste dr. M.H. Cnossen, lieve Marjon, in het tweedejaars keuzeonderwijs heb ik je leren 
kennen als een bevlogen arts en een enthousiaste onderzoeker. Keer op keer kruisten 
onze paden. Ik vind het een eer dat ik één van jouw promovendi mag zijn. Ik heb be-
wondering voor jouw passie en enthousiasme voor patiënten en onderzoek. Je bent 
een inspiratie voor mij. Dank voor het vertrouwen dat je me gegeven hebt om nieuwe 
avonturen aan te gaan en ‘out of the box’ te denken. Met jou kon ik altijd even sparren, 
vrij associëren en discussiëren en daarbij niet alleen denken in problemen, maar juist 
in oplossingen. Als we niet linksaf kunnen, gaan we toch rechtsaf? Een wijze levensles. 
256 • Appendices
Dank aan prof. dr. T. van Gelder, prof. dr. C.M. Zwaan, prof. dr. R.E.G. Schutgens, prof. dr. K. 
Fijnvandraat, prof. dr. P.W. Collins en prof. dr. M. de Hoog voor het plaatsnemen in mijn 
promotiecommissie.
Met heel veel plezier heb ik samen met alle leden van de OPTI-CLOT werkgroep en de 
verschillende OPTI-CLOTters in alle deelnemende centra aan mooie studies mogen 
werken. Zonder de hulp en steun van (research)verpleegkundigen, secretaressen, labo-
ratoriummedewerkers, datamanagers en vele anderen zou dit boekje niet bestaan. Dank 
voor jullie enthousiasme en inzet! 
Prof. dr. T. van Gelder en prof. dr. S.N. de Wildt, beste Teun en lieve Saskia, ik heb jullie 
leren kennen als bevlogen en enthousiaste klinisch-farmacologen. Met veel geduld en 
passie maken jullie eenieder enthousiast voor het vakgebied farmacologie. Dank voor 
jullie begeleiding en de leuke besprekingen en het oplossen van de casuïstiek. Het niet-
ziekmakende farmacologie-virus heeft ook mij bereikt! 
Prof. dr. K. Fijnvandraat, lieve Karin, dank voor jouw kritische blik op mijn manuscripten 
en onze telefonische overleggen en daarmee de leuke discussies. Jij weet altijd verder 
te denken en mij te stimuleren om me verder te verdiepen in de pathofysiologie. Hier 
heb ik veel van geleerd. Ik heb een enorme bewondering voor jouw gedrevenheid in het 
doen van onderzoek. 
Dear prof. dr. P.W. Collins and dr. R. Liesner, dear Peter and dear Ri, thank you very much 
for your effort and help in the OPTI-CLOT goes UK study. Dear Peter, you are a very inspir-
ing clinician and researcher. You make time for everyone and I enjoyed our conversations 
and discussions very much. 
Dear Ri, thank you for the opportunity to stay at the Great Ormond Street Hospital. It was 
wonderful to be a part of your team. I hope to come back in the future. Thank you both 
for your trust, knowledge and efforts. 
Dear Anja, Mary, Nicola, Jamie, Nicola, Alpha, Kate, Keath, Julia, Melanie, Jemma, David 
and Paul, thank you for making me feel welcome at the Great Ormond Street Hospital. I 
was the strange girl from Holland, who didn’t drink milk in her very light tea. I very much 
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enjoyed my stay. Without your help I would not have accomplished what I have done 
now. 
I would also like to thank the people in all participating Hemophilia Treatment Centers 
of the United Kingdom for their participation in the OPTI-CLOT goes UK study, especially 
dr. Dan Hart, dr. Pratima Chowdary and dr. David Keeling. 
Discussies leiden tot nieuwe inzichten en geven soms een verrassende nieuwe invals-
hoek voor het doen van onderzoek. Bij deze wil ik dan ook alle mensen bedanken van 
diverse werkgroepen en de daarbij behorende werkbesprekingen, namelijk werkgroep 
hematologie, werkgroep (kinder)farmacologie en de NONMEM-werkgroep. 
Maaike van den Akker, beste Maaike, dank voor het tot leven brengen van onze eigen 
stripheld. Dank ook aan de NVHP, de Nederlandse Vereniging van Hemofilie-Patiënten. 
Er kwamen al snel via Facebook vele ideeën binnen voor de naam. Het is Felix Factor 
geworden. In vier delen hebben wij de PK-avonturen uiteen kunnen zetten. En wie weet, 
welke rol Felix Factor in de toekomst nog meer zal gaan spelen. 
Het secretariaat van de hematologie, kindergeneeskunde en farmacologie wil ik graag 
bedanken voor alle hulp en ondersteuning. Ontzettend knap hoe jullie alles managen, 
jullie zijn het middelpunt en het hart van de afdeling. 
Lieve collega’s van de (kinder)hematologie, dank voor jullie gezelligheid, kletspraatjes, 
hulp, zowel klein als groot. 
Mijn speciale dank gaat uit naar mijn directe collega’s en kamergenoten: Lieve Michelle, 
jij was altijd onze fotograaf en wist alle leuke momenten vast te leggen. Jouw vrolijk-
heid en relativeringsvermogen zijn een voorbeeld voor mij. Dank voor de gezellige tijd. 
Janske, samen hebben we veel data verzameld voor de studies van de OPTI-CLOT. Wat 
een drukke tijd! Dank voor de samenwerking. Lieve Iris, de OPTI-CLOT trial managen, dat 
is geen makkelijke taak, maar jou gaat het gemakkelijk af. Echt super knap! Jouw labo-
ratoriumachtergrond maakt het discussiëren over de ins en outs van de stolling en de 
rol in PK-PD modellen nog leuker. Ik hoop dat we nog vaak samen kunnen discussiëren. 
Lieve Hilde, jouw begeleiden als keuze-onderzoekstudent was ontzettend leuk. Wat heb 
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jij in korte tijd bergen verzet! Beste Tim, wat kun jij ongelooflijk snel modelleren, petje 
af! Succes met het maken van alle PK-modellen. Lieve Jossi, je bent enorm gedreven, 
jou is niet snel iets te veel. Samen sparren over statistiek of regressievergelijkingen. Ook 
jouw promotie komt al snel dichterbij. Heel veel succes met de laatste loodjes. Lieve 
Caroline, mijn halve naamgenoot, met ine of ien? Het werd nog moeilijker toen wij op 
onze kamer het Caroline/Carolien eiland werden. Hoe leuk was het dat jij in London een 
concert gaf en ik jou daar mocht ontmoeten. Joyce, Shiraaz, Shirley, Jessica en Lisette 
ook bedankt voor alle gezelligheid. Ja Johan, bij jou aangekomen, last but not least. Jij 
bent een vrolijke noot, maar ook een serieus gesprek ga je niet uit de weg. Ik stel voor 
dat we de gordijnen discussie laten voor wat het is…
Lieve Eva, Corien, Alice, Janneke, Hilde en Sophie, dank voor jullie interesse en dat ik ook 
met vragen bij jullie terecht kon. Het NVTH congres zou zonder jullie nooit zo leuk zijn 
geweest. Tiramisu maken met 40 liter slagroom en hoeveel liter drank? Ik weet het niet 
meer. Wat een gezellige tijd! 
Vanaf september 2016 een nieuwe uitdaging als arts-assistent kindergeneeskunde in het 
Elisabeth-TweeSteden Ziekenhuis in Tilburg. Lieve collega’s, dank voor de gezelligheid 
en onze samenwerking in de kliniek. In het bijzonder wil ik graag dr. Charlie Obihara en 
drs. Carien Smeets bedanken, als opleider en mentor kan ik altijd op jullie steun rekenen 
en kan ik bij jullie terecht. Ik geniet volop in de kliniek!
Beste Antoinette, na mijn eerste schilderavonturen op de kunstacademie in Londen was 
het super fijn om onder jouw begeleiding verder te gaan met schilderen. Dank voor 
de gezellige tijd en tips tijdens de verschillende schilderlessen. Ik ben enorm trots op 
mijn schilderij dat op de voorkant van mijn boekje staat. Voor menigeen zal het niets 
betekenen, maar voor mij betekent het de verschillende wegen die wij afleggen in ons 
leven, mooie avonturen! Mijn promotieonderzoek is er daar één van. 
Lieve vrienden/vriendinnen (Yvonne & Bouke, Carina & Maarten, Dianne & Ruud, Step-
hanie & Alexander, Kim & Erwin, Lisette, Bart, Bart & Erica, Bram & Emmy, Ronny & Wendy, 
Suzanne & Pieter, Karin & Ferdi, Cynthia & Marc, Niels & Maartje), er is altijd weinig tijd 
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om af te spreken met alle drukke agenda’s, maar we hebben het altijd weer gezellig. 
Dank voor jullie steun en alle gezellige etentjes en uitjes.  
Lieve Carina en Yvonne, wat fijn dat jullie mijn paranimfen willen zijn. Lieve Carina, dank 
voor jouw steun en dat ik bij je terecht kan. Samen discussiëren, een heerlijk tijdverdrijf. 
De gezellige etentjes, met een lekkere kop thee en ‘wat lekkers’ zijn altijd te snel voorbij. 
Het betekende erg veel voor mij/ons dat jij op onze bruiloft in de kerk wilde zingen. 
Lieve Yvonne, op dag één zorgde jij dat ik me meteen thuis voelde. Jouw openheid en 
rust zorgen ervoor dat iedereen zichzelf kan zijn. Ik kan altijd bij je terecht, samen lachen, 
samen huilen. Een woord is vaak niet eens nodig om elkaar te begrijpen. Een gedeelde 
passie is schilderen, wie had dat kunnen denken? Jullie betekenen veel voor mij. 
Lieve familie, dank voor jullie interesse in mij en de gezelligheid tijdens de verjaardagen, 
etentjes en borrels. Op naar nog vele mooie momenten die we met elkaar mogen delen! 
Lieve opa & oma, we mogen altijd bij jullie aankloppen. Oma, van u heb ik leren schrij-
ven. U liet mij niet alleen zien dat letters woorden vormen, woorden zinnen vormen, 
maar ook dat zinnen een verhaal worden. U bent een echte inspiratie voor mij. 
Lieve opa Willem & oma Sina, dank voor jullie liefde voor ons. 
Lieve Tein, wat een inspiratie en bron van energie ben jij. Samen gezellig fietsen voor de 
boodschappen en de trucjes voor het snijden van een paprika; ik voel me al bijna een 
professionele kok! 
Lieve Jolanda, Piet-Hein, Hidde en Mats; heerlijk om samen met jullie het leven te vieren 
en te genieten van mooie momenten. 
Lieve Paul en Nadya, ik heb bewondering voor jullie reislust en nu ook jullie nieuwe 
avontuur met de zoektocht naar een mooi (vakantie)huis in het buitenland. Wij komen 
graag klussen! 
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Lieve schoonouders, wat fijn dat jullie mij een plekje hebben gegeven in jullie gezin. 
Een promotietraject is voor jullie niet nieuw. Dank dat ik met al mijn verhalen en vragen 
terecht kan. Fijn dat wij altijd op jullie mogen en kunnen terugvallen. 
Lieve Nicole & Marjolein, lieve zusjes, we zijn de ‘haasjes’ en daar zijn we trots op! Nicole, 
jij straalt als je het over je werk hebt. Jij bent zorgzaam en gaat voor je patiënt. Als 
patiënt zou ik geen andere verpleegkundige aan mijn zijde willen hebben. Marjolein, 
jij bent mijn kleine zusje. Jij bent super goed in je werk als mondhygiëniste, weet ik als 
ervaringsdeskundige. En wat was het leuk dat jouw artikel zo snel was geaccepteerd. Ik 
ben trots op jullie! Dank dat jullie er altijd voor mij zijn. 
Lieve papa & mama, dank dat jullie mij al deze jaren hebben gesteund. Jullie zijn echt 
voorbeelden voor mij. Papa, jouw analytisch vermogen herken ik in mezelf en mama 
jouw gedrevenheid om ‘jouw leerlingen het juiste te leren op school en daar alles voor 
te laten’ is mij ook niet helemaal vreemd. Dank dat jullie altijd achter me staan. 
Lieve Sjors, jij bent er altijd voor mij. Aan mijn zijde sta jij. Jij stimuleert mij om mijn 
dromen waar te maken. Niet alleen leren of doen, maar ook het leven beleven is jouw 
motto. Samen staan wij sterk! 
Lieve groet, Carolien 
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Carolien Hazendonk was born on the 23th of October 1987 in Utrecht, the Netherlands. 
After graduating from secondary school at the Heerenlanden College in Leerdam, she 
went to the Erasmus University Medical Center Rotterdam to study medicine. During 
her study, she took part in various small research projects at the Department of Pediatric 
Hematology under supervision of dr. M.H. Cnossen. In October 2012, she graduated with 
honors.
In November 2012, she started with her PhD project which is part of the “OPTI-CLOT” 
study program initiated by the Department of Pediatric Hematology of the Erasmus 
University Medical Center Rotterdam under supervision of dr. M.H. Cnossen (pediatric 
hematologist and principal investigator “OPTI-CLOT”), prof. dr. F.W.G. Leebeek (hema-
tologist) and prof. dr. R.A.A. Mathot (clinical pharmacologist and hospital pharmacist; 
Academic Medical Center Amsterdam ).
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supervision of dr. C.C. Obihara.
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PHD PORTFOLIO
Name PhD student: H.C.A.M. Hazendonk
Erasmus MC Department: Pediatric Hematology
Research School: COEUR
PhD period: November 2012 to August 2016
Promotors: prof.dr. F.W.G. Leebeek, prof.dr. R.A.A. Mathôt
Copromotor: dr. M.H. Cnossen
 
1. PhD training year Workload
(ECTS)
General academic skills    
Biomedical English Writing and Communication 2013 4.0 
Systematic Literature Retrieval (medical library) 2013 0.5 
BROK (Basiscursus Regelgeving Klinisch Onderzoek) Erasmus MC 2013 1.0 
Research Integrity 2014 0.3 
Symposium Implementatie en Kwaliteit 2013 0.3 
ZonMw Doelmatigheidsonderzoek 2013 0.1 
Research skills    
Principles of Research in Medicine (NIHES) 2014 0.7 
Introduction to Data-analysis (NIHES) 2014 0.7 
Regression Analysis (NIHES) 2014 1.4 
NIH – Principles of Clinical Pharmacology, course of webinars 2014 2.0 
NIH – Pediatric Clinical Pharmacology webinars 2014 1.0 
In-depth courses (e.g. Research school, Medical Training)    
2x NVTH annual AIO course on hemostasis and thrombosis 2013-2014 2.0 
COEUR Symposium Personalized Medicine 2015 0.1 
NONMEM journal club 2013-2016 2.0 
Oral presentations    
Dutch Society of Pediatrics 2013 0.5 
Von Creveld symposium (invited speaker) 2014 0.5 
Dutch Hematology Congress 2015 0.5 
International Society on Thrombosis and Haemostasis Congress 2015 0.5 
NVTH symposium 2015 0.5 
FIGON Dutch medicines day 2015 0.5 
Sophia Research day 2016 0.5 
COEUR PhD day 2016 0.5 
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Poster presentations     
International Society on Thrombosis and Haemostasis Congress 2013, 2015 0.4 
Bari International Conference 2014 0.2 
Dutch Society of Pediatrics 2014 0.2 
Sophia Research day 2014 0.2 
European Association of Hemophilia and Allied Disorders Congress 2015 0.2 
European Congress on Thrombosis and Haemostasis 2016 0.2 
National Conferences    
Nationaal Trombo-Embolie Symposium 2013 0.3 
Annual meeting of the Dutch Society of Pediatrics 2013, 2014 0.6 
Dutch Hematology Congress 2013, 2015 0.6 
NVTH symposium 2013-2015 1.4 
Von Creveld Symposium 2014 0.3 
AMSTOL Symposium 2014, 2016 0.6 
FIGON Dutch Medicine Days 2015 0.6 
NVT Pediatric drug development 2016 0.3 
International Conferences     
3x European Association of Hemophilia and Allies Disorders Congress 2013-2015 2.7 
2x International Society on Thrombosis and Haemostasis Congress 2013,2015 3.6 
Bari International Conference 2014 0.9 
Seminars and workshops    
Young Investigators day TULIPS 2013-2015 0.9 
Sophia research day 2013,2014, 2016 0.9 
COEUR PhD day, Rotterdam 2013, 2014, 2016 0.9 
Lareb - introduction day and adverse events day 2014 0.3 
Masterclass Timothy Springer 2014 0.3 
Masterclass David Lillicrap 2016 0.3 
Didactic skills    
Teach the Teacher course 2013 0.5 
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2. Teaching activities
Lecturing    
Tutor first year medical students 2013 1.5 
Teaching polypharmacy medical students 2014-2015 0.2 
Supervising Master’s theses    
Supervising final year medical student (1x 27 weeks) 2015 1.0 
Hematology PhD training    
Work discussions and literature discussions 2012-2016 8.0 
Other     
Pediatric Pharmacology Research Meetings 2013-2015 1.0 
Clinical Pharmacology and Pharmacogenetics meetings 2014-2016 1.0 
COEUR PhD committee and organizing COEUR PhD day 2013-2015 2.0 
Total 52.2
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